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Malaria and tuberculosis (TB) are infectious microbial diseases contributing to a major 
global health problem and remain a high priority. The problem is further compounded by 
the emergence of drug resistant strains of the respective causative agents. New therapies 
and drug design strategies are thus continually required to overcome this resistance. A 
unique approach in tackling rising resistance is the use of hybrid chemotherapy, which 
involves the combination of two or more pharmacophores into a single compound. This 
study investigated the synthesis, characterisation and pharmacological properties of new 
organic and ferrocenyl aminoquinoline-benzimidazole hybrid compounds, as well as the 
corresponding Platinum Group Metal (PGM)-containing complexes. The compounds 
were screened for their activity against Plasmodium falciparum, and for their cytotoxicity 
against the Chinese hamster ovarian (CHO) cell-line. In addition, the compounds were 
also evaluated against Mycobacterium tuberculosis.   
A series of aminoquinoline-benzimidazole hybrid compounds were prepared. The 
2-position of the benzimidazole was substituted with an organic phenyl or pyridyl group, 
or an organometallic ferrocenyl group. The 5-position of the benzimidazole was varied 
using substituents with varying hydrophobic and electron-withdrawing or -donating 
properties, in order to probe the effect on biological activity. These compounds were fully 
characterised using 1H, 13C{1H}, COSY and HSQC NMR spectroscopy, IR spectroscopy and 
electrospray ionisation mass spectrometry.  
The organic and ferrocenyl aminoquinoline-benzimidazole hybrids were screened in 
vitro against the chloroquine-sensitive (CQS) NF54 strain and multidrug-resistant (MDR) 
K1 strain of P. falciparum. Most compounds displayed good activity against the sensitive 
NF54 strain, with IC50 values in the low to sub-micromolar range. With the exception of 
the pyridyl analogues, most compounds were more potent in the resistant K1 strain. 
Resistance indices lower than one (RI < 1) were observed in most cases, indicating 
greater applicability in the resistant strain. The individual aminoquinoline and 
benzimidazole components were also evaluated in order to determine the value in the 





hybrid proved more potent than either of the individual components. Using isobologram 
analysis in the NF54 strain, additive and antagonistic relationships were revealed for the 
co-administration of the aminoquinoline and benzimidazole components in different 
relative concentrations.  
All of the tested hybrids displayed low or no cytotoxicity towards CHO cells and 
consequent selectivity towards Plasmodium strains. The most active phenyl and 
ferrocenyl hybrids were subsequently screened for in vivo efficacy against P. berghei-
infected mice. Treatment with the ferrocenyl hybrid resulted in a 92% reduction in 
parasitemia, proving a more potent inhibitor than the phenyl hybrid (58%).  
The haem degradation pathway is a known target of many antimalarials, and thus 
haemozoin inhibition was investigated as a possible mechanism of action of these hybrid 
compounds. All screened hybrids were found to inhibit synthetic haemozoin 
(β-haematin) formation in a cell-free assay. A cellular haem fractionation assay was 
performed on the most active ferrocenyl hybrid, confirming haemozoin inhibition in the 
parasite. In addition, reactive oxygen species (ROS) generation by this ferrocenyl hybrid 
was explored using a DNA-cleavage assay, revealing insignificant ROS-generating ability.   
Furthermore, the aminoquinoline-benzimidazole hybrids were evaluated in vitro against 
the H37Rv strain of M. tuberculosis. For the phenyl and ferrocenyl hybrids, those with the 
less hydrophobic 5-position substituents were inactive, while those with the more 
hydrophobic substituents showed moderate to good activity. Based on logP values, there 
was a positive correlation between lipophilicity and antimycobacterial activity. In line 
with this, the more lipophilic ferrocenyl hybrids were consistently more active than their 
corresponding less lipophilic phenyl analogues. Additionally, in an evaluation of the 
individual aminoquinoline and benzimidazole components, the hybrid compound was 
more potent than either component administered individually. 
The active phenyl hybrid ligands were reacted with [Ir(Cp*)Cl2]2 and [Rh(Cp*)Cl2]2 to 
yield neutral C^N-coordinated and N-coordinated hybrid complexes. Furthermore, the 
pyridyl hybrid ligands were reacted with [Ir(Cp*)Cl2]2, [Rh(Cp*)Cl2]2, as well as 
[Rh(ppy)2Cl]2 to afford cationic N^N-coordinated hybrid complexes. The complexes were 





The C^N- and N^N-coordinated PGM-containing complexes were screened against the 
NF54 and K1 strains of P. falciparum, generally displaying low to sub-micromolar IC50 
values across both strains. In the sensitive NF54 strain, the cationic Rh(III)-ppy 
complexes were most potent, outperforming the neutral and cationic M-Cp* complexes. 
The selected complexes (NF54 IC50 ≤ 2 µM) tested in the resistant K1 strain, generally had 
activity comparable to or lower than that in the NF54 strain (RI ≥ 1). The active hybrid 
complexes were evaluated against the non-tumorigenic CHO cell-line, displaying low or 
no cytotoxicity overall. With regards to a possible mechanism of action, the hybrid 
complexes were found to be potent inhibitors of β-haematin formation.  
The catalytic ability of selected Ir(III) and Rh(III) C^N-coordinated hybrid complexes, in 
the transfer hydrogenation of NAD+ to NADH, was also investigated. Using sodium 
formate as the hydride source, both complexes demonstrated the ability to catalyse the 
conversion under cell-free assay conditions. However, co-administration of the Ir(III) 
complex with sodium formate did not have a significant effect on parasite viability. 
When evaluated against the H37Rv strain of M. tuberculosis, the hybrid complexes 
generally displayed moderate to good activity. The neutral M-Cp* and cationic 
Rh(III)-ppy complexes significantly outperformed the cationic M-Cp* complexes. Overall, 
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Malaria is a life-threatening infectious disease caused by parasites of the Plasmodium 
genus, and is transmitted through the bite of a female Anopheles mosquito vector. In 
humans, malaria is caused by five different species; P. ovale, P. malariae, P. knowlesi, as 
well as P. vivax and P. falciparum, which are the most severe and pose the greatest threat 
in South America and Africa, respectively.1 According to the World Health Organisation 
(WHO), there were approximately 219 million new malaria cases and 435 000 deaths in 
2017.1 Figure 1.1 shows the global distribution of indigenous malaria cases in 2017. 
 
Figure 1.1 Countries with indigenous cases of malaria in 2017.1  
Numerous factors related to the parasite, vector, host and environmental conditions 
affect the transmission of this infectious disease. The tropical and subtropical climates, 
densely-populated areas and the long lifespan of the African vector species lend itself well 
to the high transmission of malaria in the region.2 WHO reports that in 2017, 92% of new 
malaria cases and 93% of malaria deaths occurred in Africa.1 





Malaria is both preventable and curable. In terms of prevention of the disease, vector 
control is the main way to block transmission of malaria.3 This takes the form of 
insecticide-treated mosquito nets (ITNs), as well as indoor residual spraying (IRS) of 
insecticides.4 In addition, antimalarial drugs are used for travellers entering malaria-risk 
areas, which prevents malaria disease through chemoprophylaxis.3, 4 With regards to 
both preventing and curing malaria, an understanding of the life cycle of the Plasmodium 
parasite is crucial. 
 
1.1.1 Life cycle of the Plasmodium parasite 
The malaria parasite life cycle involves two hosts, a mosquito and a human, as depicted 
in Figure 1.2.5 The parasite is injected into the human host in the form of asexual 
sporozoites, through the bite of an infected mosquito vector. These sporozoites travel to 
the liver to invade hepatocytes, where they divide by schizogony, producing haploid 
merozoites. The merozoites are then released into the bloodstream. In some Plasmodium 
species, the sporozoites remain dormant (hypnozoites) in the hepatocytes, and may be 
activated at a later stage, leading to relapses of active infection in the bloodstream.5  
 
Figure 1.2 Life cycle of the malaria parasite.5  





Once in the bloodstream, merozoites invade erythrocytes. This is the beginning of the 
blood stage, which is the only stage in which the parasite is pathogenic.5 Inside the 
erythrocytes, the merozoites mature to form trophozoites. The nucleus of the trophozoite 
then divides asexually to produce a multinucleated schizont. Each schizont then divides 
further to form a new generation of mononucleated merozoites. The erythrocyte 
inevitably ruptures, releasing its contents, resulting in pathogenic symptoms in the 
human host. The released merozoites invade further erythrocytes as the erythrocytic 
stage undergoes multiple cycles. Alternatively, the merozoites develop sexually into 
gametocytes, which can be transmitted to a mosquito when it takes a blood meal from an 
infected human host. Once in the gut of the mosquito, the gametocytes develop into 
microgametes (male) and macrogametes (female) through gametogenesis. Fertilisation 
results in the formation of zygotes, which become ookinetes, penetrating the midgut wall 
of the mosquito, and then developing into oocysts. Within the oocyst, sporozoites develop 
by mitotic division. The oocysts eventually rupture, releasing sporozoites, which travel 
to the salivary gland of the mosquito, where the life cycle begins again.5  
 
1.1.2 Haemozoin formation 
Malaria pathogenesis begins once the parasite has entered the host erythrocytes. 
Parasites in the trophozoite and schizont stage ingest large quantities (60 – 80%) of host 
haemoglobin, transporting it to the parasitic digestive vacuole to be degraded.6 This 
acidic organelle has a pH range of 5.2 – 5.6,7 and contains a series of proteolytic enzymes, 
including plasmepsins (I, II and IV), histoaspartic protease, falcipains (2 and 3) and the 
metalloprotease falcilysin.8-10 Once in the digestive vacuole, the catabolism of 
haemoglobin is catalysed by the aforementioned enzymes, to afford short peptides, which 
are further degraded to amino acids by aminopeptidases in the parasite cytoplasm.11 
These amino acids provide a source of nutrients, which is essential for parasite growth 
and maturation. 
During the process of catabolism, the free haem by-product (Fe(II)PPIX) derived from 
haemoglobin is released into the digestive vacuole, as depicted in Figure 1.3. The iron 
centre of Fe(II)PPIX is oxidised from Fe(II) to Fe(III), likely through auto-oxidation by 
molecular oxygen (O2), to produce haematin (ferriprotoporphyrin IX, Fe(III)PPIX).6 This 





free haem species has been demonstrated to induce free radical production,12 
peroxidation of lipid membranes,13 as well as protein and DNA oxidation,14, 15 and is thus 
toxic to the parasite. The Plasmodium parasite, however, employs a haem detoxification 
mechanism in order to overcome its harmful effects. In this process, the toxic haematin is 
converted to non-toxic haemozoin (malaria pigment), a highly insoluble microcrystalline 
substance, via biomineralization.16 The chemically inert haemozoin accumulates in the 








Figure 1.3 Haemoglobin degradation and haem detoxification.  
 
 
1.1.3 Antimalarial therapies and modes of action 
Quinoline-based antimalarials 
The chemotherapeutic treatment of malaria has seen the use of a wide range of 
compounds with varying scaffolds and mechanisms of action. Perhaps the most highly 
efficacious of past antimalarials is the class of quinoline-based drugs (Figure 1.4). Drugs 
incorporating this heterocyclic scaffold have low toxicity, few side effects and low-cost 
preparation.17 Successful drugs of this type include quinine (1.1), primaquine, 









Chloroquine (CQ) and other quinoline-based antimalarials are known to act against the 
pathogenic erythrocytic stage of the parasite life cycle, during which haemoglobin is 
ingested and transported to the digestive vacuole of the parasite.18 CQ, a diprotic weak 
base, passes through the cell and parasite membranes unprotonated and accumulates in 
the acidic digestive vacuole.18-20 Upon accumulation, CQ targets the parasite-induced host 
haem detoxification pathway, preventing the parasite from converting toxic haematin to 
the non-toxic haemozoin pigment.18-20 The resulting build-up of toxic haem (Fe(III)PPIX) 







Figure 1.4 Quinoline-based antimalarials; quinine (1.1), mefloquine (1.2) and 
chloroquine (1.3). 
Microbes such as P. falciparum undergo mutations in order to survive, allowing them to 
develop resistance to previously effective treatments. CQ accumulates to a much lesser 
extent in resistant Plasmodium falciparum parasites, as a result of a point mutation in the 
P. falciparum CQ resistance transporter (PfCRT).21, 22 In the presence of the mutated form 
of this transporter, the protonated CQ present in the digestive vacuole is transported out, 
resulting in lower accumulation and thus a decrease in activity.21, 22 As a result of 
widespread resistance, the use of quinoline-based drugs as monotherapies have been 
rendered largely ineffective. As part of combination therapies, certain quinoline-based 
drugs remain effective in specific parts of the world. 
Antifolate drugs 
Administering two or more drugs in combination reduces the risk of resistance and 
treatment failure. Antifolate drugs are a widely used class of antimalarials, acting by 
inhibition of enzymes involved in folate metabolism.23, 24 This results in decreased 
pyrimidine synthesis, which is essential for DNA and other biomolecule synthesis. 
Antifolates are divided into two classes, dihydropteroate synthase (DHPS) inhibitors and 





dihydrofolate reductase (DHFR) inhibitors, and are often administered in drug pairs.24 
Sulfadoxine (1.4) and pyrimethamine (1.5), depicted in Figure 1.5, are examples of DHPS 
and DHFR inhibitors, respectively.24 Resistance to these antifolate drugs is brought about 





Figure 1.5 DHPS inhibitor, sulfadoxine (1.4) and DHFR inhibitor, pyrimethamine (1.5). 
 
Artemisinin-based combination therapy 
The current and most effective treatment against malaria infections is the artemisinin-
based combination therapy (ACT).26 Isolated from the Chinese sweet wormwood plant, 
artemisinin was traditionally used in the treatment of fever. Artemisinin and its 
derivatives, shown in Figure 1.6, were found to be highly effective antimalarials, capable 
of rapidly eliminating Plasmodium parasites from its human host.27 ACT involves the use 
of two drugs, an artemisinin derivative together with another antimalarial of known 
efficacy and with a different mechanism of action.28, 29 As a result of the short elimination 
half-life of artemisinin derivatives, a longer half-life partner drug is required.28, 29 This 
combination gives enhanced activity, in addition to decreasing or delaying the 









Figure 1.6 Artemisinin (1.6) and derivatives artemether (1.7), artesunate (1.8) and 
dihydroartemisinin (1.9). 





Artemisinin derivatives show antiparasitic activity at multiple stages of the parasite life 
cycle, demonstrating activity against the asexual and sexual forms of the parasite.29 The 
latter activity against sexual gametocytes, which are taken up by the mosquito vector, can 
thus lead to decreased transmission of malaria infection.30 The exact mechanism of action 
of the artemisinins is not fully understood, however, the endoperoxide moiety of these 
compounds is thought to be essential for antimalarial activity.31 Reactive oxygen species, 
generated through cleavage of the endoperoxide bridge, may result in parasite damage.32 
Although the ACT regimen is currently the most efficacious antimalarial treatment, there 




Tuberculosis (TB) is caused by a bacterial pathogen known as Mycobacterium 
tuberculosis and typically infects the lungs of its host, in the form of pulmonary TB. 
Tuberculosis remains a major global health problem, and is one of the top ten causes of 
death worldwide.35 The WHO reports that in 2018, there were 10 million new cases of TB 
and 1.5 million deaths from the disease, with over 95% of cases and deaths occurring in 
developing countries.36 Figure 1.7 shows the estimated TB incidence worldwide. 
 
Figure 1.7 Estimated incidence of tuberculosis infection worldwide in 2018.36  
 





1.2.1 Tuberculosis pathogenesis 
Tuberculosis spreads through the air, when people who are infected with active 
pulmonary TB expel bacteria through coughing, sneezing or spitting. Inhalation of only a 
few tubercle bacilli is enough to result in the spread of TB infection. The pathogenic cycle 
of M. tuberculosis is depicted in Figure 1.8. Upon inhalation, TB infection begins once the 
tubercle bacilli bacteria reach the alveolar space in the lungs, where macrophages 
preferentially ingest the bacilli.37 The macrophages proceed to eliminate the foreign 
bacteria by phagocytosis. Through this process, within the macrophage, the bacteria are 
stored in a phagosome, which combines with a lysosome to produce a phagolysosome. A 
combination of acidic pH, reactive oxygen species and lysosomal enzymes are employed 
to kill the bacteria.37 Additional macrophages and other immune cells are recruited to the 
original infected macrophage, forming an aggregate called a granuloma.37 The majority 
of the bacteria are inhibited by this innate immune response. Within the granuloma, the 
bacteria may remain alive and dormant, resulting in latent TB infection.37 Approximately 
a quarter of the world’s population are asymptomatically infected with latent TB, which 
can be reactivated at a later time.35 
 
Figure 1.8 Pathogenic cycle of M. tuberculosis.38 





On the other hand, M. tuberculosis is also able to resist antimicrobial mechanisms and 
disrupt macrophage signalling pathways in order to persist within the granuloma.39 In 
this case, bacteria are able to evade or overcome the immune response, and bacterial 
replication takes place within the macrophage.38 Under certain conditions, the infected 
granuloma may undergo necrosis, expelling the tubercle bacteria, where they replicate 
extracellularly.38 Some bacteria can enter lymphatic channels or the bloodstream, and be 
further disseminated throughout the body. A further immune response is then triggered 
at the target tissues and organs.38   
 
1.2.2 Anti-tuberculosis therapies and modes of action 
The treatment of tuberculosis has involved the use of chemically diverse antimicrobial 
agents, with varying mechanisms of action. In the past, both monotherapies and 
combination therapies were utilised. Currently, however, long-term treatment with 
multiple drugs is required in order to cure the disease without relapse, and to prevent 
transmission and drug resistance.  
Four-drug regimen 
Current chemotherapy for drug susceptible TB (DS-TB) involves the use of isoniazid (INH, 
1.10), rifampicin (RIF, 1.11), pyrazinamide (PZA, 1.12) and ethambutol (EMB, 1.13), 
known as the first-line drugs (Figure 1.9).40 Used in a six-month regimen, all four drugs 
are administered for the first two months (intensive phase), followed by only INH and 









Figure 1.9 First-line drugs used against DS-TB; isoniazid (1.10), rifampicin (1.11), 
pyrazinamide (1.12) and ethambutol (1.13). 





Isoniazid and pyrazinamide are pro-drugs, and are activated intracellularly through 
bacteria-specific metabolism. INH diffuses across the M. tuberculosis cell membrane 
through small water-filled pores.41 It subsequently undergoes oxidative activation by the 
catalase-peroxidase katG to form an isonicotinyl radical.42 Upon reaction with oxidised 
NAD+ cofactors, several 4-isonicotinyl-NAD adducts are generated.43 These active 
metabolites primarily inhibit the synthesis of mycolic acids, an essential component of 
the mycobacterial cell wall.44, 45 RIF easily diffuses across the bacterial cell membrane as 
a result of its highly lipophilic nature.46 The bactericidal properties of RIF are attributed 
to its ability to bind to mycobacterial DNA-dependent polymerases, resulting in the 
inhibition of mRNA synthesis.47 
PZA enters the bacterium via ATP-dependent transport systems.48 It is activated 
intracellularly by the bacterial pyrazinamidase pncA, to give the active pyrazinoic acid 
(POA).49 The mechanism of action of PZA is poorly understood, however, it is 
hypothesised to act against non-replicating tubercle bacilli present in acidic 
compartments of the lungs during the early stages of TB infection.50 This is consistent 
with the clinical observation that PZA is most active during the first two months of 
chemotherapy.50 The mechanism of action of EMB is not fully understood and appears to 
be multifaceted. It is known to inhibit several mycobacterial cellular pathways, including 
RNA metabolism, phospholipid synthesis and mycolic acid transport.50 The primary 
target of EMB, however, is the biosynthesis of arabinogalactan, an essential component 
of the mycobacterial cell wall.51 Disruption of this pathway is achieved through inhibition 
of arabinan polymerisation.52  
Through microbial mutations and the misuse of anti-TB treatments, drug-resistant 
mutant strains of M. tuberculosis have emerged. Multi-drug resistant TB (MDR-TB) is 
caused by strains that are resistant to INH and RIF, the most potent first-line drugs. 
Treatment for MDR-TB utilises second-line drugs, such as the fluoroquinolones.40 
Furthermore, extensively drug-resistant TB (XDR-TB) refers to strains of M. tuberculosis 
which are resistant to several first- and second-line drugs. Cases of totally drug-resistant 
TB (TDR-TB) have also been reported.53  
 






Fluoroquinolones represent a class of bactericidal fluorine-substituted quinolone 
antibiotics which are active against Gram-positive and Gram-negative bacteria, and have 
been repurposed for their use as anti-TB agents. The WHO recommends the use of 
fluoroquinolones, such as levofloxacin (1.14), moxifloxacin (1.15) and ofloxacin (1.16), 
shown in Figure 1.10, as second-line drugs, in the treatment of MDR-TB.40 This class of 
drugs have shown activity against both extracellular replicating bacteria and intracellular 
non-replicating bacteria.54 Against M. tuberculosis, moxifloxacin (1.15) has bactericidal 
and sterilising activity similar to that of INH, and has thus been investigated as a potential 







Figure 1.10 Second-line fluoroquinolone drugs; levofloxacin (1.14), moxifloxacin (1.15) and 
ofloxacin (1.16). 
With regards to their mode of action, fluoroquinolones target two essential bacterial 
enzymes; DNA gyrase (topoisomerase II) and the closely related topoisomerase IV.56 The 
drug traps the topoisomerase enzyme on DNA through formation of a complex containing 
the quinolone, DNA and the enzyme.56 The ternary complex blocks the movement of 
transcription complexes and replication forks, thereby blocking DNA replication.56  
 
  





1.3 Heterocyclic compounds  
1.3.1 4-Aminoquinolines 
Structure and chemotherapeutic application 
Quinoline is a nitrogen-containing heterocyclic aromatic compound, comprising a 
benzene ring fused to a pyridine ring. The quinoline nucleus, depicted in Figure 1.11 
(1.17), is present in many natural products, such as alkaloids extracted from Cinchona 
plants. The quinoline ring represents a popular scaffold in medicinal chemistry as a result 
of its diverse range biological properties,57 which include anticancer,58 
antimycobacterial,59, 60 antifungal61 and anti-inflammatory activity.62 However, quinoline 
derivatives have been most prominently applied in antimalarial chemotherapy,63 as 
discussed earlier (Section 1.1.3).  
 
1.17 
Figure 1.11 Structure of the quinoline nucleus. 
The use of quinoline derivatives in the treatment of malaria began with quinine, an 
alkaloid consisting of a quinoline-alcohol group. Over the years, various other quinoline-
containing drugs (Figure 1.12) were developed, as the result of drug toxicity, undesirable 
side-effects and drug-resistance.63, 64 Pamaquine (1.18), an 8-aminoquinoline, represents 
the first synthetic antimalarial drug, however, its toxicity and multiple side-effects led to 
limited use. The less toxic analogue, primaquine (1.19), is known to eradicate 
hypnozoites of P. vivax and P. ovale.65 The 4-aminoquinoline drug, chloroquine, was 
derived from an acridine-containing antimalarial, quinacrine (1.20), and became the 
most successful single drug in the treatment of malaria.63, 64 Other 4-aminoquinoline 
drugs include amodiaquine (1.21) and piperaquine (1.22). The rise of chloroquine-
resistant parasites led to the development of mefloquine, a potent 4-quinolinemethanol 
drug.63, 64 















Figure 1.12 Structures of 8-aminoquinoline drugs (1.18 and 1.19), an acridine-containing drug 
(1.20) and 4-aminoquinoline drugs (1.21 and 1.22). 
Despite the presence of parasite resistance to some quinoline-based drugs, extensive 
studies to derivatise the scaffold continue to be done, to afford new and more effective 
treatments. Furthermore, the quinoline scaffold has also been repurposed for its use 
against other diseases.    
 
4-Aminoquinolines against malaria and TB 
Since the success of drugs such as chloroquine, amodiaquine and piperaquine, 4-
aminoquinoline derivatives (Figure 1.13) have been further explored, with great 
potential in overcoming resistance.66, 67 Ridley et al. reported the antimalarial activity of 
cyclohexane-linked bisquinoline analogues.68 The S,S enantiomer, Ro 47-7737 (1.23) 
displayed low nanomolar in vitro activity against the chloroquine-sensitive (CQS) NF54 
and chloroquine-resistant (CQR) K1 strains of P. falciparum, enhanced compared to 
chloroquine and mefloquine. In terms of a mode of action, Ro 47-7737 was a more potent 
inhibitor of haem polymerisation than CQ.68 In addition, Ro 47-7737 was found to be a 
potent inhibitor of P. vivax ex vivo and P. berghei in vivo, however, its toxicity excluded the 
bisquinoline from further development. On the other hand, Delarue-Cochin et al. 
investigated the effect of shifting and modifying the 4’-phenolic group of amodiaquine in 
a series of related analogues.69 The 5’-amino-substituted analogue (1.24) displayed in 





vitro activity in the nanomolar range, against sensitive and resistant strains (Thai, FcB1R 
and K1) of P. falciparum. Compound 1.24 significantly inhibited P. berghei in vivo and 








Figure 1.13 Antimalarial 4-aminoquinolines; bisquinoline Ro 47-7737 (1.23),68 amodiaquine 
derivative (1.24)69 and TDR 58845/6 (1.25 and 1.26)70 
The antimalarial properties of two aminoquinoline derivatives, TDR 58845 (1.25) and 
TDR 58846 (1.26) were also reported.70 Both analogues displayed potent in vitro activity 
(5.52 – 89.8 nM) against various sensitive and resistant P. falciparum strains, in addition 
to activity against early and late gametocyte stages. TDR 58845 and TDR58846 also cured 
P. berghei infected mice at 40 mg/kg. Furthermore, in combination studies, TDR 58845 
(1.25) was synergistic with verapamil, desipramine and chlorpromazine, compounds 
known to reverse CQ resistance in vitro.70  
Numerous aminoquinoline derivatives have been investigated for activity against 
M. tuberculosis, many displaying potency against drug-sensitive and MDR-TB strains.59, 60, 
71 Ngwane et al. screened a series of 2(5H)-furanone-aminoquinoline derivatives against 
strains of M. tuberculosis.72 A biphenyl-containing analogue (1.27) was most potent, 
displaying comparable mycobacterial inhibition in both the H37Rv and MDR-TB strains. 
Additionally, when evaluated in two-drug combinations, compound 1.27 showed 
synergistic activity with RIF, and additive activity with INH and EMB.72 With regards to 





the mechanism of action of aminoquinolines against M. tuberculosis, recent research has 
shown various aminoquinoline derivatives to inhibit the mycobacterial DNA gyrase,73, 74 
in a similar way to the anti-TB fluoroquinolones. An anthranilamide-aminoquinoline 
derivative (1.28), displayed potent low micromolar activity (MIC = 1.56 µM) against the 
H37Rv strain, greater than pyrazinamide, a first-line anti-TB drug.74 Furthermore, 





Figure 1.14 Furanone-aminoquinoline derivative (1.27)72 and an anthranilamide-




Structure and synthesis 
Benzimidazole is a nitrogen-containing heterocyclic compound, consisting of a benzene 
ring fused at the 4,5-positions of an imidazole ring. The structures and systematic 
numbering of the imidazole and benzimidazole ring systems are shown in Figure 1.15. 
These aromatic N-heterocycles are abundant in many natural products. The imidazole 
ring is present in many alkaloids and proteins, the α-amino acid histidine, the hormone 
histamine, as well as purine and biotin. The bicyclic benzimidazole occurs in N-ribosyl-
dimethylbenzimidazole, an axial ligand of the cobalt metal atom in vitamin B12. 
 









Figure 1.15 Structures of imidazole (1.29) and benzimidazole (1.30). 
Benzimidazole and its derivatives are most commonly synthesised by condensation of a 
1,2-diaminobenzene with a carbonyl compound (aldehydes, carboxylic acids and 
derivatives), as shown in Scheme 1.1. The reaction is performed under dehydrating 
conditions and in the presence of a strong acid (e.g. hydrochloric acid or boric acid) or a 
milder acidifying reagent (Lewis acids or mineral acids). When condensing with an 
aldehyde, an oxidising reagent is required to achieve the benzimidazole core.75  
 
Scheme 1.1 General scheme for synthesis of a benzimidazole. (i) strong acid/milder 
reagents/oxidising agent; R’ = aldehyde, carboxylic acid or derivatives. 
 
Benzimidazoles in chemotherapy 
The abundance of benzimidazoles in nature has led to the investigation into their 
potential as therapeutic agents. In the 1940s, Woolley76 and Folkers77 speculated that 
benzimidazoles may elicit similar biological responses or activity as purines and vitamin 
B12, respectively. To date, extensive research has proven the benzimidazole nucleus to 
have a wide range of therapeutic applications owing to its presence in a host of 
biologically active compounds. These include anticancer and antihistaminic agents, as 
well as antiviral and antiparasitic (anthelmintic) agents.75, 78 Examples of benzimidazole-
based drugs are shown in Figure 1.16.  
 













Figure 1.16 Benzimidazole-based pharmaceuticals; astemizole (1.31) – antihistaminic, 
bendamustine (1.32) – anticancer, enviradene (1.33) – antiviral, 
albendazole (1.34) – anthelmintic.  
 
Benzimidazoles against malaria and TB 
The antiplasmodium activity of various benzimidazole derivatives has been explored and 
in many cases, display potent in vitro activity against P. falciparum, as well as good in vivo 
efficacy in animal models.75, 79, 80 Benzimidazoles may exert their antimalarial activity 
through various mechanisms. In a similar manner to the commercially-available 
omeprazole, benzimidazoles may inhibit proton pumps.81 Artemisinin-derived 
benzimidazoles have been reported to exhibit in vitro and in vivo antimalarial activity, 
and may act accordingly.82 Recent research has shown the β-haematin inhibition ability 
of some benzimidazole derivatives, exerting their antiparasitic activity in a manner 
similar to that of chloroquine.83, 84 A 1,4-bis(3-aminopropyl)piperazine-derived 
benzimidazole, depicted in Figure 1.17 (1.35), has been shown to inhibit β-hematin 
formation.84 On the other hand, a benzimidazole-thiophene-2-carboxamide derivative 
(Figure 1.17, 1.36), reported by Skerlj et al., displayed significant inhibition of parasite 
dihydroorotate dehydrogenase (DHODH), as well as inhibition of parasite growth.85  
 









Figure 1.17 Antiparasitic benzimidazole derivatives; a β-haematin inhibitor (1.35)84 and a 
dihydroorotate dehydrogenase inhibitor (1.36).85  
In addition to antiplasmodium activity, the activity of benzimidazole-derived compounds 
against various strains of Mycobacterium tuberculosis has been explored. The in vitro 
antimycobacterial screenings of large libraries of benzimidazole derivatives have yielded 
promising results for the use of this scaffold.75, 86, 87 The in vivo activities of some 
derivatives against TB in a murine model have also been investigated.88 A 
pyrido[1,2-α]benzimidazole reported by Pieroni et al., shown in Figure 1.18 (1.37), 
displayed good activity against five multidrug-resistant (MDR) and extensively drug-
resistant (XDR) M. tuberculosis strains.89 In another study, a nitrofuranyl benzimidazole 
(Figure 1.18, 1.38), exhibited potent activity, high bactericidal selectivity and killed 




Figure 1.18 Benzimidazole-based antimycobacterial agents; A pyrido[1,2-α]benzimidazole 
derivative (1.37)89 and a nitrofuranyl benzimidazole derivative (1.38).90  
  





1.4 Metals in medicine 
1.4.1 Background  
The application of metal-based compounds in medicinal chemistry is a research field that 
has gained significant interest over the past fifty years and has reached many different 
therapeutic areas. Compared to organic drugs, metal complexes offer diverse biological 
and chemical properties, which can be tuned through the choice of metal, oxidation states, 
ligands and various geometries.91 With this in mind, metal-based therapeutic agents are 
conferred unique redox properties, new biological targets and increased lipophilicity, 
which may result in enhanced biological activity.91, 92  
The use of metal-containing complexes in chemotherapy is thought to have begun with 
Paul Ehrlich’s discovery of an arsenic-based drug known as Salvarsan, which was used to 
treat syphilis.93 Much attention was drawn to the field of metal-based chemotherapy 
following the success of the platinum-based anticancer drug cisplatin, shown in Figure 
1.19 (1.39).94 To date, cisplatin and its derivatives are still the most widely used drugs in 
the treatment of many cancers, but their high toxicity and side effects, as well as 







Figure 1.19 Cisplatin (1.39),94 ferrocifens (1.40)97 and NKP-1339 (1.41).99 
New drug design strategies continue to be explored in order to overcome the drawbacks 
of current chemotherapies, and numerous metal-based compounds (Figure 1.19) have 
been investigated.92, 96 These strategies include the incorporation of metals into 
compounds of known therapeutic value. In this regard, Jaouen and co-workers reported 





on the potent anticancer activity of ferrocifen-type compounds (1.40), which are 
ferrocenyl derivatives of the breast cancer drug, tamoxifen.97 On the other hand, the use 
of alternative metals to platinum, which may reduce toxicity, and ligand modification 
have also been explored as important strategies for improving biological activity. 
Ruthenium complexes have featured prominently amongst metal-based anticancer 
agents, demonstrating much lower toxicity compared to platinum-based drugs.98 Most 
notably, a Ru(III)-imidazole complex (NAMI-A) and Ru(III)-indazole complexes (KP1019 
and NKP-1339) represent iconic anticancer drug candidates displaying potent activity, 
low general toxicity and tumour selectivity.99 NKP-1339 (1.41) is the latest and most 
promising analogue to reach clinical trials.100 Metal-based compounds are also being 
applied in antimalarial and antimycobacterial research. 
 
1.4.2 Metal-containing antimalarial agents 
Transition metal-based quinoline complexes 
A range of transition metals have been incorporated into the quinoline scaffold with the 
aim of enhancing the activity and overcoming resistance of P. falciparum strains.101, 102 
The first application of metal-based complexes in antimalarial research is thought to have 
been initiated by Wasi et al., who evaluated the antiplasmodium activity of transition 
metal-containing complexes of known antimalarial drugs, amodiaquine and 
primaquine.103 This modification did not result in enhanced activity. Using a similar 
principal, Sanchez-Delgado et al. incorporated rhodium and ruthenium into the CQ 
scaffold (Figure 1.20), to afford metal-CQ conjugates which were evaluated against 
P. berghei in vitro and in vivo.104 The Rh-CQ conjugate [RhCl(COD)CQ] (1.42) exhibited 
nanomolar activity, comparable to that of CQ, while the Ru-CQ conjugate [RuCl2(CQ)]2 
(1.43) was 5 times more active. However, [RhCl(COD)CQ] and [RuCl2(CQ)]2 were both 
more potent than CQ in vivo, reducing parasitemia by 73 and 94%, respectively, at low 
doses (1 mg/kg). [RuCl2(CQ)]2 was further screened in vitro against CQR FcB1 and FcB2 
strains of P. falciparum and was found to be 2-5 times more active than CQ.104 
Gold-CQ complexes have also been investigated, with varying degrees of antimalarial 
activity.105, 106 Most notably, the antimalarial properties of a cationic gold(I)-CQ complex 





were investigated. [Au(PPh3)(CQ)]PF6  (1.44) displayed IC50 values in the nanomolar 
range against the CQR FcB1 and FcB2 strains of P. falciparum.106 Screened in vivo against 
P. berghei infected mice, [Au(PPh3)(CQ)]PF6 (1.44) inhibited parasitemia by 84% at a low 
dose of 1 mg/kg, at which CQ only afforded a 44% reduction in parasitemia.106 A series of 
organometallic Ru(II)-arene complexes of CQ was evaluated against various sensitive and 
resistant strains of P. falciparum.107 The dicationic quinoline N-coordinated complex 
(1.45) presented the highest activity in the series, displaying significantly enhanced 
activity compared to CQ in the resistant Dd2, K1 and W2 strains.107 The antiplasmodium 
activity of CQ conjugates of other transition metals, such as iridium, manganese, cobalt, 





Figure 1.20 Rhodium-, ruthenium- and gold-CQ conjugates with antimalarial activity.104, 106, 107 
On the other hand, extensive work has also been done in exploring the antiplasmodium 
activity of metal-based complexes in which the aminoquinoline ligands are bound in a 
bidentate chelating mode.110-112 Stringer et al. investigated the activity of mono- and 
polynuclear N^O-coordinated Rh(I) aminoquinoline-salicylaldimine complexes against 
the sensitive NF54 and resistant K1 strain of P. falciparum.113 In general, the 









complexes. The mononuclear Rh(I) complex 1.46, shown in Figure 1.21, was the most 
potent complex in the series, displaying IC50 values of 98 and 866 nM against the NF54 




Figure 1.21 Rhodium and iridium aminoquinoline complexes with in vitro antiplasmodium 
activity.113, 114 
A series of N^N- and N^O-coordinated Rh(III) and Ir(III) aminoquinoline complexes were 
evaluated for their in vitro activity against the CQS NF54 and CQR Dd2 strains of 
P. falciparum.114 All complexes displayed nanomolar activity, with the Rh(III) complexes 
proving more potent than their Ir(III) analogues in all cases.114 The fluoro-substituted 
Rh(III) and Ir(III) complexes (1.47a and 1.47b) were most active overall. Complex 1.47a 
(0.016 and 0.20 µM) and 1.47b (0.030 and 0.26 µM) displayed IC50 values lower than and 
comparable to that of CQ (0.027 and 0.22 µM) in the NF54 and Dd2 strains, 
respectively.114 In both of the aforementioned series, the complexes were less active in 
the resistant strains, suggesting cross-resistance with CQ.113, 114 
The use of ferrocene, an organometallic sandwich compound, in potential therapeutic 
agents has garnered attention as a result of its favourable properties.115 The chemical 
stability, low toxicity, ease of derivatisation and redox accessibility of the metallocene are 
useful for biological application. The ferrocenyl derivatisation of known drugs (Figure 
1.22) is a popular strategy for enhancing efficacy and overcoming drug-resistance, 
however, it should be noted that this strategy may not be effective in all cases.115 The 
incorporation of a ferrocenyl moiety into antimalarial drugs such as quinine (1.48), 
mefloquine and artemisinin (1.49) did not lead to improved antimalarial activity 
compared to the parent compounds.116, 117 
1.47a (M = Rh) 
1.47b (M = Ir) 











Figure 1.22 Ferrocenyl conjugates of known antimalarials (1.48 – 1.50).116-118 
The incorporation of ferrocene into the lateral side chain of chloroquine by Biot et al., to 
afford ferroquine (FQ, 1.50), represents the most promising organometallic 
derivatisation in antimalarial research to date.118 In the in vitro antiplasmodium 
screening against various CQ-sensitive  and CQ-resistant strains of P. falciparum, FQ 
displayed comparable activity to CQ in the sensitive strains, and was 22-times more 
potent than CQ in the resistant strains.118 FQ was also potent in vivo against P. berghei, 
P. yoelii and P. vinckei vinckei infected mice, most significantly curing P. berghei and 
P. vinckei infections at low doses (8.3 mg/kg) compared to CQ.118, 119 FQ is thought to exert 
its antimalarial activity through a dual mode of action. In a similar manner to CQ, 
FQ accumulates in the parasite digestive vacuole, where it inhibits haemozoin 
formation.120, 121 In addition, FQ generates reactive oxygen species (ROS) under oxidising 
conditions, via Fenton-like reactions, which cause parasite damage.122 FQ is currently in 
Phase IIb clinical trials in combination with artefenomel, a synthetic trioxolane.123 
 
Transition metal-based benzimidazole complexes 
Metal-based benzimidazole complexes have been applied in antifungal studies124 and 
anticancer studies,125 however, their application as antiplasmodium agents is limited. 
The in vitro activity of a series of ferrocenyl and cyrhetrenyl benzimidazole complexes 
against the 3D7 (CQS) and W2 (CQR) strains of P. falciparum was reported by Toro 
et al.126 All complexes displayed moderate micromolar antiplasmodium activity, with the 
nitro-substituted cyrhetrenyl complex (Figure 1.23, 1.51) proving most active.126 The in 
vitro activity of ferrocenylmethyl-substituted benzimidazoles and benzimidazolium 
iodide salts in the CQS NF54 strain of P. falciparum was investigated.127 In all cases, the 
ferrocenyl benzimidazolium iodides were significantly more potent than their neutral 





counterparts, displaying IC50 values in the nanomolar range. The thiophene-substituted 





Figure 1.23 Cyrhetrenyl and ferrocenyl benzimidazole complexes (1.51 and 1.52),126,127 and a 
PGM-containing benzimidazole complex (1.53).128  
More recently, Rylands et al. investigated the antiplasmodium activity of cyclometalated 
ruthenium(II), iridium(III) and rhodium(III) benzimidazole complexes against the CQS 
NF54 and CQR K1 strains.128 These PGM-containing complexes displayed good activity in 
the low micromolar range, improved compared to the respective ligands. Overall, the 
Ru(II) and Ir(III) complexes proved more active than the Rh(III) complexes, and the 
methyl-substituted Ru(II) complex (1.53) was most potent, displaying an IC50 value of 
0.97 µM in the resistant K1 strain.128  
 
1.4.3 Metal-containing anti-tuberculosis agents 
There are numerous examples of metal-based and organometallic complexes applied in 
antimycobacterial screenings, incorporating metals such as gold,129 silver,130 platinum,131 
palladium,132 ruthenium133 and iron in the form of ferrocene.134-136 Based on the success 
of ferroquine, the strategy of ferrocenyl derivatisation of therapeutic compounds has also 
been applied in the search for new antimycobacterial agents. Pelinski and co-workers 
reported on the antimycobacterial activity of a series of ferrocenyl analogues of 
ethambutol (EMB) and isoniazid (INH), two first-line anti-TB drugs.137-139 The ferrocenyl-
INH analogues, shown in Figure 1.24 (1.54), were most potent, displaying sub-
micromolar MIC values (0.75 and 0.72 µM), better than that of EMB (9.8 µM), against the 
H37Rv strain of M. tuberculosis.139  
1.53 











Figure 1.24 Ferrocenyl-INH analogue (1.54)139 and heterobimetallic PGM-containing 
ferrocenyl-INH complexes (1.55 and 1.56).140 
Recently, N^O-coordinated iridium-, rhodium- and ruthenium-arene derivatives of a 
ferrocenyl-INH analogue were prepared and evaluated against the H37Rv strain of 
M. tuberculosis.140 These heterobimetallic PGM-containing complexes, which are shown 
in Figure 1.24 (1.55 and 1.56), displayed moderate glycerol-dependent inhibitory 
activity.140 
 
1.5 Hybrid chemotherapies 
1.5.1 History and motivation 
The current and most effective treatment for malaria and tuberculosis makes use of 
combination therapies or multi-drug regimens. The strategy is brought about by the 
emergence of drug-resistant microbes, and are utilised in order to overcome this 
resistance, reduce the risk of treatment failure and shorten treatment periods. 
Monotherapies, previously used in the treatment of both malaria and tuberculosis, are no 
longer a viable option due to the selection for resistant mutants of microbes and the speed 
with which this arises. A unique approach to achieving combination therapies is through 
molecular hybridisation or the use of hybrid chemotherapy. This strategy involves the 
combination of two or more bioactive moieties or pharmacophores into a single chemical 
compound, a ‘hybrid’.141 The combination of entities to form the hybrid agent may confer 
enhanced biological activity compared to the individual parent compounds, through 
multiple possible modes of action and enhanced uptake.141-143 The hybrid is also afforded 
new physical and chemical properties, which may attribute interesting biological 





properties to these systems. Optimisation of these properties may lead to improved 
solubility, pharmacokinetics and metabolic stability.141-143 In addition, drug resistance 
may be bypassed or overcome through the attachment of known therapeutic compounds 
to inhibitors of antimicrobial resistance mechanisms.141, 143 
 
1.5.2 Hybrid compounds against P. falciparum and M. tuberculosis 
Molecular hybridisation is an emerging strategy in drug design and discovery and has 
been well applied in numerous therapeutic areas. The field of hybrid chemotherapy has 
been dominated by hybrids designed to target nitric oxide and cyclooxygenase-mediated 
inflammatory events.144, 145 Other literature examples include hybrid agents targeting 
events mediated by histamine,146 as well as hybrids designed to inhibit enzymes such as 
metalloproteinase-1 and cathepsin L.147 With regards to infectious diseases, hybrid 
compounds have been applied in antimalarial and anti-tuberculosis research. To date, 
almost all classes of antimalarial drugs have been combined to produce hybrid 
compounds, the quinoline scaffold featuring prominently in many of these 
combinations.143, 148-151 These hybrids (Figure 1.25), combining known antimalarial and 
repurposed pharmacophores, exhibit good in vitro activity against P. falciparum, and 




Figure 1.25 Antimalarial hybrids; trioxaquine hybrid (1.57)152 and primaquine-pyrimidine 
hybrid (1.58).153 
Most significantly, Cosledan et al. investigated the antimalarial activity of a trioxaquine 
compound (PA1103/SAR116242), which combines a 1,2,4-trioxane moiety with the 
4-aminoquinoline structure.152 The 1,2,4-trioxane moiety is present in the antimalarial 
artemisinin derivatives. This trioxaquine hybrid, depicted in Figure 1.25 (1.57), was 
highly active against CQS and CQR strains of P. falciparum in vitro, exhibited good in vivo 
1.58 





efficacy in mouse models, as well as a good drug-like profile. The trioxaquine hybrid drug 
is the first antimalarial hybrid to reach clinical trials against P. falciparum.152 More 
recently, Kaur et al. investigated the antimalarial properties of a novel class of hybrids 
combining a pyrimidine-5-carboxylate with the antimalarial primaquine.153 One of the 
primaquine-pyrimidine hybrids (Figure 1.25, 1.58) displayed good blood and liver stage 
activities, suggesting dual-stage antiplasmodium activity.153 This is a promising result in 
terms of tackling resistant strains. 
Antimycobacterial hybrids have been explored to a lesser extent. Cinnamic acid-
guanylhydrazones154 and quinoline coupled 1,2,3-triazoles155 are among the hybrids 
displaying promising activity against the H37Rv strain of M. tuberculosis. A benzofuran-
isatin hybrid (Figure 1.26, 1.59) proved more potent than the first-line drug RIF against 
H37Rv and MDR-TB strains of M. tuberculosis.156 Several fluoroquinolone-isatin hybrids 
have been investigated as anti-tuberculosis agents, showing great promise.157 In a study 
by Sriram et al., a gatifloxacin-isatin hybrid (1.60) was 16- and 64-fold more potent than 
second-line drug gatifloxacin against DS-TB and MDR-TB strains, respectively.158  
Additionally, compound 1.60 was efficacious in vivo, showing a reduction in bacterial 
load in lung and spleen tissues in a mouse model.158  
 
1.59 
                                      
Figure 1.26 Antimycobacterial hybrid agents; Isatin-benzofuran hybrid (1.59)156 and 
gatifloxacin-isatin hybrid (1.60).158 
1.60 





1.5.3 Metal-based hybrid complexes 
Literature reports on the biological activity of metal-based hybrids complexes are largely 
limited to the use of ferrocene as the metal entity.151 These include ferrocenyl 
carbohydrate-aminoquinoline conjugates,159 ferroquine conjugates with glutathione-
depletors and -reductase inhibitors,160 ferrocenyl chalcone-aminoquinoline hybrids,161 
and ferroquine-thiosemicarbazone hybrids.162 Bellot et al. investigated the antimalarial 
properties of trioxaferroquines, organometallic hybrid complexes incorporating a 
1,2,4-trioxane group covalently linked to ferroquine as the bioactive moieties.163 All of 
the trioxaferroquine compounds displayed potent activity in the nanomolar range 
against CQR strains of P. falciparum. The most active trioxaferroquine hybrid (Figure 
1.27, 1.61) displayed IC50 values of 20 and 17 nM against the CQR FcB1 and FcM29 
strains, respectively. Compound 1.61 was efficacious in vivo, clearing parasitemia in P. 







Figure 1.27 Metal-containing antimalarial hybrids; trioxaferroquine hybrid (1.61),163 
Ir(III)-containing quinoline-sulfadoxine hybrid complex (1.62)164 and piperazine-linked 
aminoquinoline-ferrocenylchalcone (1.63).165 
PGM-based hybrid complexes have also been investigated for their antimicrobial activity. 
Chellan et al. reported on the antiplasmodium and antimycobacterial activity of cationic 
ruthenium(II), iridium(III) and rhodium(III) complexes of hybrids incorporating a 





quinoline moiety and the antimalarial sulfadoxine.164 The in vitro screening against 
P. falciparum and M. tuberculosis, revealed that the Ru(II) hybrid complexes were inactive 
and in general, the Rh(III) complexes were more active than their Ir(III) analogues. 
However, an Ir(III) hybrid complex (1.62) had the best antimicrobial activity overall, 
displaying nanomolar IC50 values against the CQS 3D7 and CQR Dd2 strains of 
P. falciparum.164 In a recent study, the antimycobacterial activity of piperazine-linked 
aminoquinoline-ferrocenylchalcone conjugates against the mc26230 strain of 
M. tuberculosis was evaluated.165 Ferrocenyl derivatisation resulted in enhanced 
activities compared to the organic analogues and compound 1.63 was most active 
overall.165  
There remains great scope for the preparation of metal-based hybrid complexes, and 
their application in biological studies. This is particularly true for antiplasmodium and 
antimycobacterial research. Thus, this project encompasses the combination of 
pharmacophores to prepare different series of hybrid compounds, and the incorporation 
of PGMs into these scaffolds to afford metal-containing hybrid complexes. These hybrids 
and their corresponding complexes were applied in pharmacological evaluations against 
P. falciparum and M. tuberculosis and contribute to the growing library of tested 









1.6 Aims and Objectives 
1.6.1 General aims 
The incorporation of transition metals, specifically PGMs, into the structures of 
hybrid compounds is an emerging field, and is of great interest in the design and 
development of novel therapeutic agents. The purpose of this study was to prepare and 
develop hybrid ligands and their transition metal-containing complexes as potential 
antimicrobial agents. The proposed general structure of these hybrid compounds is 




Figure 1.28: Proposed general structure of hybrid compounds to be prepared. 
 
The overall aims of the project were as follows: 
i. To prepare organic and ferrocenyl aminoquinoline-benzimidazole hybrid 
compounds (Figure 1.29). 
ii. To prepare neutral and cationic PGM-containing hybrid complexes of the most 
pharmacologically-active hybrid ligands (Figure 1.31). 
iii. To evaluate the pharmacological properties of all hybrid ligands and complexes 
against microbial strains. 
iv. To investigate potential mechanisms of antimicrobial action of the hybrid ligands 
and complexes. 
 
1.6.2 Specific objectives 
Synthetic objectives 
• The rational design and synthesis of a series of organic and ferrocenyl aminoquinoline-
benzimidazole hybrid compounds as shown in Figure 1.29. The 2-position of the 
benzimidazole was substituted with either an organic phenyl or pyridyl group, or an 
organometallic ferrocenyl group. The 5-position of the benzimidazole was varied using 
substituents from the Craig Plot (Figure 1.30), commonly used in rational drug design, 
AMINOQUINOLINE BENZIMIDAZOLE LINKER 





which categorises substituents based on hydrophobicity (π) and electron-
withdrawing/donating nature (σ).   
 
Figure 1.29 General structure of the organic and ferrocenyl aminoquinoline-benzimidazole 
hybrid compounds. 
                    
Figure 1.30 Craig Plot 
 
• The synthesis of neutral and cationic iridium(III) and rhodium(III) complexes of 
selected 2-phenyl and 2-pyridyl aminoquinoline-benzimidazole ligands, as shown in 
Figure 1.31. Complexation was achieved through C^N- and N^N-coordination modes.  






Figure 1.31 General structures of neutral and cationic PGM-containing aminoquinoline-
benzimidazole hybrid complexes. 
Characterisation 
• The full characterisation of all compounds using 1H, 13C{1H}, 31P{1H}, COSY and 
HSQC nuclear magnetic resonance (NMR) spectroscopy, infrared (IR) 
spectroscopy, and electron impact (EI) or electrospray ionisation (ESI) mass 
spectrometry. High-performance liquid chromatography (HPLC) was used to 
confirm purity and melting points were determined. The molecular structures of 
selected compounds were confirmed using single-crystal X-ray diffraction. 
 
Pharmacological studies 
• The evaluation of the hybrid ligands and PGM-containing complexes against the 
chloroquine-sensitive NF54 and multidrug-resistant K1 strains of Plasmodium 
falciparum. Cytotoxicity was determined against the non-tumorigenic Chinese 
hamster ovarian (CHO) cell-line. Selected compounds were screened for their in 
vivo efficacy against Plasmodium berghei-infected mice. 
 
• The evaluation of their activity against the H37Rv strain of Mycobacterium 
tuberculosis, in the interest of drug repurposing and repositioning. 
 





• Mechanistic studies of selected pharmacologically active hybrid compounds. 
Active compounds from each series were tested for their ability to inhibit β-
haematin formation using the NP-40 detergent-mediated assay. A cellular haem 
fractionation assay was used to confirm haemozoin inhibition. A DNA cleavage 
assay was employed to determine reactive oxygen species (ROS) generation for a 
ferrocenyl hybrid compound.  
 
• Investigation of the catalytic ability of selected Ir(III) and Rh(III) hybrid 
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Synthesis and characterisation of 2-phenyl, 2-ferrocenyl 
and 2-pyridyl aminoquinoline-benzimidazole hybrids 
 
2.1 Introduction 
As mentioned in Chapter 1, molecular hybridisation has become an increasingly popular 
strategy in drug design and discovery.1 The design of such hybrids has become a more 
rational process, where careful consideration is given to the possible intracellular targets 
and modes of action of the pharmacophore building blocks.2, 3 Once the pharmacophore 
building blocks and appropriate binding sites have been chosen, the nature of the 
intermolecular linker becomes the next important consideration. Based on how the 
hybrid drug is designed to act, a linker with the desired properties is used. A linker 
capable of intracellular cleavage (cleavable linker) allows the hybrid to dissociate into 
individual active components and act independently.2, 3 Alternatively, a linker which is 
resistant to metabolic cleavage (non-cleavable linker) would allow the hybrid to remain 
intact and act as one intracellularly.2, 3 The latter may be desirable in cases where the aim 
is to overcome drug resistance and an overall synergistic effect is required.  
Based on the past success of antimalarial drugs such as chloroquine (CQ) and 
amodiaquine, 4-aminoquinolines have featured prominently in antimalarial hybrid 
literature. Some examples of 4-aminoquinoline hybrids in the literature include 
combinations with triazines,4 pyrimidines,5 triazoles,6 and most notably trioxanes.7, 8 CQ 
and other 4-aminoquinolines act against the pathogenic erythrocytic stage of the 
Plasmodium life cycle.9-11 CQ interferes with the parasite haem degradation pathway by 
inhibiting haemozoin formation in the acidic digestive vacuole, and thereby, kills the 
parasite.9-11 Resistant Plasmodium falciparum mutants have developed a CQ resistance 
transporter (PfCRT), which transports CQ out of the digestive vacuole, resulting in lower 
accumulation and decreased activity.12 The design of hybrid compounds to overcome 
such mechanisms of resistance is of paramount importance in drug discovery. 




Burgess et al. reported on the synthesis, in vitro antiplasmodium activity and in vivo 
antimalarial efficacy of a CQ-like hybrid designed to reverse or overcome resistance in 
resistant P. falciparum strains.13 The hybrid structure, shown in Figure 2.1 (I), 
encompasses a chloroquine analogue covalently linked to an analogue of imipramine,13 a 
reversal agent (RA) which is hypothesised to inhibit PfCRT-associated CQ expulsion from 
the digestive vacuole.14 In the in vitro screening, the hybrid maintained comparable low 
nanomolar IC50 values in both D6 (CQS) and Dd2 (CQR) strains, unlike the CQ control, 








Figure 2.1 Chloroquine-imipramine hybrid (I).13 
On the other hand, the benzimidazole scaffold represents another important class of 
heterocyclic pharmacophores. There are a number of benzimidazole-based drugs across 
the different pharmacological areas such as anti-tumour, antimicrobial, antiviral and 
antihistaminic to name a few.15  The search for new benzimidazole-based agents for 
infectious diseases such as malaria and TB is ongoing, as reflected in the literature.15-17 
With regards to malaria, potential modes of action of benzimidazole derivatives have 
been elucidated. These include β-haematin (synthetic haemozoin) inhibition,18, 19 as well 
as inhibition of parasitic dihydroorotate dehydrogenase (DHODH).20  
Work by Chong et al. brought to light the antimalarial properties of benzimidazole-based 
antihistamine drug astemizole.21 Following on from this, Musonda et al. reported on the 
synthesis and potent in vitro antiplasmodium activity and in vivo antimalarial activity of 
chloroquine-astemizole hybrids, shown in Figure 2.2.22 In the K1 (CQR) strain of 
P. falciparum, hybrids III, IV and V were 3- to 10-fold more active in vitro than CQ, with 
IC50 values in the range 0.023 – 0.064 µM.22 In addition, these hybrids displayed 
favourable cytotoxicity and in vivo antimalarial profiles.22  
CQ analogue 
imipramine analogue - RA 












Figure 2.2 Chloroquine-astemizole hybrids.22 
As seen for the chloroquine-imipramine hybrid, these chloroquine-astemizole hybrids 
demonstrate the potential to overcome or circumvent P. falciparum resistance using the 
hybrid approach. Based on these promising reports, this chapter focusses on the 
synthesis and characterisation of organic and organometallic aminoquinoline-
benzimidazole hybrids with a non-cleavable propyl chain linker.   
 
2.2 Results and Discussion 
2.2.1 Synthesis and characterisation of nitro-containing and 1,2-diamine 
aminoquinoline precursors 
Synthesis  
The aminoquinoline precursor, N1-(7-chloroquinolin-4-yl)-propane-1,3-diamine (1), was 
prepared using a modified literature method.23 The nitro-containing precursors 2a – 2e 
and 1,2-diamine precursors 3a – 3e were prepared as illustrated in Scheme 2.1. 
Compound 1 was reacted with various nitrobenzene halide derivatives in N,N-
dimethylformamide (DMF) to afford the five nitro-containing aminoquinoline precursors 
(2a – 2e), via nucleophilic aromatic substitution reactions. Compounds 2a – 2e were 
isolated as bright yellow and orange powders in moderate yields (43 – 57%), displaying 
partial solubility in polar organic solvents.  The nitro group in compounds 2a – 2e was 




reduced by reaction with a zinc powder reducing agent, in the presence of ammonium 
chloride in anhydrous methanol. These reactions were performed under nitrogen 
atmosphere and the desired compounds (3a – 3e) were isolated as either brown, beige, 
pink or purple powders, in high yields (76 – 98%). Compounds 3a – 3e display solubility 
in alcoholic solvents, as well as enhanced solubility in polar organic solvents such as 
dichloromethane, ethyl acetate and chloroform, compared to their nitro-containing 
precursors. 
 
Scheme 2.1 Synthesis of aminoquinoline-containing precursors 1, 2a – 2e and 3a – 3e. 
Reagents and conditions (i) 1,3-diaminopropane / 140 °C / 17 h; (ii) nitrobenzene 
derivative / DMF / 25 °C / 24 h; (iii) Zn / NH4Cl / MeOH / rt / 24 h. 
 
Motivation for the choice of X group 
In this study, the substituent (X) at the 5-position of the benzimidazole moiety was varied 
with different groups chosen from the Craig Plot, which is often used in rational drug 
design. The Craig Plot categorises substituents based on their differing hydrophobicity 
(π) and electron-withdrawing/donating nature (σ). Specific substituents (CH3, CF3, 
SO2CH3 and CN) were chosen in order to probe the effect of the varying hydrophobic and 
electron-withdrawing/donating properties on the biological activity. 





The nucleophilic aromatic substitution reaction proceeds via the proposed mechanism 
shown in Figure 2.3. The lone pair of electrons on the primary amine of N1-(7-
chloroquinolin-4-yl)-propane-1,3-diamine (1) acts as the nucleophile, attacking the 
electrophilic aromatic halide-bonded carbon atom, in a nucleophilic addition (AN) step. 
This results in the delocalisation of electrons in the phenyl ring and through the nitro 
group. The nitro group of 1-fluoro-2-nitrobenzene is an activator toward nucleophilic 
substitution. Delocalisation of the negative charge into the phenyl ring results in 
elimination (E) of fluoride. Subsequent proton transfer generates a hydrogen halide (HF) 
and the desired product, N1-(7-chloroquinolin-4-yl)-N3-(2-nitrophenyl)-propane-1,3-
diamine (2a). 
 
Figure 2.3 Nucleophilic aromatic substitution reaction mechanism in the formation of 
compound 2a.  
The reduction of a nitro group to an amine using zinc and ammonium chloride is 
proposed to occur by a succession of one-electron transfer steps, where zinc is the 
electron donor. Ammonium chloride in methanol provides mildly acidic conditions. The 
reaction proceeds via an N-phenyl hydroxylamine intermediate (R-NHOH), which is 
further reduced to afford the desired primary amine (R-NH) product. 
 
 





Compounds 2a – 2e and 3a – 3e were fully characterised using 1H and 13C{1H} nuclear 
magnetic resonance (NMR) spectroscopy, infrared (IR) spectroscopy and electron impact 
mass spectrometry (EI-MS). All characterisation attests to the successful synthesis of the 
desired products.  
NMR spectroscopy 
The 1H NMR spectrum of compound 2a, shown in Figure 2.4, displays aromatic proton 
signals at 8.39, 8.25, 7.79, 7.45 and 6.49 ppm for the five protons of the quinoline moiety. 
The four protons of the disubstituted phenyl ring are observed as four signals at 8.06, 
7.50, 7.08 and 6.68 ppm, respectively. The amine proton adjacent to the phenyl moiety 
gives rise to a triplet at 8.20 ppm, and the amine proton adjacent to the quinoline moiety 
gives rise to a triplet at 7.35 ppm. The presence of the additional signals for the aromatic 
and amine protons confirms successful aromatic substitution.  
 
Figure 2.4 The 1H NMR spectrum of compound 2a in DMSO-d6.  
Additionally, the N-substituted methylene (CH2) protons are observed as quartets at 3.51 
and 3.40 ppm, respectively, both CH2 groups coupling to their adjacent NH groups. The 
two more shielded methylene protons are displayed as a multiplet at 2.03 ppm. All 


























The 1H NMR spectra of compounds 2b – 2e display peaks corresponding to the protons 
of the quinoline moiety and propyl spacer at similar chemical shifts, with similar 
multiplicities and coupling constants to that of compound 2a.  However, there is one 
fewer aromatic proton and, depending on the electronic nature of the phenyl ring 
substituent (X), the chemical shifts of the phenyl proton signals differ (shifting upfield 
or downfield) compared to that of compound 2a. The stacked 1H NMR spectra of 
compounds 2b and 2d are shown in Figure 2.5 as an example of this trend. The 
methylsulfonyl (SO2CH3) and trifluoromethyl (CF3) groups of compounds 2d and 2c are 
electron-withdrawing, while the methyl (CH3) of compound 2b is inductively electron-
donating in nature. As denoted by the asterisk in Figure 2.5, the triplet signal for the 
phenyl amine proton shifts significantly downfield in the spectrum of compound 2d 
(8.70 ppm), and shifts slightly upfield in compound 2b (8.12 ppm), compared to that of 
compound 2a (8.21 ppm).  
 
Figure 2.5. Stacked 1H NMR spectra of compounds 2a, 2b and 2d.  
The 13C{1H} NMR spectra of compounds 2a – 2e display all expected carbon atom signals. 
The aromatic carbon atoms of the quinoline and phenyl moieties give rise to fifteen 
signals in the characteristic region between 152 and 99 ppm. The signals assigned to the 
nitro-substituted carbon atoms appear relatively downfield between 144 and 148 ppm.  
The signals corresponding to the three methylene carbon atoms are observed between 
41 and 27 ppm. Additionally, the spectra of compounds 2b and 2d display a signal at 19.9 
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methylsulfonyl groups, respectively. The trifluoromethyl carbon atom and CF3-
substituted aromatic carbon atom of compound 2c give rise to signals between 130 and 
110 ppm, appearing as multiplets as a result of 13C-19F coupling.  
The 1H NMR spectrum of compound 3a is shown in Figure 2.6. The two protons of the 
new amine group give rise to a broad singlet at 4.49 ppm, giving evidence of reduction of 
the nitro group in compound 2a. The protons of the secondary amine adjacent to the 
phenyl group appears at 4.44 ppm, overlapping with the new primary amine signal. The 
five signals corresponding to the aromatic quinoline protons are retained at similar 
chemical shifts to that seen in the spectrum of nitro-containing precursor 2a. However, 
the electron-donating effect of the amine (NH2) group, which replaces the electron-
withdrawing nitro (NO2) group, has an overall shielding effect on the protons of the 
phenyl moiety, resulting in the coalescence of these signals between 6.57 and 6.39 ppm. 
These signals are more upfield compared to compound 2a. This provides further 
evidence of amine formation.  Once again, the two groups of methylene protons adjacent 
to the amine groups give rise to quartets at 3.41 and 3.18 ppm, respectively, and the more 
shielded methylene CH2 signal appears at 2.00 ppm.  
  
Figure 2.6 The 1H NMR spectrum of compound 3a in DMSO-d6.  
The 1H NMR spectra of compounds 3b – 3e retain the proton signals of the quinoline 



























constants to that of their respective precursors. The electronic nature of the phenyl ring 
substituent (X) has shielding and deshielding effects on the phenyl aromatic and amine 
protons (NH and NH2) only. The stacked NMR spectra of compounds 3a, 3b and 3d, 
displayed in Figure 2.7, show these effects. Compared to compound 3a, the methyl group 
of compound 3b has a shielding effect, shifting the aromatic, NH and NH2 proton signals 
slightly upfield. The trifluoromethyl group of compound 3c has an overall deshielding 
effect, shifting the aromatic, NH an NH2 proton signals significantly downfield. 
 
Figure 2.7 Stacked 1H NMR spectra of compounds 3a, 3b and 3d. 
The 13C{1H} NMR spectra of compounds 3a – 3e display all expected peaks. The carbon 
atoms of the quinoline moiety and propyl spacer give rise to signals at similar chemical 
shifts to that seen in the spectra of the nitro-containing precursors. However, the signals 
corresponding to the carbon atoms of the phenyl group show a significant upfield shift 
due to the electron-donating nature of the new primary amine group. 
Infrared spectroscopy 
The solid-state infrared analysis of compounds 2a – 2e and 3a – 3e was carried out using 
Fourier Transform Infrared (FT-IR) spectroscopy, utilising Attenuated Total Reflectance 
(ATR). The IR spectra of compounds 2a – 2e display several significant absorption bands 
which further confirm their structures. Two amine ν(N-H) absorption bands are observed 
around 3300 cm-1, as well as two bands corresponding to the ν(N-O) absorption around 
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between 1609 and 1621 cm-1. These spectra also display an alkenyl ν(C=C) stretch 
between 1560 and 1580 cm-1, for the aromatic rings of compounds 2a – 2e. Additionally, 
the IR spectrum of compound 2c displays a ν(C-F) absorption band corresponding to the 
trifluoromethyl moiety at 1324 cm-1, compound 2d displays ν(S=O) bands of the sulfonyl 
moiety at 1368 and 1136 cm-1, and the spectrum of compound 2e has a characteristic 
nitrile (C≡N) absorption band at 2222 cm-1. These characteristic absorption bands for 
the X substituents are retained in the spectra of compounds 3c – 3e. The IR spectra of 
compounds 3a – 3e display four characteristic stretches. As expected, two ν(N-H) bands 
are present around 3400 and 3300 cm-1, and the alkenyl ν(C=C) band appears at 
1580 cm-1. The quinoline ν(C=N) absorption band has shifted to a slightly lower 
wavenumber (1607 – 1611 cm-1) compared to that in the respective precursors.  
Mass spectrometry 
The masses of the aminoquinoline precursors were determined using EI-MS. The mass 
spectra of compounds 2a – 2e and 3a – 3c reveal peaks corresponding to the molecular 
ions [M]+, while the spectra of compounds 3d and 3e display peaks for the protonated 
molecular ion [M+H]+. These results further confirm the structures of the desired 
compounds. The experimental and calculated m/z values are summarised in Table 2.1.  
Table 2.1 Experimentally determined m/z values and their corresponding calculated values for 
compounds 2a – 2e and 3a – 3e.  
Compound Found m/z Calculated m/z 
2a 355.95 [M]+ 356.10 
2b 370.04 [M]+ 370.12 
2c 423.99 [M]+ 424.09 
2d 433.97 [M]+ 434.08 
2e 381.02 [M]+ 381.10 
3a 326.10 [M]+ 326.13 
3b 340.15 [M]+ 340.15 
3c 394.11 [M]+ 394.12 
3d 405.12 [M+H]+ 405.11 
3e 352.14 [M+H]+ 352.14 
 




2.2.2 Synthesis and characterisation of 2-phenyl, 2-ferrocenyl and 2-pyridyl 
aminoquinoline-benzimidazole hybrids  
Synthesis 
The final step in the synthetic route for the preparation of the aminoquinoline-
benzimidazole hybrid targets, was the cyclo-condensation reaction of the 1,2-diamine 
precursors with various aldehydes. Compounds 3a – 3e were reacted with either 
benzaldehyde, ferrocenecarboxaldehyde or 2-pyridinecarboxaldehyde in the presence of 
a catalytic amount of trifluoroacetic acid (TFA) and anhydrous magnesium 
sulphate in ethanol. These reactions afforded 2-phenylbenzimidazoles 4a – 4e, 
2-ferrocenylbenzimidazoles 5a – 5e and 2-pyridylbenzimidazoles 6a – 6c as shown in 
Scheme 2.2.  
 
Scheme 2.2 Synthesis of 2-phenyl, 2-ferrocenyl and 2-pyridyl aminoquinoline-benzimidazole 
hybrids. Reagents and conditions (i) benzaldehyde / TFA / MgSO4/ EtOH / 80 °C / 24 h; (ii) 
ferrocenecarboxaldehyde / TFA / MgSO4 / EtOH / 80 °C / 48 h; (iii) 2-pyridinecarboxaldehyde / 
TFA / MgSO4 / EtOH / 80 °C / 24 h. 




Compounds 4a – 4e were isolated as either white, beige or pale-yellow powders in 
moderate to good yields (61 – 81%), while compounds 5a – 5e were isolated as orange 
powders in moderate yields (44 – 64%) and compounds 6a – 6c were isolated as yellow 
or beige powders in moderate yields (59 – 64%). All of the 2-substituted benzimidazole 
hybrids are soluble in polar organic solvents such as dichloromethane and ethanol, and 
insoluble in non-polar organic solvents. 
Reaction mechanism 
The cyclo-condensation reaction mechanism for the formation of benzimidazoles from 
1,2-diamines and aldehydes under acidic conditions is not well described in the 
literature. Two recent articles proposed a mechanism for the formation of 
benzimidazoles from o-phenylenediamine and aldehydes under acidic conditions 
(p-toluenesulfonic acid or ammonium acetate).24, 25 Based on these reports, the proposed 
cyclo-condensation reaction mechanism for the formation of these aminoquinoline-
benzimidazole hybrids is depicted in Figure 2.8.  
The presence of a catalytic amount of TFA activates the carbonyl group towards 
electrophilic attack. The lone pair of electrons on the secondary amine acts as the 
nucleophile, attacking the carbonyl carbon atom. This is followed by proton transfer and 
dehydration to form a reactive iminium ion intermediate. The primary amine nucleophile 
then attacks the benzylic carbon atom (δ+) and subsequent proton transfer results in the 
formation of a dihydrobenzimidazole derivative. The final step in the proposed 
mechanism involves the oxidation of this derivative to afford the desired 
benzimidazole 4a. As oxidation is required to form the double bond, the reaction must 
proceed under oxidative conditions. Literature has reported on the use of air or oxidising 
agents such as copper(II) acetate, sodium metabisulfite, mercuric acetate and lead 
tetraacetate for this purpose.17, 26 In this study, oxidation was brought about by air.  





Figure 2.8 Proposed cyclo-condensation reaction mechanism in the formation of compound 4a.  
The proposed mechanism shown in Figure 2.8 depicts the secondary amine as the initial 
nucleophile, on the basis that it is the stronger nucleophile of the two amines. In general, 
in the absence of special circumstances, nucleophilicity follows the same trend as basicity, 
which would imply that the more substituted amine is more basic and thus more 
nucleophilic. Alternatively, the primary amine could initiate the nucleophilic attack on 
the electrophilic carbon atom, forming an alternate reactive iminium intermediate 
(under acidic conditions). The secondary amine would then execute the second 
nucleophilic attack on this intermediate, which, followed by air oxidation would afford 
the same desired product 4a.   
Characterisation 
The organic and organometallic aminoquinoline-benzimidazole hybrids discussed here 
were fully characterised by NMR and IR spectroscopy, and high-resolution electrospray 
ionisation mass spectrometry (ESI-MS). The 1H and 13C{1H} NMR assignments were made 
with the aid of 2D NMR experiments such as correlation spectroscopy (COSY) and 
heteronuclear single-quantum correlation spectroscopy (HSQC). 





The 1H NMR spectrum of compound 4a, shown in Figure 2.9, displays distinct signals at 
8.35, 8.14, 7.80, 7.44 and 6.31 ppm, corresponding to the five quinoline protons. The 
remaining aromatic protons of the benzimidazole and 2-phenyl moiety, as well as the 
secondary amine proton, are observed as two overlapping multiplet signals between 7.72 
and 7.20 ppm.  
 
Figure 2.9 The 1H NMR spectrum of compound 4a in DMSO-d6. 
The signals in the region 8.50 – 6.00 ppm collectively integrate for fourteen aromatic 
protons, confirming incorporation of the 2-phenyl moiety, compared to the precursor 3a 
(nine aromatic protons), and that the correct structure has been formed. No other amine 
proton signals are present in the spectrum, giving further evidence of cyclisation. The 
signal for the methylene protons adjacent to the newly formed benzimidazole moiety 
shows a significant downfield shift compared to that of compound 3a, appearing as a 
triplet at 4.47 ppm. This provides further evidence of cyclisation, as this shift results from 
the electron-withdrawing inductive effect of the benzimidazole moiety. Furthermore, the 
remaining two groups of methylene protons give rise to a quartet (3.20 ppm) and pentet 






















As seen in the 1H NMR spectrum of compound 4a (Figure 2.9), the aromatic protons of 
compounds 5a – 5e give rise to a series of distinct signals and overlapping multiplets in 
the region between 8.45 and 6.62 ppm. The 1H NMR spectrum of compound 5a is shown 
in Figure 2.10. Evidence of cyclisation with the ferrocenyl moiety is seen in the presence 
of a singlet (3.99 ppm) corresponding to the protons of the unsubstituted 
cyclopentadienyl (Cp) ring, as well as two triplets (4.75 and 4.14 ppm) for the four 
protons of the substituted Cp ring. 
 
Figure 2.10 The 1H NMR spectrum of compound 5a in DMSO-d6. 
Further evidence of cyclisation can be seen in the downfield shift of the triplet 
corresponding to the methylene protons adjacent to the new benzimidazole moiety, 
which now appears at 4.62 ppm. The remaining methylene protons are observed as a 
quartet and pentet at 3.60 and 2.23 ppm, respectively. 
The 1H NMR spectrum of compound 6a is displayed in Figure 2.11. Signals corresponding 
to the five quinoline protons are present at 8.34, 8.21, 7.79, 7.44 and 6.34 ppm. The four 
protons of the 2-substituted pyridyl ring give rise to peaks at 8.48, 8.27, 7.91 and 


























benzimidazole moiety and the quinoline amine proton give rise to two overlapping 
multiplet signals between 7.75 and 7.25 ppm, integrating for five protons. Furthermore, 
signals for the protons of the propyl spacer are present at 4.99 (triplet), 3.29 (overlapping 
with the H2O signal) and 2.23 ppm (pentet). 
 
Figure 2.11 The 1H NMR spectrum of compound 6a in DMSO-d6. 
The 1H NMR spectra of compounds 4b – 4e, 5b – 5e and 6b – 6c shows some variation 
from that of compounds 4a, 5a and 6a, respectively. The quinoline and amine protons 
show no significant shift, appearing at similar chemical shifts across all spectra. The 
aromatic protons of the newly formed benzimidazole ring shift depending the electronic 
effect of substituent at the 5-position. There is one less aromatic proton on the 
benzimidazole, and thus the signals in the aromatic region show less overlap and are 
more distinct, as depicted in Figure 2.12 for compounds 4b and 4c. The methyl group of 
compound 4b has an inductively electron-donating effect, shifting the aromatic proton 
signals of the benzimidazole moiety upfield, to lower chemical shifts. The trifluoromethyl 
group of compound 4c has an electron-withdrawing effect, resulting in the aromatic 
benzimidazole protons resonating more downfield, at higher chemical shifts. 
Additionally, a singlet for the methyl protons (CH3) of compounds 4b, 5b and 6b appears 
around 2.4 ppm, and the methyl protons (SO2CH3) of compounds 4d and 5d resonate 


























Figure 2.12 The aromatic region of the 1H NMR spectra of compounds 4b and 4c in DMSO-d6. 
The 13C{1H} NMR spectra of compounds 4a – 4e, 5a – 5e and 6a – 6c display all expected 
signals in the appropriate regions. All aromatic carbon atoms resonate between 156 and 
99 ppm, while the methylene carbons give rise to three signals between 44 – 28 ppm. 
With the formation of the 2-substituted organic and organometallic benzimidazole 
moiety, new peaks are introduced into the spectra compared to the 1,2-diamine 
precursors. In addition to the new imine carbon, the spectra of compounds 4a – 4e and 
6a – 6c gain seven and six additional carbons, respectively.  The 2-ferrocenyl hybrids gain 
an imine carbon as well as ten Cp carbons. In the spectra of compounds 5a – 5e, these 
ferrocenyl carbons resonate as four distinct signals between 74.3 and 69.0 ppm; one 
signal for the quaternary Cp carbon, two signals for the four carbons of the substituted 
Cp ring, and one intense signal for the five carbons of the unsubstituted Cp ring. 
Infrared spectroscopy 
The IR spectra of compounds 4a – 4e, 5a – 5e and 6a – 6c differ slightly from that of their 
1,2-diamine precursors, possessing the same characteristic absorption bands at slightly 
different wavenumbers. There is only one amine ν(N-H) absorption band around 
3200 cm-1 for the lone quinoline amine moiety, compared to two bands (around 3400 and 
3300 cm-1) for the corresponding precursors. The alkenyl ν(C=C) stretch is retained and 
appears between 1570 and 1580 cm-1. In addition, the ν(C=N) band, which corresponds 














between 1609 and 1613 cm-1. Compounds 6a – 6c give rise to an additional ν(C=N) 
absorption band for the pyridyl moiety at the 2-position of the benzimidazole. This band 
appears in the region 1590 – 1592 cm-1, slightly overlapping with the ν(C=C) band. The 
ν(C=N) bands of compounds 4b, 5b and 6b are shown in Figure 2.13. Furthermore, there 
are several diagnostic absorption bands present in the spectra. The trifluoromethyl 
ν(C-F) absorption band of compounds 4c, 5c and 6c appears around 1330 cm-1, the two 
sulfonyl ν(S=O) bands of compounds 4d and 5d are observed around 1367 cm-1 and in 
the region 1130 – 1170 cm-1, while compounds 4e and 5e have nitrile a ν(C≡N) band 
between 2214 and 2222 cm-1.  
 
Figure 2.13 Stacked IR spectra of compounds 4b, 5b and 6b. 
Mass spectrometry 
The masses of the 2-substituted aminoquinoline-benzimidazole hybrids (4a – 4e, 5a – 5e 
and 6a – 6c) were determined using high-resolution ESI-MS. Analysed in the positive 
mode, the mass spectra of the synthesised organic and organometallic hybrids all display 
similar fragmentation patterns. The experimentally determined m/z values and their 















Table 2.2 Experimentally determined m/z values and their corresponding calculated values for 
compounds 4a – 4e, 5a – 5e and 6a – 6c.  
Compound Base peak (100% abundant) 
Found m/z Calculated m/z 
4a 413.1534 [M+H]+ 413.1528 
4b 214.0882 [M+2H]2+ 427.1684 
4c 481.1410 [M+H]+ 481.1401 
4d 246.0693 [M+2H]2+ 246.0688 
4e 219.5773 [M+2H]2+ 219.5776 
5a 521.1207 [M+H]+ 521.1190 
5b 268.0718 [M+2H]2+ 268.0710 
5c 295.0572 [M+2H]2+ 295.0568 
5d 599.0969 [M+H]+ 599.0965 
5e 273.5657 [M+2H]2+ 273.5608 
6a 414.1485 [M+H]+ 414.1480 
6b 428.1644 [M+H]+ 428.1637 
6c 482.1353 [M+H]+ 482.1354 
 
In the spectra of compounds 4a, 4c, 5a, 5d, 6a, 6b and 6c, the [M+H]+ fragment is 
observed as the 100% abundant base peak. For the remaining compounds 4b, 4d, 4e, 5b, 
5c and 5e, base peaks corresponding to the [M+2H]2+ fragment are observed in the mass 
spectra. For the compounds with the [M+2H]2+ fragment as the base peak, the next most 
abundant peak in each spectrum corresponds to the [M+H]+ fragment.  
Molecular structures 
Crystals of compounds 4b and 5c, suitable for single-crystal X-ray diffraction, were 
obtained and analysed. Crystals of compound 4b were obtained by crystallisation in 
DMSO-d6, forming colourless block crystals in a monoclinic crystal system with the P21/c 
space group. Crystals of compound 5c were obtained by slow evaporation in 
dichloromethane, forming red block crystals in a triclinic crystal system with the P1̅ space 
group. The molecular structures of compounds 4b and 5c are shown in Figure 2.14 and 
Figure 2.15, respectively.  





Figure 2.14 Molecular structure of compound 4b at 40% probability ellipsoids (CCDC 1907165). 
 
Figure 2.15 Molecular structure of compound 5c at 40% probability ellipsoids (CCDC 1907167). 
Selected bond lengths and angles are reported in Table 2.3 and crystallographic data in 
Table 2.4. The C(benzimidazole)-C(phenyl/ferrocenyl) bonds of 4b and 5c are similar in 
length, as well as the C(benzimidazole)-C(CH3/CF3) bonds. The C-F bonds of compound 
5c vary in length (1.330, 1.314 and 1.341 Å), in the range corresponding with lengths 
expected for this strong polar covalent bond. It is worth noting that in both 4b and 5c, the 
benzimidazole and its 2-substituted ring (phenyl for 4b and substituted Cp for 5c) are 
not co-planar. The torsion angle between the two ring systems is 45.2° in compound 4b 
and a significantly lower value of 17.5° in compound 5c. 




Table 2.3 Selected bond lengths and torsion angles of compounds 4b and 5c. 
 4b 5c 
Bond lengths (Å)   
C(13) – C(20) 1.471(2) –  
C(1) – C(6) – 1.456(3) 
C(16) – C(26) 1.508(3) – 
C(9) – C(13) – 1.498(4) 
C(13) – F(1) – 1.330(3) 
C(13) – F(2) – 1.341(3) 
C(13) – F(3) – 1.314(4) 
Torsion angles (°)   
N(3) – C(13) – C(20) – C(25) 45.2(2) – 
C(2) – C(1) – C(6) – N(2) – 17.5(4) 
 
Table 2.4 Crystallographic data for compounds 4b and 5c. 
 4b 5c 
Chemical formula  C26H23ClN4   C30H24ClF3FeN4 
Formula weight 426.93 588.83 
Crystal system  Monoclinic Triclinic 
Space group P21/c P1̅ 
Crystal size (mm) 0.09 x 0.14 x 0.26 0.10 x 0.22 x 0.27 




α, β, γ (°) 90, 102.539(2), 90 65.375(2), 82.417(3), 68.426(2) 
V/ Å3 2185.6(3) 1384.0(3) 
Z 4 2 
T/K 173 173 
Dc/g.cm-3 1.298 1.413 
µ/mm-1 0.196 0.688 
Scan range/° 2.0 < θ < 27.2 1.8 < θ < 28.4 
Unique reflections  4838 6923 
Reflections used [I>2σ(I)]  3637 5461 
Rint  0.067 0.050 
R indices (all data) R 0.0381, wR2 0.0952, S 1.03 R 0.0438, wR2 0.1168, S 1.05 
Goodness-of-fit 1.03 1.05 
Max, Min Δρ/e Å  -0.29, 0.22 -0.75, 0.60 




2.3 Summary  
Five new nitro-containing aminoquinoline precursors (2a – 2e) were synthesised via 
nucleophilic aromatic substitution (SNAr) reactions with various nitrobenzene halide 
derivatives.  Compounds 2a – 2e were isolated as yellow or orange powders in moderate 
yields, displaying limited solubility in polar organic solvents. The nitro groups of 
compounds 2a – 2e were subsequently reduced using zinc and ammonium chloride, to 
afford 1,2-diamine aminoquinoline precursors 3a – 3e. These brown, white, purple and 
pink powders were isolated in high yields (> 85%), displaying enhanced solubility in 
polar organic solvents. The aminoquinoline precursors were characterised using various 
spectroscopic and analytical techniques, such as 1H and 13C{1H} NMR spectroscopy, IR 
spectroscopy and electron impact mass spectrometry (EI-MS). 
The 1,2-diamines were reacted with benzaldehyde or ferrocenecarboxaldehyde in a 
cyclo-condensation reaction to yield organic 2-phenylbenzimidazoles 4a – 4e or 
organometallic 2-ferrocenylbenzimidazoles 5a – 5e. Based on preliminary 
pharmacological results, selected aminoquinoline-benzimidazole hybrid scaffolds were 
altered to incorporate a pyridyl moiety. Compounds 3a – 3c were cyclo-condensed with 
2-pyridinecarboxaldehyde to afford 2-pyridylbenzimidazoles 6a – 6c. These cyclo-
condensation reactions produced moderate yields. Crystals of compounds 4b and 5c 
were grown and their molecular structures determined using single-crystal X-ray 
diffraction. The compounds were fully characterised using 1H, 13C{1H}, COSY and HSQC 
NMR spectroscopy, IR spectroscopy and electrospray ionisation mass spectrometry 
(ESI-MS). The purity of the aminoquinoline-benzimidazole hybrids was determined by 
HPLC and all confirmed to be greater than 97%.  
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Pharmacological evaluation and mechanistic studies of 




In the continued search for antimicrobial agents, the determination of in vitro drug 
efficacy represents a crucial preliminary step in the discovery process. For the various 
infectious diseases, in vitro screening protocols and detection methods have evolved over 
the years. With regards to Plasmodium falciparum, in vitro assays take advantage of the 
fact that asexual parasites can be cultured in vitro in human erythrocytes, to which 
multiple sensitive and resistant strains have been adapted. The cultured parasites are 
then dosed with different concentrations of the test compound and control drugs, such as 
chloroquine. Numerous assay protocols have been described, including assessment of 
3H-hypoxanthine uptake inhibition1 and the microscopic analysis of Giemsa-stained 
parasites.2, 3 Flow cytometry2, 3 and fluorescence-based4 approaches have also been 
described in recent literature.  
Another assay protocol involves the determination of Plasmodium lactate dehydrogenase 
(pLDH) activity,5 which was used to evaluate the compounds herein. This enzyme assay 
is based on the ability of lactate dehydrogenase (LDH) to catalyse the conversion of 
lactate to pyruvate, using 3-acetyl pyridine adenine dinucleotide (APAD) as a co-
enzyme.5, 6 APAD is reduced to 3-acetyl pyridine adenine dinucleotide reduced (APADH) 
in the process and its formation forms the basis of this assay. Human LDH catalyses this 
glycolytic reaction at a very slow rate, while pLDH rapidly catalyses the conversion.5 
Levels of parasitemia correlate well with pLDH activity, which is assessed 
colorimetrically, as illustrated in Figure 3.1. Parasite viability is detected using the 
MalstatTM method, which involves the addition of a tetrazolium dye.6, 7 The APADH 




formed reduces the tetrazolium dye (yellow) to formazan (blue) in the presence of 
phenazine ethosulfate.  
 
Figure 3.1 Principle of pLDH assay and MalstatTM method, used to determine parasite viability. 
Cytotoxicity studies are often undertaken to determine the effect of test compounds on 
tumorigenic and non-tumorigenic cell lines. These screenings also aid in evaluating 
selectivity toward various microbes or cells. A common assay protocol assessing 
cytotoxicity is the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay, which is also a colorimetric tetrazolium-based method.8-10 In terms of 
Mycobacterium tuberculosis, there are a number of methods for determination of 
antibacterial susceptibility of test compounds.11 Dilution methods allow the 
determination of minimum inhibitory concentrations (MICs), while disk diffusion 
methods generate results as zone diameter measurements.11   
 
3.2 Pharmacological evaluation of aminoquinoline-benzimidazole hybrids 
The pharmacological properties of the 2-phenyl, 2-ferrocenyl and 2-pyridyl 
aminoquinoline-benzimidazole hybrids (Figure 3.2), described in Chapter 2, were 
investigated. The hybrid compounds were screened in vitro against the NF54 
chloroquine-sensitive (CQS) and K1 multidrug-resistant (MDR) strain of Plasmodium 
falciparum and their cytotoxicity was determined against the Chinese Hamster Ovarian 
(CHO) non-tumorigenic cell-line. Selected active and non-cytotoxic phenyl and ferrocenyl 
hybrids were evaluated for their in vivo efficacy in a Plasmodium berghei mouse model. 
Mechanistic studies to investigate the potential cell-free β-haematin inhibition activity, 




cellular haemozoin inhibition activity and reactive oxygen species (ROS) generating 
ability, were performed on selected compounds. Furthermore, all hybrid compounds 
were evaluated for their in vitro antimycobacterial activity against the H37Rv strain of 
Mycobacterium tuberculosis.  
 
Figure 3.2 Pharmacologically-screened aminoquinoline-benzimidazole hybrids (4a – 4e, 
5a – 5e and 6a – 6c). 
 
3.2.1 Predicting lipophilicity 
The logP values of these hybrid compounds were estimated in order to gain insight into 
the relationship between their lipophilicity and pharmacological activity. The partition 
coefficient, logP, is the most commonly used measure of lipophilicity. The calculated logP 
(clogP) values of the organic hybrid compounds (4a – 4e and 6a – 6c) were estimated 
using MarvinSketch V17.3.13.0, while that for the ferrocenyl hybrids (5a – 5e) required 
an alternative method. A method combining calculated values from MarvinSketch, the 
fragmental approach proposed by Mannhold and Rekker12 and the ferrocenyl adaptation 
developed by Ahmedi and Lanez,13-15 was employed.  
The fragmental method, described by Rekker et al., makes use of theoretical constants for 
molecular substructures derived from experimental logP values of simple organic 
compounds.12 The method takes into account differing chemical characteristics such as 
hydrogen bonding, electronegative centres and resonance, by the incorporation of 
correction values.12 Lanez et al. adapted this method for the calculation of logP values of 
ferrocenyl compounds.14 In this adapted method, the theoretical logP value of 




ferrocene (Fc) is equal to the experimental value of 2.66.14, 16 The logP contribution of a 
ferrocenyl group (Fc–H) is obtained by subtracting the fragmental constant of a hydrogen 
atom from that of Fc, to afford a value of 2.456.14 In our modified approach, the latter 
value (Fc–H = 2.456), as well as the calculated values for corresponding phenyl 
derivatives from MarvinSketch, were combined to calculate the logP values of the 
ferrocenyl compounds. Twenty reference compounds (Figure 3.3), with known 
experimental logP values, were used to validate this method. 
The following equation was used to calculate logP values for the ferrocenyl derivatives: 
logP(Fc derivative) = logP(benzene derivative) – f(C6H5) + f(Fc-H) 
where: clogP(benzene derivative) calculated using MarvinSketch, 
  f(C6H5) obtained from fragmental approach,12 
  f(Fc-H) obtained from Lanez et al.14 
               
  
 
   





Figure 3.3 Reference ferrocenyl and organic derivatives (D1-D20) used to validate the method. 





A representative calculation of the logP value of the ferrocenyl compound D1 is shown 
below. The calculated logP (clogP) value of the benzene derivative was determined using 
MarvinSketch v17.3.13. The logP value of the ferrocenyl derivative was calculated using 
the equation described previously. 
 
 
logP(Fc derivative) = logP(benzene derivative) – f(C6H5) + f(Fc-H) 
             = 4.336 – [6×C + 5×H] + 2.456 
                = 4.336 – [6(0.110) + 5(0.204)] + 2.456 
                = 5.112 
Table 3.1 Experimental and estimated logP values for compounds D1 – D20. 
Compound Experimental logP Estimated logP 
D1 5.2717 5.11 
D2 4.5913 4.40 
D3 4.4218 4.66 
D4 5.2314 4.89 
D5 4.6819 4.90 
D6 5.0414 5.19 
D7 6.4715 6.49 
D8 4.6318 4.23 
D9 6.7015 6.61 
D10 6.6015 6.53 
D11 -0.7020 -0.69 
D12 3.8621 3.84 
D13 -0.0220 -0.012 
D14 2.1222 2.25 
D15 2.8221 3.08 
D16 4.6521 4.39 
D17 2.6820 2.49 
D18 2.1020 1.89 
D19 2.6123 2.64 
D20 1.2923 1.36 




Theoretical clogP values were determined for ferrocenyl compounds D1 – D10, using the 
aforementioned calculation, while the clogP values of compounds D11 – D20 were 
determined directly in MarvinSketch. The experimental values, taken from the literature, 
and estimated values are listed in Table 3.1. The data was plotted (Figure 3.4) and a 
regression analysis (Microsoft Excel) was used to determine the correlation between 
estimated and experimental values. The scatter plot resulted in a linear line of best fit, 
with a gradient close to 1 (m = 1.0105), an intercept approximately equal to zero 
(c = 0.0007) and R2 of 0.9918, indicating a good correlation between the two sets of 
values. In addition, the regression analysis revealed a p-value (3.08×10-20) smaller than 
0.05, indicating no significant difference.    
 
Figure 3.4 Linear relationship between experimental and estimated logP values. 
  


























Predicting the logP values of the aminoquinoline-benzimidazole hybrids 
The calculated logP values of the ferrocenyl aminoquinoline-benzimidazole hybrids 
(5a – 5e) were determined using this modified method. The clogP values of all of the 
hybrid compounds are listed in Table 3.2. 
 
Table 3.2 Estimated logP values of compounds 4a – 4e, 5a – 5e and 6a – 6c. 




4b CH3 6.12 
4c CF3 6.48 
4d SO2CH3 4.44 





5b CH3 6.90 
5c CF3 7.26 
5d SO2CH3 5.22 




6b CH3 5.29 




logP(Fc derivative) = logP(compound 4a) – f(C6H5) + f(Fc-H) 
     = 5.604 – [6(0.110) + 5(0.204)] + 2.456 








3.2.2 In vitro antiplasmodium activity and cytotoxicity 
The 2-phenyl, 2-ferrocenyl and 2-pyridyl aminoquinoline-benzimidazole hybrids 
(4a – 4e, 5a – 5e and 6a – 6c) were evaluated for their in vitro antiplasmodium activity 
using the Plasmodium lactate dehydrogenase (pLDH) assay.5 All compounds were 
screened against the CQS NF54 and MDR K1 strains of Plasmodium falciparum. 
Chloroquine (CQ) and artesunate (AS) were used as positive control drugs. The IC50 
values and resistance indices (RI) are listed in Table 3.3. 
 
Table 3.3 In vitro antiplasmodium data and resistance indices of compounds 4a – 4e, 5a – 5e, 
6a – 6c, CQ and AS. 
   IC50 (µM) ± SE  
Compound R X NF54 K1 RIa 
4a 
 
H 5.553 ± 0.063 0.201 ± 0.003 0.036 
4b CH3 0.784 ± 0.016 0.457 ± 0.095 0.583 
4c CF3 0.431 ± 0.012 0.151 ± 0.004 0.350 
4d SO2CH3 0.559 ± 0.011 1.832 ± 0.080 3.280 




H 2.882 ± 0.048 0.339 ± 0.011 0.118 
5b CH3 0.329 ± 0.005 0.283 ± 0.004 0.860 
5c CF3 1.223 ± 0.100 0.658 ± 0.039 0.538 
5d SO2CH3 0.848 ± 0.007 0.579 ± 0.008 0.683 
5e CN 0.909 ± 0.019 0.565 ± 0.008 0.622 
6a 
 
H 1.089 ± 0.168 > 20 - 
6b CH3 4.984 ± 0.613 NDb - 
6c CF3 0.410 ± 0.028 > 20 - 
CQ - - 0.0102 ± 0.0023 0.205 ± 0.007 20.098 
AS - - 0.0098 ± 0.0011 NDb - 
aRI = IC50(K1) / IC50(NF54); 
bND = not determined 




All of the phenyl-, ferrocenyl- and pyridyl-derived hybrids display good antiplasmodium 
activity, with most IC50 values in the sub-micromolar range. The IC50 values obtained in 
the CQS NF54 strain are graphically represented in Figure 3.5. In all cases except one, 
incorporation of the X substituent at the 5-position of the benzimidazole moiety 
significantly enhanced the antiplasmodium activity. This derivatisation resulted in 
mostly sub-micromolar IC50 values across the phenyl, ferrocenyl and pyridyl series, 
compared to the unsubstituted analogues (X = H). An exception in this case is the methyl-
substituted pyridyl hybrid 6b (IC50 = 4.984 µM), which is approximately 5-fold less active 
than the unsubstituted analogue 6a (IC50 = 1.089 µM). The decreased activity of this 
analogue may be related limited solubility in the assay media observed at the test 
concentration.  
















Figure 3.5 IC50 values of compounds 4a – 4e, 5a – 5e and 6a – 6c against the CQS NF54 strain of 
P. falciparum. 
Comparing the organic phenyl hybrids and their corresponding organometallic 
ferrocenyl analogues in the NF54 strain reveals contrasting trends. Some of the 
ferrocenyl hybrids (5a and 5b) displayed enhanced activity over their organic analogues 
(4a and 4b). In addition, the phenyl hybrids 4c and 4d are more active than their 
ferrocenyl analogues 5c and 5d. With regards to ferrocenyl derivatisation, literature 
reports comparable in vitro CQS strain activity of organic drug chloroquine, and its 
ferrocenyl analogue ferroquine.24 Furthermore, the activity of these hybrids does not 




compare to that of the control drugs, CQ and AS, displaying at least 30-fold lower IC50 
values.  
As a result of their mostly sub-micromolar IC50 values, selected hybrids were evaluated 
against the MDR K1 strain of P. falciparum, and the IC50 values of compounds 4a – 4e and 
5a – 5e are graphically represented in Figure 3.6. The pyridyl hybrids 6a and 6c were 
inactive at the highest concentration tested. In contrast to their activity in the CQS NF54 
strain, the phenyl hybrids 4a (0.201 µM), 4c (0.151 µM) and 4e (0.179 µM) gave rise to 
IC50 values comparable or lower than that of CQ (0.205 µM) in the MDR K1 strain. In 
general, most of the phenyl and ferrocenyl hybrids (4a – 4c, 4e and 5a – 5e) were more 
active in the resistant strain. The methylsulfonyl-substituted phenyl hybrid 4d provides 
an exception, with greater than 3-fold lower activity in the resistant strain compared to 
the sensitive strain. Resistance indices (RI), defined as the quotient of IC50(K1) and 
IC50(NF54), were calculated. RI values equal to or less than one are favourable, and 
indicate that the compound is equally or more active in the resistant strain compared to 
the sensitive strain. Most hybrids had RI values less than 1, significantly lower than that 
of CQ (RI = 20), suggesting that they may not be susceptible to cross-resistance, and have 
potential greater applicability against resistant strains of P. falciparum.  
















Figure 3.6 IC50 values of compounds 4a – 4e and 5a – 5e against the MDR K1 strain of 
P. falciparum. 




In some cases, introduction of the organometallic ferrocenyl moiety resulted in enhanced 
antiplasmodium activity in the K1 strain, however, this trend is not consistent, as seen in 
the NF54 strain. The ferrocenyl hybrids 5b and 5d displayed enhanced activity compared 
to their organic phenyl analogues 4b and 4d. The phenyl hybrids 4a, 4c and 4e proved 
more active than their ferrocenyl analogues 5a, 5c and 5e. This is contrary to what was 
expected as there is a precedent for enhanced activity of ferrocenyl analogues in resistant 
strains. Literature reports 20-fold greater in vitro activity of ferroquine compared to 
chloroquine in CQR strains.24 
The most active compound in the chloroquine-sensitive strain was the ferrocenyl-derived 
5b (0.329 µM), while in the resistant strain the phenyl-derived 4c (0.151 µM) was most 
active. The most active analogues across the phenyl-, ferrocenyl and pyridyl series overall 
are compounds 4c (CF3), 5b (CH3) and 6c (CF3). Interestingly, all three of the most active 
analogues have a more hydrophobic substituent at the 5-position of the benzimidazole, 
suggesting a correlation between hydrophobicity and antiplasmodium activity. Although 
these analogues have relatively high logP values (Table 3.2) of 6.48 (4c), 6.90 (5b) and 
5.65 (6c), there was no correlation between lipophilicity and antiplasmodium activity. It 
may also be interesting to note that compound 4d (1.832 µM), which was comparatively 
less active in the resistant K1 strain, has the lowest logP value of 4.44. 
 
Evaluation of individual components 
These hybrid agents were prepared and pharmacologically evaluated on the basis that 
combination of the two pharmacophores would potentially result in enhanced activity 
compared to their parent compounds. Therefore, it is a worthwhile study to compare the 
pharmacological activity of the individual components of the hybrid with that of the 
hybrid itself. The structures of the individual components, the aminoquinoline B1 and 
benzimidazole B2, are shown in Figure 3.7. A propyl chain was incorporated into the 
structures of both components in order to represent the propyl linker which is present in 
the hybrid structure. 







Figure 3.7 Structures of hybrid 4a and components B1 and B2. 
Both components, B1 and B2, were screened against the CQS NF54 and MDR K1 strains 
of P. falciparum, and their activity compared to the corresponding unsubstituted phenyl 
hybrid 4a (Figure 3.7). The IC50 values obtained are represented graphically in Figure 3.8. 
In the NF54 strain, the aminoquinoline compound B1 gave rise to a sub-micromolar IC50 
value of 0.640 µM, displaying almost 9-fold greater activity than the hybrid 
4a (5.553 µM). The benzimidazole compound B2 was inactive at the maximum 
concentration tested. It may be speculated that in the NF54 strain, the activity of the 
hybrid 4a may be solely attributed to the presence of the aminoquinoline moiety, while 
the benzimidazole moiety has no effect, or in fact decreases the activity.  
When evaluated in the K1 strain, hybrid 4a displays superior activity compared to both 
components B1 and B2, with an IC50 value of 0.201 µM. As mentioned earlier, the hybrid 
4a is more active in the resistant strain (RI = 0.036). The aminoquinoline B1 does not 
maintain its potent activity in the resistant strain, displaying an almost 2-fold lower IC50 
value of 1.13 µM (RI = 1.77). Once again, the benzimidazole B2 was inactive. These results 
may suggest that it is the combination of the two pharmacophores, to form the hybrid 
compound 4a, that gives rise to enhanced activity in the resistant strain, rather than the 
influence of the individual components. This may imply unique mechanisms of action, 
attributed to the hybrid structure, that allows it to overcome resistance mechanisms of 
the parasite.  


















Figure 3.8 Antiplasmodium activity of hybrid 4a, components B1 and B2, and equimolar 
physical mixture B1+B2. 
In addition, an equimolar physical mixture of the components (B1+B2) was also screened 
against the NF54 strain. The mixture B1+B2 gave rise to an IC50 value of 0.740 µM, 
displaying comparable activity to the aminoquinoline B1 alone. This may indicate that 
the activity of the physical mixture is attributed to the aminoquinoline B1 alone, with 
little to no contribution from the benzimidazole B2. Furthermore, the equimolar mixture 
B1+B2 proved significantly more active than the hybrid 4a in the sensitive NF54 strain, 




An isobologram analysis was utilised in order to further explore and visualise the 
interaction between the two components, B1 and B2, when tested in vitro. An 
isobologram analysis is a type of drug combination study, introduced by Loewe and 
Muischnek,25 in which the combined effects or interactions of two or more drugs are 
analysed. A general example of an isobologram is shown in Figure 3.9,26 depicting the 
different interactions that are possible for compound combinations. In a two-compound 
isobologram graph, the X and Y axes represent the dose axes of each compound and the 





























interaction, the points will form a straight line and the relationship is additive. When the 
combination is more effective than the individual compounds, the points lie below (to the 
left of) the zero interaction (additive) line and the relationship is synergistic. On the other 
hand, when the combination is less effective than the individual compounds, the points 
lie above (to the right of) the additive line and the relationship is antagonistic.26 
 
Figure 3.9 Typical isobologram depicting component relationships.26 
The individual components (B1 and B2) were tested in fixed ratios against the CQS NF54 
strain of P. falciparum, following a modified isobologram method described by Fivelman 
et al.27 The IC50 values of compounds B1 and B2 in the fixed ratio mixtures were 
determined and using their individual IC50 values (Figure 3.8), the fractional IC50 (FIC50) 
values of compounds B1 and B2 were calculated (Table 3.4).  
Table 3.4 Compound B1 and B2 ratios and fractional IC50 values. 
Mixture B1 ratio B2 ratio B1 FIC50a B2 FIC50a 
1 5 0 1 0 
2 4 1 0.85 0.08 
3 3 2 0.82 0.21 
4 2 3 0.90 0.50 
5 1 4 0.65 0.92 
6 0 5 0 1 
7 1 1 1.12 0.32 
aFIC50 = IC50 of compound in mixture / IC50 of compound only 




These FIC50 values were plotted to construct the isobologram shown in Figure 3.10. As 
seen in the isobologram, the relationship between compounds B1 and B2 is antagonistic 
for mixtures 4, 5 and 7. Mixtures 2 and 3 display additive relationships between 
compounds B1 and B2. Antagonism is seen for the mixtures with equal or greater 
proportions of compound B2. Additivity is indicated for the mixtures with greater 
proportions of compound B1. These trends indicate that aminoquinoline B1 confers the 
antiplasmodium activity, while benzimidazole B2 exerts an antagonistic effect, 
decreasing the activity. This result confirms what was seen in the evaluation of the 
individual components and equimolar physical mixture, discussed earlier. 















Figure 3.10 Isobologram of components B1 and B2. 
 
Cytotoxicity 
The 2-phenyl and 2-ferrocenyl hybrids (4a – 4e and 5a – 5e) were also screened for their 
cytotoxicity against the non-tumorigenic Chinese hamster ovarian (CHO) cell line, using 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.8, 9 
Emetine was used as the positive control drug. The cytotoxicity of the 2-pyridyl hybrids 
(6a – 6c) was not evaluated as a result of their comparatively lower NF54 activity, which 
was not maintained in the resistant K1 strain.  Compounds 4a and 4c – 4e display low 
toxicity against the CHO cells, with moderate micromolar IC50 values in the 
range 16.2 – 42.0 µM, at least 1000-fold less active than the positive control, 
emetine (0.0162 µM). Compounds 4b and 5a – 5e were non-cytotoxic (IC50 > 50 µM) at 




the highest concentration tested. The selectivity indices (SI), shown in Table 3.5, were 
greater than 7 and 22 for the sensitive (SI1) and resistant (SI2) parasite strains, 
respectively. These values (> 1) indicate that these aminoquinoline-benzimidazole 
hybrids are selective towards the Plasmodium parasites, and suggests that their activity 
may attributed to mechanisms other than general cytotoxicity.   
Table 3.5 Cytotoxicity data and selectivity indices of compounds 4a – 4e, 5a – 5e and emetine.  
Compound CHO IC50 (µM) SI1a SI2b 
4a 42.01 7.57 209 
4b > 50 - - 
4c 16.16 37.5 107 
4d 40.93 73.2 22.4 
4e 38.87 39.9 217 
5a > 50 - - 
5b > 50 - - 
5c > 50 - - 
5d > 50 - - 
5e > 50 - - 
Emetine 0.0162 - - 
aSI1 = IC50(CHO) / IC50(NF54);  
bSI2 = IC50(CHO) / IC50(K1) 
 
3.2.3 In vivo antimalarial activity 
Based on their favourable in vitro activity and low cytotoxicity, the most active phenyl 
and ferrocenyl aminoquinoline-benzimidazole hybrids (4c and 5b) were evaluated for 
their in vivo antimalarial efficacy in Plasmodium berghei-infected mice. Murine (rodent) 
Plasmodium species provide a practical model for the study of mammalian Plasmodium 
species. With regards to structure, physiology and life cycle, rodent plasmodia are 
analogous to mammalian malaria parasites.28 Mice infected with the CQS P. berghei ANKA 
strain, were dosed orally at 4 × 50 mg/kg and the reduction in parasitemia relative to the 
control determined. Results of the in vivo screening are summarised in Table 3.6. None of 
the three dosed mice were cured at this concentration and thus lower concentrations 
were not administered. Dosing with the ferrocenyl hybrid 5b resulted in significantly 




enhanced inhibition of parasitemia (92%), compared to the phenyl hybrid 4c (58%). 
Despite this vast difference in parasite inhibition, mice administered with either 
compound had the same mean survival time of seven days. This may suggest that 
compound 4c has some immune-modulating properties, allowing the mice to survive for 
an extended period of time. Conversely, it may also suggest that the pharmacokinetic 
profile of compound 5b is not optimal, with solubility-limited absorption a likely 
contributing factor, decreasing the survival time of the mice. 
Table 3.6 In vivo data for compounds 4c and 5b. 
Compound R X 
oral dose 
(mg/kg) 





CF3 4 × 50 58 (7) 0/3 
5b 
 
CH3 4 × 50 92 (7) 0/3 
aMSD = mean survival days 
 
3.2.4 Mechanistic studies 
3.2.4.1 β-haematin inhibition 
Chloroquine and other quinoline-containing antimalarials are known to target the 
parasite-induced host haemoglobin degradation pathway by preventing the parasite 
from converting toxic haem to the non-toxic malaria pigment, haemozoin.29-31 This 
results in the build-up of toxic haem, which damages the parasite.29-31 In order to 
elucidate whether these aminoquinoline-benzimidazole hybrids inhibit haemozoin 
formation as a potential contributing mechanism, the most active 2-phenyl-, 2-ferrocenyl 
and 2-pyridyl-derived hybrids (4c, 5b and 6c) were evaluated for their ability to inhibit 
β-haematin (synthetic haemozoin) formation. The inhibition properties of these hybrid 
compounds were investigated using the Nonidet P-40 (NP-40) detergent-mediated assay, 
developed by Sandlin et al.32 The β-haematin inhibition activity was quantified using the 
colorimetric pyridine ferrihaemochrome method developed by Egan et al.33  




The log-based dose-response curves for compounds 4c, 5b and 6c obtained from the 
NP-40 detergent-mediated assay, are shown in Figure 3.11, with CQ as the positive 
control. The IC50 values are reported in Table 3.7. The phenyl and ferrocenyl hybrids (4c 
and 5b) are potent β-haematin inhibitors, both displaying IC50 values of 16 μM, at least 
four times more active than CQ (74 μM). The pyridyl hybrid 6c was significantly less 
potent in comparison to the phenyl and ferrocenyl analogues, with a higher IC50 value of 
54 µM, however, still lower than that of CQ. These results suggest that this series of 
hybrids may act by inhibition of haemozoin formation. However, this result is obtained 





























Figure 3.11 Dose-response curves of compounds 4c, 5c, 6c and chloroquine (CQ). 
Table 3.7 β-Haematin inhibition IC50 values of compounds 4c, 5b, 6c and CQ. 
Compound IC50 (µM) [95% confidence interval] 
4c 15.90 [15.31 to 16.51] 
5b 15.80 [13.68 to 18.25] 
6c 54.08 [51.22 to 57.09] 
CQ 73.98 [71.14 to 76.94] 
 
In addition, no direct correlation can be drawn between the β-haematin inhibition activity 
and the in vitro NF54/K1 strain antiplasmodium activity of these compounds, reported 
in Section 3.2.2. There is, however, a correlation between the β-haematin inhibition 
IC50 (βHIAIC50) values and the lipophilicity of compounds 4c, 5b and 6c. Compounds 4c 
and 5b, which have higher logP values of 6.48 and 6.90, respectively, display lower IC50 




values. Compound 6c, which has a lower logP value of 5.65, displays a higher IC50 value. 
This suggests a positive correlation between lipophilicity and β-haematin inhibition 
activity, where greater lipophilicity of a compound results in enhanced activity. 
 
3.2.4.2 Cellular haem fractionation  
The β-haematin inhibition assay is routinely used to identify potential haemozoin 
inhibitors. Egan et al. translated this concept into malaria parasites cultured in vitro, to 
determine in-cell haemozoin inhibition ability.34 The cellular haem fractionation assay 
directly quantifies the different haem species present in CQS P. falciparum parasites.34 
Originally applied to CQ, the method was modified and applied to different 
antimalarials.35 True inhibitors of haemozoin formation gave rise to a dose-dependent 
increase in the amount of free haem and a corresponding decrease in the amount of 
haemozoin.34, 35 In order to validate that these hybrid compounds are true haemozoin 
inhibitors, based on their β-haematin inhibition activity (Section 3.2.4.1), compound 5b 
(βHIAIC50 = 15.8 µM) was subjected to a cellular haem fractionation assay. Parasites of the 
CQS NF54 strain were treated with increasing concentrations of compound 5b and the 
amount of free haem, haemozoin and haemoglobin were determined. The graphs shown 
in Figure 3.12, depict the effect of compound 5b on the amounts of the three species. 
Following treatment with compound 5b, there is a dose-dependent increase in the 
amount of free haem (Figure 3.12 – I), and a corresponding decrease in the amount of 
haemozoin (Figure 3.12 – II). The free haem referred to here is ferriprotoporphyrin IX 
(Fe(III)PPIX or haematin).33, 35 The increase in Fe(III)PPIX and decrease in haemozoin 
indicates that compound 5b inhibits the biocrystallisation process required to form 
haemozoin. Thus, this confirms that compound 5b is a true inhibitor of haemozoin 
formation. Furthermore, there is also a dose-dependent increase in the amount of 
haemoglobin present in the parasite (Figure 3.12 – III). This is in agreement with 
previous studies, which have shown the presence of undigested haemoglobin in 
CQ-treated P. falciparum parasites.36, 37 Literature has also suggested a causal link 
between the increase in free haem and the increase in haemoglobin, with the former 
occurring first.34 Therefore, we speculate that upon treatment with compound 5b, the 
accumulation of free haem results in the accumulation of undigested haemoglobin. 














































































Figure 3.12 Amount of iron (Fe) present as (I) free haem, (II) haemozoin and (III) haemoglobin 
at varying concentrations of the compound 5b. 
 
3.2.4.3 Reactive oxygen species (ROS) 
Hybrid chemotherapeutic agents are proposed to have dual or multiple modes of action, 
thus further mechanistic studies were pursued. The presence of a ferrocenyl moiety in 
compounds 5a – 5e, brings a potential additional mechanism of antiplasmodium action 
into consideration.  Ferroquine, the ferrocenyl analogue of the antimalarial drug, 
chloroquine, is proposed to have a multifaceted mode of action, including the ability to 
generate reactive oxygen species (ROS).38-41 This is ascribed to the ability of the redox-
active iron (Fe) centre to cycle between Fe2+ and Fe3+ (ferrocene to ferrocenium), via a 
Fenton-like process (Equation 1 and 2), generating ROS and ultimately causing parasite 
damage.38-41 Thus, a preliminary DNA cleavage study was undertaken in order to 
investigate whether the 2-ferrocenyl hybrids are able to generate ROS. Compound-DNA 
interaction assays were performed using the most active 2-ferrocenyl hybrid (5b). These 
experiments work on the principle that radicals are generated by reaction of the 




compound of interest with hydrogen peroxide (H2O2) and ascorbic acid (AA). Cleavage of 
one or both strands of circular plasmid DNA (pUC57), which is used as the reporter 
molecule, is the result, and indicates the formation, of ROS. Results of the dose-dependent 
DNA-cleavage of pUC57 is measured by agarose gel electrophoresis, as depicted in 
Figure 3.13. 
Equation 1   Fe2+ + H2O2 → Fe3+ + HO˙+ OH- 
Equation 2    Fe3+ + H2O2 → Fe2+ + HOO˙ + H+ 
 
Figure 3.13 Agarose gel electrophoresis displaying DNA cleavage. Lin = linear DNA, SC = super-
coiled DNA. 
The gel displayed a slight increase in the amount of linear DNA on the addition of the 
compound 5b. The small degree of DNA cleavage may be due to decreased solubility of 
compound 5b in the mixtures over a period of time, as there was evidence of precipitation 
in wells at the 50 and 100 µM concentrations (lanes 10 and 11). Comparing lane 6 versus 
lane 7, it should be noted that a mixture of compound 5b and ascorbic acid (lane 6) 
produced more linear (Lin) DNA than a mixture of compound 5b and H2O2 (lane 7). This 
indicates that H2O2 was not completely necessary for DNA cleavage, while ascorbic acid 
was required. Overall, there remains a greater amount of super-coiled (SC) DNA than the 




amount of linear DNA formed, suggesting that ROS generation is not appreciable. This 
assay thus suggests that the generation of ROS, via a Fenton-like process, is not a valid 
mechanism of activity for the 2-ferrocenyl hybrid compounds. 
 
3.2.5 In vitro antimycobacterial activity 
Within the context of repurposing and repositioning known drugs and scaffolds,42 the 
2-phenyl, 2-ferrocenyl and 2-pyridyl aminoquinoline-benzimidazole hybrid compounds 
were also screened for their in vitro antimycobacterial activity against the H37Rv strain 
of Mycobacterium tuberculosis. The minimum inhibitory concentration (MIC) values were 
determined using the broth micro dilution method.11 Rifampicin was used as a positive 
control, and the 7-day MIC90 values are summarised in Table 3.8. 






Alamar blue assay: 
Calculated MIC90 






Alamar blue assay: 
Calculated MIC90 
(µM) [media: 7H9 
GLU CAS] 
4a 125 38.8 62.5 50.6 
4b 125 >62.5 31.2 32.7 
4c 62.5 89.1 15.6 15.8 
4d >125 >62.5 125 >125 
4e >125 >62.5 62.5 >125 
5a 62.5 60.1 31.2 31.3 
5b 31.2 29.7 15.6 28.7 
5c 62.5 64.2 15.6 10.8 
5d >125 >125 125 >125 
5e >125 >125 31.2 >62.5 
6a - >125 - >125 
6b - >125 - >125 
6c - >125 - >125 
Rifampicin 0.018 0.0156 0.018 0.0217 
 
 




Compounds were screened in two different growth media, glucose-based Middlebrook 
7H9-ADC (albumin-dextrose complex) and 7H9-CAS (casitone). Selected hybrids were 
moderately active against M. tuberculosis, generally exhibiting better activity in the 
7H9-CAS medium.   The calculated MIC90 values determined in 7H9-CAS media are 
graphically depicted in Figure 3.14. The pyridyl hybrids 6a – 6c were all inactive at the 
concentration tested. Compounds 4a – 4c and 5a – 5c showed moderate 
antimycobacterial activity (10.8 – 50.6 µM), while compounds 4d – 4e and 5d – 5e were 
inactive at the tested concentration. Considering only the phenyl and ferrocenyl hybrids, 
the more active hybrids (4b – 4c and 5b – 5c) have the more hydrophobic X substituents 
(CH3 or CF3), while the inactive hybrids (4d – 4e and 5d – 5e) have the less hydrophobic 
X substituents (SO2CH3 or CN). This suggests a link between hydrophobicity of the hybrid 
and its antimycobacterial activity.  
















Figure 3.14 MIC90 values of compounds 4a – 4e, 5a – 5e and 6a – 6c against the H37Rv strain 
of M. tuberculosis. 
It is noteworthy that there is a correlation between the MIC90 values of compounds 
4a – 4c and 5a – 5c, and their lipophilicity, determined using logP values (Table 3.2). The 
graphs in Figure 3.15 depict the relationship between the logP and MIC90 values for the 
active hybrids. As the logP value of the compound increases, its MIC90 value decreases, 
indicating that antimycobacterial activity increases with increasing lipophilicity. This 








































antimycobacterial activity and lipophilicity.43, 44 Some studies have also indicated that 
selected lipophilic drugs had favourable activity against dormant and replicating 
M. tuberculosis compared to selected hydrophilic drugs.45 The inactivity of the pyridyl 
hybrids 6a – 6c against the H37Rv strain may be the result of their relatively lower 
lipophilicity (logP), compared to their corresponding phenyl and ferrocenyl analogues. 
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Figure 3.15 (I) Increase in clogP values; (II) Decrease in MIC90 values. 
Furthermore, for the active hybrids (4a – 4c and 5a – 5c), introduction of the 
organometallic ferrocenyl moiety (5a – 5c) resulted in an overall enhancement in the 
activity compared to the corresponding phenyl-derived analogues (4a – 4c). This trend, 
once again, may be related to lipophilicity. The ferrocenyl moiety contributes greater 
lipophilicity to the hybrid than the phenyl moiety, leading to overall higher logP values 
and resulting in lower MIC90 values (enhanced activity). These aminoquinoline-
benzimidazole hybrids were, however, significantly less active than the positive control, 
the clinically-available drug rifampicin (0.0217 µM).  
 
Evaluation of individual components 
In a similar way to the individual component antiplasmodium study, the 
antimycobacterial activity of the aminoquinoline B1 and the benzimidazole B2 was 
evaluated and compared to that of the corresponding unsubstituted phenyl hybrid 4a. 
The components, B1 and B2, were screened against the H37Rv strain of M. tuberculosis. 
The MIC90 values obtained are represented graphically in Figure 3.16. 
















Figure 3.16 MIC90 values of hybrid 4a and components B1 and B2, against the H37Rv strain of 
M. tuberculosis. 
Interestingly, the results of the antimycobacterial screening are contrary to the results 
observed in the antiplasmodium assay. The aminoquinoline B1 was inactive at the tested 
concentration (MIC90 > 125 µM), while the benzimidazole B2 had moderate micromolar 
activity (MIC90 = 62.0 µM). This vast difference in activity indicates that with regard to 
antimycobacterial activity, the benzimidazole moiety confers greater activity than the 
aminoquinoline moiety, and may suggest a greater contribution towards activity in the 
hybrid. However, hybrid 4a outperformed both components B1 and B2, with a lower 
MIC90 value of 50.6 µM. This suggests that the enhanced activity is the result of the 
combination of the two pharmacophores, rather than it being attributed to the influence 









The 2-phenyl, 2-ferrocenyl and 2-pyridyl aminoquinoline-benzimidazole hybrids 
(4a – 4e, 5a – 5e and 6a – 6c) were evaluated in vitro as potential antiparasitic agents 
against the chloroquine-sensitive NF54 strain and multidrug-resistant K1 strain of 
Plasmodium falciparum. In the sensitive strain, all compounds displayed good activity in 
the low micromolar and sub-micromolar range. In the resistant strain, the phenyl and 
ferrocenyl hybrids (4a – 4e and 5a – 5e) were potent, with mostly sub-micromolar IC50 
values and resistance indices less than one (RI < 1). The pyridyl hybrids (6a and 6c) were 
inactive against K1 parasites at the test concentration. Compounds 4c (phenyl-CF3), 5b 
(ferrocenyl-CH3) and 6c (pyridyl-CF3) were the most active hybrids across the three 
series.  
The in vitro antiplasmodium activity of the individual aminoquinoline and benzimidazole 
components (B1 and B2) and an equimolar physical mixture (B1+B2) was also 
evaluated. The aminoquinoline B1 displayed potent sub-micromolar activity against the 
CQS NF54 strain, while the benzimidazole B2 was inactive. Against MDR K1 parasites, 
compound B1 displayed decreased activity, while compound B2 remained inactive. The 
hybrid 4a was more active than either component in the resistant K1 strain. In the NF54 
strain, the mixture B1+B2 was significantly more potent than hybrid 4a. An isobologram 
analysis of compounds B1 and B2 revealed an additive relationship between B1 and B2 
at higher concentrations of B1 and lower concentrations of B2. Conversely, an 
antagonistic relationship was observed at higher concentrations of B2 and lower 
concentrations of B1.   
Selected compounds were screened for their in vitro cytotoxicity against the Chinese 
hamster ovarian cell line (CHO) cell line. Some of the hybrids (4a and 4c – 4e) displayed 
low cytotoxicity, while others (4b and 5a – 5e) were inactive against the non-tumorigenic 
cell line at the concentration tested. All of the tested hybrids showed selectivity towards 
Plasmodium parasites, compared to the CHO cells.  
The most active phenyl and ferrocenyl hybrids (4c and 5b) were screened for their in vivo 
efficacy in mice infected with Plasmodium berghei. Dosed at a concentration of 
4 × 50 mg/kg, the ferrocenyl hybrid 5b was a significantly more potent inhibitor of 




parasitemia than the phenyl hybrid 4c. Despite this, the mean survival time of mice dosed 
with either compound was the same (7 days).  
Mechanistic studies were performed on selected hybrids in order to elucidate possible 
contributing mechanisms of antiplasmodium action. The most active compounds (4c, 5b 
and 6c) were evaluated for their ability to inhibit β-haematin formation. Compounds 4c, 
5b and 6c were found to be moderate or potent inhibitors, with IC50 values lower than 
that of CQ. Compound 5b was subjected to a cellular haem fractionation assay to validate 
the β-haematin inhibition assay result in the parasite. Treatment of NF54 parasites 
resulted in a dose-dependent increase in free haem, decrease in haemozoin, and increase 
in haemoglobin, confirming compound 5b as a true haemozoin inhibitor. A preliminary 
DNA cleavage assay was performed to assess the reactive oxygen species (ROS) 
generating ability of compound 5b. DNA cleavage to form linear DNA was not sufficient, 
indicating that ROS generation by compound 5b was not appreciable. 
All of the hybrid compounds were also evaluated as antimycobacterial agents against 
Mycobacterium tuberculosis H37Rv. The compounds with the less hydrophobic 
methylsulfonyl and nitrile substituents (4d – 4e and 5d – 5e), as well as the 2-pyridyl 
hybrids (6a – 6c) were inactive at the highest concentration tested. The inactive 
compounds are less lipophilic, displaying lower logP values. The more lipophilic 
compounds (4a – 4c and 5a – 5c), with the more hydrophobic methyl and trifluoromethyl 
substituents, displayed moderate to good antimycobacterial activity. For these active 
compounds, the 2-ferrocenyl hybrids consistently displayed enhanced activity compared 
to their 2-phenyl analogues. Furthermore, the individual components (B1 and B2) were 
also screened for their antimycobacterial activity. The benzimidazole B2 was moderately 
active against the H37Rv strain and the aminoquinoline B1 was inactive, while the hybrid 
4a was more active than either individual component.   
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Synthesis and characterisation of neutral and cationic 
PGM-containing complexes of aminoquinoline-
benzimidazole hybrids 
 
4.1 Introduction  
The previous use of arsenic-containing drugs in antibacterial (syphilis)1 and antiparasitic 
(trypanosomiasis)2 chemotherapy bodes well for the application of metal-based agents 
in the treatment of infectious diseases. On the other hand, the platinum-based anticancer 
drug cisplatin represents a landmark example of the use of Platinum Group Metals 
(PGMs) in chemotherapy.3 As mentioned in Chapter 1 (Section 1.3.2), Sanchez-Delgado 
and co-workers reported some of the first organometallic PGM complexes in 
antiplasmodium studies, using rhodium and ruthenium metals.4 These Rh- and Ru-
chloroquine analogues presented promising results, particularly against resistant strains 
of the parasite4 and this work was extended to the use of various other metals and 
scaffolds.5  
More recently, strategies to incorporate organometallic PGM moieties into potential 
antimicrobial agents have extended to multidentate modes of coordination. Smith and co-
workers have reported on the antiplasmodium activity of numerous complexes, 
incorporating various ligands and all six PGMs (Ru, Rh, Pd, Os, Ir and Pt).6 Cyclometalated 
ruthenium(II), iridium(III) and rhodium(III)-benzimidazole complexes displaying good 
activity against sensitive and resistant strains of P. falciparum were recently reported.7 
The trifluoromethyl-substituted Ru(II) and Ir(III) analogues (Figure 4.1, I and II) proved 
more potent in the resistant K1 strain, displaying the lowest resistance indices (RIs) in 
the series (0.34 and 0.74, respectively).7 In another study, the antiplasmodium activity of 
Rh(III) and Ir(III) aminoquinoline-based complexes, with N^N and N^O-coordination 
modes in the lateral side-chain, was presented.8 Good sub-micromolar activity 
(IC50 < 1 µM) was observed for most complexes, with the Rh(III) N^O complexes 




displaying superior activity. However, the Rh(III) N^N complex (III) was one of the only 
complexes in the series which maintained comparable activity against both the CQS NF54 









IV: M = Rh, V: M = Ir 
Figure 4.1 PGM-containing complexes active against P. falciparum and M. tuberculosis. 
Examples of PGM-containing antimycobacterial agents in the literature are limited. Most 
relevant to this study, Ekengard et al. prepared cationic Rh(III) and Ir(III) complexes of 
pyrazinamide-aminoquinoline hybrids (Figure 4.1, IV and V), reporting on their 
antiplasmodium and antimycobacterial activity.9 Against the CQS NF54 strain, the Rh(III) 
complex (IV) proved more active than the Ir(III) complex (V). In the antimycobacterial 
evaluation against the H37Rv strain, the two complexes showed comparable moderate 
micromolar activity (MIC99 = 20 µM), 16-fold greater than the corresponding ligand 
(MIC99 = 320 µM).9  
With regards to metal-based hybrid agents, ferrocenyl derivatisation of organic-based 
hybrids has been explored, showing promising results in antiplasmodium screenings, as 
mentioned in Chapter 1 (Section 1.5.3). To our knowledge, reports on the preparation 
and antimicrobial application of half-sandwich PGM-containing hybrid compounds are 
limited. In this chapter, the synthesis and characterisation of iridium- and rhodium-
containing aminoquinoline-benzimidazole hybrids is described.  




4.2 Results and Discussion 
Choice of ligands for subsequent complexation reactions 
In the initial rational design of the aminoquinoline-benzimidazole hybrid ligands 
(Chapter 2), the substituent (X) at the 5-position of the benzimidazole scaffold was 
chosen from the Craig Plot in order to explore the effect of differing hydrophobic and 
electron- withdrawing/donating properties on the pharmacological activity. The ligands 
to be used in subsequent complexation reactions were chosen based on favourable 
antiplasmodium and antimycobacterial activity, as described in Chapter 3. On this basis, 
the hydrophobic methyl (4b and 6b) and trifluoromethyl (4c and 6c) analogues were 
accordingly selected to be taken further. The unsubstituted phenyl and pyridyl 
derivatives (4a and 6a) were also included, in order to determine the effect of the 
electron-withdrawing or -donating 5-position substituent on the pharmacological 
properties relative to analogues lacking a substituent.   
 
4.2.1 Synthesis and characterisation of neutral iridium(III) and rhodium(III) 
hybrid complexes 
4.2.1.1 C^N-coordinated Ir(III) and Rh(III) pentamethylcyclopentadienyl (Cp*) 
complexes (7a – 7c and 8a – 8b) 
Synthesis 
Cyclometalated complexes were prepared by reacting selected phenyl aminoquinoline-
benzimidazole hybrid ligands with various metal dimers, via C-H activation, as shown in 
Scheme 4.1. Compounds 4a – 4c were reacted with sodium acetate and 
pentamethylcyclopentadienyliridium(III) chloride dimer10 in dichloromethane and 
ethanol at room temperature. This afforded the cyclometalated Ir(III) complexes (7a – 
7c) as dull yellow powders in moderate yields (52 – 63%). On the other hand, successful 
synthesis of the cyclometalated Rh(III) complexes required higher reaction 
temperatures, as reactions at room temperature afforded product mixtures with a low 
proportion of the desired product. Thus, compounds 4a – 4b were reacted with sodium 
acetate and pentamethylcyclopentadienylrhodium(III) chloride dimer10 in 
dichloromethane and methanol at 65 °C. The desired cyclometalated Rh(III) complexes 
(8a – 8b) were isolated as dull orange powders in low to moderate yields (36 – 47%). 




The Ir(III) and Rh(III) complexes display good solubility in polar organic solvents, such 
as dichloromethane, chloroform and ethanol. 
 
Scheme 4.1 Synthesis of cyclometalated Ir(III) and Rh(III) aminoquinoline-benzimidazole hybrid 
complexes. Reagents and conditions (i) [Ir(Cp*)Cl2]2 / NaOAc / DCM:EtOH / 25 °C / 24 h; 
(ii) [Rh(Cp*)Cl2]2 / NaOAc / DCM:MeOH / 65 °C / 96 h. 
Reaction mechanism 
The term ortho-metalation is used to describe metalations of phenyl-substituted ligands, 
such as the 2-phenyl hybrid ligands described in Chapter 2. The mechanism of 
cyclometalation via C-H activation has been widely studied and has been proposed for 
various Platinum Group Metal precursors including Pd(OAc),11 [(η6-arene)RuCl2]212, 13 
and [(PMe3)3Ir(neopentyl)].14 Most relevant to the study at hand, is the mechanism of the 
acetate-promoted cyclometalation of nitrogen donor ligands with half-sandwich Ir(III) 
and Rh(III) precursors. Mechanisms have been proposed by Davies and co-workers,15, 16 
as well as Jones and co-workers.17, 18 The full mechanism is not fully understood and 
differs for various ligands, metal precursors and catalysts/bases. However, the respective 
groups of Davies and Jones have conducted experimental, theoretical and kinetic studies, 




and have identified key steps and intermediates in the process.15-18 Based on these 
studies, the proposed mechanism for the cyclometalation of the aminoquinoline-
benzimidazole hybrids (4a – 4c) is illustrated in Figure 4.2. 
 
Figure 4.2 Proposed cyclometalation mechanism for the formation of complex 7a. 
It is widely accepted that the initial step is loss of a chloride anion and coordination of a 
bidentate acetate ligand, where it has a key role as an intramolecular base.11 The 
remaining chloride anion then dissociates and the nitrogen-donor ligand coordinates to 
generate a positively charged iridium species, from which electrophilic C-H activation can 
occur.15, 16 The mechanism then proceeds via a single, low-energy six-coordinate 
transition state, corresponding to displacement of an acetate oxygen atom by the 
incoming ortho C-H bond of the phenyl group (concerted metalation-deprotonation with 
assistance from the acetate group), leading to a C-H activated product.16 This proposed 
transition state is similar to that calculated for acetate-assisted C-H activation of imines 
and amines using Ir(III), Rh(III) and Pd(II) precursors. The acetate-coordinated complex 
product is then formed, regenerating a neutral complex, followed by rapid conversion to 
the chloride product.   




As mentioned previously, the cyclometalation reactions using [Rh(Cp*)Cl2]2 proved 
challenging. Under the same mild reaction conditions as that for [Ir(Cp*)Cl2]2, the 
reactions with [Rh(Cp*)Cl2]2 were sluggish, only forming a small amount of the desired 
cyclometalated product. Using altered reaction conditions with elevated temperatures 
resulted in the formation of the desired product in low to moderate yields. There is 
literature precedent for the decreased reactivity of Rh(III) precursors toward C-H 
activation reactions compared to Ir(III) precursors. This trend has been noted for 
benzoate complexes,19 as well as phenyl-imine and phenylpyridine complexes.18 It is 
unclear whether or not this can be attributed to the differing electrophilicity of Ir(III) 
versus Rh(III). Furthermore, the electronic nature of the phenyl ring substituents also 
dictates the rate at which cyclometalation occurs. It has been shown that ligands with 
electron-donating substituents react faster than ligands with electron-withdrawing 
substituents, which is consistent with the proposed electrophilic mechanism of C-H 
activation.17, 18 It should be noted that the trifluoromethyl-substituted Rh(III) complex 
could not be isolated with the desired purity. Reactions using various conditions resulted 
in very poor conversion to the desired product, and isolation of the pure complex 
separate from starting materials and side products was not achieved. This could be 
attributed to the decreased reactivity of the Rh(III) precursor as well as the presence of 
the electron-withdrawing CF3 substituent, which decreases the reactivity of the ortho-
position of the phenyl group.  
Characterisation 
The neutral cyclometalated iridium(III) and rhodium(III) complexes (7a – 7c and 
8a – 8b) were fully characterised using NMR (1H, 13C{1H}, COSY and HSQC) and IR 
spectroscopy, and high-resolution ESI mass spectrometry.  
NMR spectroscopy 
The 1H NMR spectra of compounds 7a – 7c and 8a – 8b all show similar trends. The 
spectrum of compound 7a, recorded at 60 °C in DMSO-d6, is shown in Figure 4.3. The 
protons of the quinoline moiety give rise to five characteristic signals at 8.40, 8.35, 7.80, 
7.45 and 6.42 ppm, respectively. The protons of the benzimidazole moiety appear as a 
doublet (7.83 ppm) and a multiplet (7.57 – 7.49 ppm), which overlaps with the quinoline 
amine proton (H-10) signal. In addition, the two deshielded protons of the 2-phenyl 




moiety (H-22/25, adjacent to the aromatic substitutions) give rise to an overlapping 
multiplet at 8.00 ppm.  Two distinct diagnostic triplets (7.28 and 6.98 ppm, 3JHH = 7.5 Hz) 
are present for H-23 and H-24 of the 2-phenyl moiety, which are indicative of the 1,2-
substitution of the phenyl ring. Signals in the aromatic region of the spectrum integrate 
for thirteen aromatic protons (fourteen aromatic protons in ligand 4a), confirming the 
loss of one aromatic proton as a result of successful cyclometalation (via C-H activation) 
at an aromatic carbon.  
 
 
Figure 4.3 1H NMR spectrum of compound 7a in DMSO-d6 at 60 °C. 
The methylene protons of the propyl linker appear as three signals at 4.99, 3.49 and 2.31 
ppm respectively. The methylene protons (H-13) adjacent to the newly coordinated 

























centre, which renders these protons diasterotopic. The presence of an intense singlet at 
1.72 ppm, corresponding to the fifteen protons of the pentamethylcyclopentadienyl (Cp*) 
ligand, provides further evidence of complexation.   
The 1H NMR spectrum of compound 8a (M = Rh, X = H) is similar to that of compound 7a, 
with signals appearing at similar chemical shifts, with similar multiplicities and coupling 
constants. However, the singlet corresponding to the Cp* protons is more shielded 
compared to that in compound 7a, appearing at a slightly lower chemical shift 
(1.64 ppm), as a result of the Rh(III) metal centre being less electronegative than Ir(III). 
The same trend is seen in the spectra of compound 7b and 8b. The 1H NMR spectra of 
compounds 7b, 7c and 8b display signals for the quinoline moiety, phenyl ring and propyl 
linker at similar chemical shifts and with similar multiplicities and coupling constants to 
that of compounds 7a and 8a. The aromatic region displays signals integrating for twelve 
aromatic protons (thirteen in ligands 4b and 4c) as a result of the 5-position substitution 
(CH3 and CF3, respectively) on the benzimidazole moiety. The loss of an aromatic proton, 
compared to the respective ligands, confirms cyclometalation. The signals corresponding 
to the three protons of the benzimidazole moiety shift slightly upfield in the spectra of 
compounds 7b and 8b, and downfield for compound 7c, as a result of the differing 
substituent electron-donating and -withdrawing effects, respectively. Additionally, the 
methyl groups of compounds 7b and 8b are observed as singlets at 2.57 and 2.55 ppm, 
respectively. 
Conformational isomerism 
Analysis of the 1H NMR spectra of complexes 7a – 7c and 8a – 8b at room temperature 
revealed a doubling up of the amine, propyl, Cp* and selected aromatic proton signals, 
suggesting the presence of two structurally similar species in solution. The duplicate 
signals vary in intensity for the different complexes, having low intensity for compounds 
7a – 7b and 8a – 8b, while appearing more intense for compound 7c (approx. 3:2 
intensity ratio). When recording the 1H NMR spectra at an elevated temperature of 60 °C, 
these duplicate signals significantly decrease in intensity. The stacked 1H NMR spectra of 
compound 7c in DMSO-d6 at room temperature and 60 °C is shown in Figure 4.4, with 
duplicate peaks marked.  





Figure 4.4 1H NMR spectra (DMSO-d6) of compound 7c at room temperature and 60 °C, 
depicting conformational isomerism. 
This solution behaviour suggests the presence of stereoisomerism in the form of 
conformational isomers, in which isomers can interconvert by rotation about single 
bonds. It is speculated that two low energy conformers (rotamers) exist by rotation about 
the metal-Cp* bond. The energy required to overcome the rotational energy barrier in 
order to convert to a single lower energy, more stable conformer may be provided by the 
elevated temperature. In addition, a time-dependent NMR study revealed that conversion 
to a single set of signals, and thus one conformer, also occurs over extended periods of 
time in solution at room temperature. 
The 13C{1H} NMR spectra of compounds 7a – 7c and 8a – 8b all display signals 
corresponding to the expected number of carbon atoms for the proposed structures. The 
presence of signals for the Cp* moiety confirms successful complexation. For the Ir(III) 
complexes 7a – 7c, the five methyl carbon atoms (C-27’) of the Cp* moiety give rise to a 
single intense signal around 9.2 ppm, all experiencing the same chemical environment. 
Similarly, the five quaternary Cp* carbon atoms (C-27) resonate as one intense signal 
around 96.3 ppm. For the Rh(III) complexes 8a and 8b, the Cp* methyl carbon atoms give 
rise to a signal at 9.9 and 9.5 ppm, respectively. In contrast, the corresponding Cp* 
quaternary carbon atoms appear as two nearly overlapping signals at 101.9 and 
102.5 ppm, respectively. The remaining aromatic carbon atoms of compounds 7a – 7c 
give rise to signals between 164.3 and 99.2 ppm, while that of compounds 8a – 8b appear 
room temperature 
60 °C 
* * * * * * 
* 
* 




in the region 158.4 – 99.4 ppm. Across all spectra, the methylene carbons of the propyl 
linker give rise to three signals in the range 43.8 – 28.3 ppm. With regards to the 5-
position substituents (X), a signal corresponding to the methyl carbon atoms of 
compounds 7b and 8b are observed around 21.9 and 21.6 ppm in either spectrum, 
respectively. Furthermore, the trifluoromethyl carbon atom (C-17’) and CF3-substituted 
aromatic carbon atom (C-17) of compound 7c resonate as two multiplets in the region 
130 – 121 ppm, with splitting resulting from 13C–19F coupling.  
Infrared spectroscopy 
The solid-state infrared spectra of compounds 7a – 7c and 8a – 8b were recorded using 
Attenuated Total Reflectance (ATR), and also provide evidence of metal coordination. The 
spectra of compounds 7a – 7c and 8a – 8b show similar absorption bands and trends. 
The IR spectra display a secondary amine ν(N-H) absorption band around 3200 cm-1, as 
well as an aromatic ν(C=C) band around 1580 – 1584 cm-1. In addition, the 
trifluoromethyl ν(C–F) stretch is observed at 1327 cm-1 in the IR spectrum of compound 
7c. The stacked spectra of ligand 4c and corresponding cyclometalated iridium 
complex 7c are shown in Figure 4.5.  
 




















The region between 1620 and 1575 cm-1 in the spectra of the cyclometalated complexes 
differ from that of the respective ligands as a result of bidentate chelation. In ligands 4a 
– 4c, a ν(C=N) band around 1609 – 1611 cm-1 corresponds to both the quinoline and 
benzimidazole C=N bond. In complexes 7a – 7c and 8a – 8b, the ν(C=N) absorption band 
around 1609 – 1611 cm-1 has decreased in intensity and now only corresponds to the 
quinoline C=N bond. Upon coordination of the metal centre, the benzimidazole ν(C=N) 
absorption band shifts to a lower wavenumber, overlapping with the ν(C=C) band and 
resulting in a significantly broadened band around 1580 – 1584 cm-1, which is seen in 
Figure 4.5. In some cases, the overlapping ν(C=N) and ν(C=C) band is so broad that the 
reduced intensity quinoline ν(C=N) band appears as only a shoulder.  
The shift of the benzimidazole ν(C=N) absorption band to lower wavenumbers (1611 to 
1584 cm-1) is expected and results from a synergistic bonding interaction, which 
strengthens/shortens the metal-nitrogen bond and weakens/lengthens the C=N bond. 
The nitrogen of the imine bond is a sigma (σ)-donor and pi (π)-acceptor ligand. The 
metal–nitrogen bond involves σ-donation of electrons from nitrogen molecular orbitals 
to vacant orbitals of the metal, and π back-donation from filled metal d-orbitals to 
π*-orbitals of the nitrogen.20 The weakening/lengthening of the C=N bond results in a 
lower infrared bond frequency compared to the ligand.  
 
Mass spectrometry 
The cyclometalated complexes were analysed by high-resolution ESI-MS to further 
confirm the proposed structures. The experimentally determined m/z values and 
corresponding calculated values are summarised in Table 4.1. All of the complexes show 
a similar fragmentation pattern. Compounds 7a – 7c and 8a – 8b have estimated 
theoretical exact molar masses of 774.1868, 788.2025, 842.1742, 684.1294 and 
698.1450 g/mol, respectively.  
  




Analysed in the positive mode, the 100% abundant base peak corresponding to the 
[M-Cl+H]2+ fragment of each complex is observed at m/z 370.1120, 377.1207, 404.1064, 
325.0846 and 332.0920 in the spectra of compounds 7a, 7b, 7c, 8a and 8b, respectively. 
In addition, peaks corresponding to the [M-Cl]+ fragment also appear in the spectra, with 
varying relative abundances (10 – 70%). Peaks at m/z 739.2164, 753.2330, 807.2064, 
649.1589 and 663.1749 are observed, respectively.  
Table 4.1 Experimentally determined m/z values and their corresponding calculated values for 
cyclometalated complexes 7a – 7c and 8a – 8b.  
Compound 
Positive mode (base peak) 
Found m/z Calculated m/z 
7a 370.1120 [M–Cl+H]2+ 370.1129 
7b 377.1207 [M–Cl+H]2+ 377.1207 
7c 404.1064 [M–Cl+H]2+ 404.1066 
8a 325.0846 [M–Cl+H]2+ 325.0842 
8b 332.0920 [M–Cl+H]2+ 332.0920 
 Negative mode 
 Found m/z Calculated m/z 
7a 773.1756 [M–H]– 773.1795 
7b 787.1949 [M–H]– 787.1952 
7c 841.1702 [M–H]– 841.1669 
 
Furthermore, analysed in the negative mode, the spectra of compounds 7a, 7b and 7c 
reveal peaks corresponding to the [M–H]– fragments at m/z 773.1756, 787.1949 and 
841.1702, respectively. No peaks were detected when compounds 8a and 8b were 
analysed in the negative mode. This mass spectral data further confirms the structures of 
the desired cyclometalated complexes. 
  




4.2.1.2 N-coordinated Ir(III) and Rh(III) pentamethylcyclopentadienyl (Cp*) 
complexes (9a – 9c and 10a – 10c) 
Synthesis 
During the process of optimisation of the cyclometalation reactions (7a – 7c and 8a – 8b), 
it was found that coordination selectively occurred at the quinoline nitrogen, in a 
monodentate mode, when using anhydrous methanol at room temperature. This 
monodentate coordination occurred preferentially, even in the presence of sodium 
acetate as a base, as shown in Scheme 4.2.  
 
Scheme 4.2 Selective synthesis of quinoline N-coordinated Ir(III) and Rh(III) complexes in 
methanol at room temperature. 
Consequently, the quinoline-coordinated Ir(III) and Rh(III) complexes (9a – 9c and 10a 
– 10c) were synthesised by reaction of ligands 4a – 4c with the appropriate metal dimers 
([Ir(Cp*)Cl2]2 or [Rh(Cp*)Cl2]2), in the absence of a base, as displayed in Scheme 4.3. The 
iridium complexes (9a – 9c) were isolated as bright yellow powders in high yields (89 – 
96%), while the rhodium complexes (10a – 10c) were formed as bright orange powders 
in moderate to high yields (65 – 90%). All of the quinoline N-coordinated complexes had 
decreased solubility compared to their corresponding ligands, with limited solubility in 
polar organic solvents such as dichloromethane, chloroform and insolubility in methanol 
and ethanol.  
x 





Scheme 4.3 Preparation of quinoline N-coordinated Ir(III) and Rh(III) complexes. 
Reagents and conditions (i) [M(Cp*)Cl2]2 / MeOH / 25 °C / 24 h. 
Characterisation 
The neutral quinoline N-coordinated iridium(III) and rhodium(III) complexes (9a – 9c 
and 10a – 10c) were characterised using NMR (1H and 13C{1H}) and IR spectroscopy and 
high-resolution ESI mass spectrometry. 
NMR spectroscopy 
The 1H NMR spectra of complexes 9a and 10a, and the ligand 4a, are displayed in Figure 
4.6, for comparison. The spectra of the quinoline N-coordinated complexes 9a and 10a 
remain largely unchanged compared to the ligand 4a, displaying a similar pattern of 
signals. This is expected as no covalent bonds have been affected, no protons have been 
displaced as seen for the cyclometalated complexes (7a – 7c and 8a – 8b). However, the 
signals corresponding to the quinoline protons shift downfield compared to that of the 
ligand, suggesting coordination of the metal at the nitrogen atom of the quinoline moiety. 
The amine proton, which is para to the coordinated nitrogen atom, is also electronically 
affected as its corresponding triplet shifts significantly downfield, from 7.22 ppm (for 
ligand 4a) to around 8.00 ppm. The presence of a singlet for the Cp* protons at 1.63 ppm 
further confirms that coordination has occurred. The 1H NMR spectra of compounds 9b 
– 9c and 10b – 10c are similar to that of compounds 9a and 10a, however, only show a 
downfield shift in the amine proton signal. The protons of the methyl substituent of 
compounds 9b and 10b resonate at 2.44 ppm in their respective 1H NMR spectra.  




Figure 4.6 Stacked 1H NMR spectra of compounds 4a, 9a and 10a in DMSO-d6. 
In the 13C{1H} NMR spectra of compounds 9a – 9c and 10a – 10c, signals corresponding 
to the newly-introduced Cp* carbon atoms confirm successful coordination. In the 
spectra of the Ir(III) complexes 9a – 9c, the five quaternary carbons atoms of the Cp* 
moiety give rise to an intense signal around 93.0 – 92.5 ppm. The Cp* quaternary carbon 
atoms of the Rh(III) complexes 10a – 10c appear as two signals between 99.9 and 
99.2 ppm. In all spectra, an intense signal in the range 9.4 – 8.6 ppm is observed for the 
Cp* methyl carbon atoms. The rest of the spectra remain largely unchanged compared to 









































Compounds 9a – 9c and 10a – 10c were analysed by solid-state IR spectroscopy using 
ATR and the absorption bands are summarised in Table 4.2. The effect of the 
monodentate coordination of the ligand can also be seen in the IR spectra. The ν(C=N) 
absorption band shifts to a slightly higher wavenumber compared to the respective 
ligands, appearing with a shoulder around 1611 to 1613 cm-1. As this absorption band 
corresponds to the C=N bond of both the quinoline and benzimidazole entities, the slight 
shift in this broad band is likely due to the change in IR frequency of the C=Nquinoline bond, 
while the C=Nbenzimidazole bond remains unchanged.  
Interestingly, the aromatic ν(C=C) absorption band shifts to higher wavenumbers in the 
complexes. In the spectra of ligands 4a – 4c, the ν(C=C) absorption band is observed at 
1578 cm-1, while it appears at 1590 cm-1 for the Ir(III) complexes 9a – 9c and at 1588 cm-1 
for the Rh(III) complexes 10a – 10c. This trend suggests that metal coordination via the 
quinoline nitrogen increases electron density in the quinoline ring, and thus increases the 
IR frequency of the aromatic C=C bonds. The trifluoromethyl substituent of compounds 
9c and 10c give rise to a ν(C-F) absorption band at 1328 and 1327 cm-1, respectively. 
Furthermore, the ν(N-H) stretching vibration is retained in all spectra, appearing around 
3300 cm-1. 
Table 4.2 Infrared absorbances for compounds 9a – 9c and 10a – 10c. 
Compound 
ν (cm-1) 
N–H C=N C=C C–F 
9a 3317 1613 1590 – 
9b 3317 1611 1590 – 
9c 3321 1613 1590 1328 
10a 3313 1613 1588 – 
10b 3306 1611 1588 – 
10c 3310 1613 1588 1327 
 
  





The mass spectra of compounds 9a – 9c and 10a – 10c revealed complex fragmentation 
patterns when recorded in the positive mode. The exact molecular masses of compounds 
9a – 9c and 10a – 10c were determined to be 810.1635, 824.1791, 878.1509, 720.1061, 
734.1217 and 788.0934 g/mol, respectively. The identities of these complexes were 
confirmed by the presence of peaks at m/z 775.1938, 789.2087, 843.1803, 685.1360, 
699.1505 and 753.1227, respectively, corresponding to [M–Cl]+ fragments.  
 
4.2.2 Synthesis and characterisation of cationic iridium(III) and rhodium(III) 
hybrid complexes 
4.2.2.1 N^N-coordinated Ir(III) and Rh(III) pentamethylcyclopentadienyl (Cp*) 
complexes (11a – 11c and 12a – 12c) 
Synthesis 
Cationic N^N-coordinated Ir(III) and Rh(III) pentamethylcyclopentadienyl (Cp*) 
complexes were prepared via successive bridge-splitting and counter-ion exchange 
reactions, as shown in Scheme 4.4. In a one-pot synthesis, the 2-pyridyl aminoquinoline-
benzimidazole ligands (6a – 6c) were reacted with either the iridium dimer [Ir(Cp*)Cl2]2 
or rhodium dimer [Rh(Cp*)Cl2]2 in dichloromethane and ethanol at room temperature. 
This was followed by counter-ion exchange using ammonium hexafluorophosphate in 
ethanol at 0 °C. These reactions afforded the desired cationic Ir(III) complexes (11a – 
11c) as yellow powders in moderate to good yields (53 – 71%), while the Rh(III) 
complexes (12a – 12c) were isolated as orange powders in high yields (70 – 83%). These 
cationic Ir(III) and Rh(III) complexes display decreased solubility compared to the 
cyclometalated complexes (7a – 7c and  8a – 8b). Complexes 11a – 11c and 12a – 12c 
are soluble in polar organic solvents such as acetone and methanol, and sparingly soluble 
in dichloromethane, chloroform and ethanol.  





Scheme 4.4 Preparation of cationic Ir(III)- and Rh(III)-Cp* complexes. Reagents and 
conditions (i) [M(Cp*)Cl2]2 / DCM:EtOH / 25 °C /16 – 24 h; (ii) NH4PF6 / 0 °C / 2 h. 
Characterisation 
The cationic iridium(III) and rhodium(III)-Cp* complexes (11a – 11c and 12a – 12b) 
were fully characterised using NMR (1H, 13C{1H}, 31P{1H}, COSY and HSQC) spectroscopy, 
IR spectroscopy, and high-resolution ESI mass spectrometry.  
NMR spectroscopy  
A general trend which is consistent across the 1H NMR spectra of compounds 11a – 11c 
and 12a – 12c, is the overall downfield shift of all proton signals compared to their 
respective ligands (6a – 6c). This is expected as a result of the positive charge generated 
at the metal centre upon complexation, and thus provides evidence of successful 
chelation. The positively charged metal centre draws more electron density from the 
ligand, resulting in the deshielding effect seen in the NMR. The 1H NMR spectrum of 
compound 11b is displayed in Figure 4.7, and assignments are made as shown. 
Complexation is evidenced by the presence of a singlet (15H) at 1.69 ppm, corresponding 
to the protons of the Cp* moiety, which is introduced with the metal. The methylene 
protons of the propyl linker give rise to three signals at 5.05, 3.53 and 2.29 ppm, 
respectively. The multiplicity of the signals for the terminal methylene protons (H-13 and 
H-11) is indicative of a chiral metal centre, which brings about diastereotopicity in the 
propyl linker. In addition, the protons of the methyl substituent appear as a singlet at 
2.57 ppm. 






Figure 4.7 1H NMR spectrum of compound 11b in DMSO-d6. 
The aromatic protons of the quinoline moiety give rise to five signals at 8.44, 8.27, 7.84, 
7.58 and 6.57 ppm, respectively. The quinoline amine proton resonates as a broad signal 
at 8.00 ppm. There is minimal variation in the quinoline proton signals across the spectra 
of compounds 11a – 11c and 12a – 12c. The three aromatic protons of the benzimidazole 
moiety of compound 11b resonate as a doublet (1H, 7.97 ppm) and an overlapping 
multiplet (2H, 7.46 – 7.42 ppm). In the spectra of compounds 11c and 12c, the electron-
withdrawing nature of the trifluoromethyl substituent results in a shift of the 
benzimidazole proton signals downfield compared to compounds 11b and 12b. With the 



























signals integrating for four aromatic benzimidazole protons. The protons, H-25 and H-22, 
of the 1,2-substituted phenyl moiety resonate most downfield in the spectrum, at 9.11 
(dd) and 8.55 ppm (d), respectively. The remaining aromatic protons, H-23 and H-24, are 
observed as a triplet at 8.12 and overlapping multiplet at 7.83 ppm, respectively. 
The 13C{1H} NMR spectra of compounds 11a – 11c and 12a – 12c all display signals 
corresponding to the expected number of carbon atoms for the proposed structures. 
Complexation is confirmed by the presence of signals for the Cp* moiety. In the spectra 
of the Ir(III) complexes 11a – 11c, the five Cp* quaternary carbon atoms (C-26) give rise 
to one intense signal between 89.3 and 89.1 ppm, all experiencing the same chemical 
environment. In a similar way, the five methyl carbon atoms (C-26’) of the Cp* moiety 
resonate as one intense signal in the range 9.4 – 9.3 ppm. On the other hand, for the Rh(III) 
complexes 12a – 12c, the five Cp* quaternary carbon atoms resonate in two different 
environments, giving rise to two nearly overlapping signals in the region 97.3 – 97.0 ppm. 
The corresponding five methyl carbon atoms of the Cp* moiety appear as one intense 
signal between 9.6 and 9.5 ppm, in similar way to that of compounds 11a – 11c. 
For compounds 11a – 11c and 12a – 12c, the three methylene carbon atoms give rise to 
three signals in the region 44.5 – 28.0 ppm. The remaining aromatic carbon atoms 
resonate in the range 154.5 – 99.2 ppm for all six compounds. A signal for the carbon of 
the CH3 substituent of compounds 11b and 12b is observed at 21.6 ppm in both spectra. 
In addition, the CF3 carbon atom and CF3-substituted aromatic carbon atom of 
compounds 11c and 12c appear as two multiplets between 128 and 121 ppm. 
Furthermore, the 31P{1H} NMR spectra of compounds 11a – 11c and 12a – 12c were 
recorded in order to confirm the presence of the hexafluorophosphate counter-ion. In the 
spectra of all complexes, a septet signal corresponding to the phosphorous atom of the 










Infrared spectral analysis of compounds 11a – 11c and 12a – 12c, performed using ATR, 
was used to further confirm successful complexation and ion exchange. A representative 
section of the IR spectra of complex 12b and the ligand 6b is displayed in Figure 4.8. The 
secondary amine ν(N-H) stretching frequency remains present upon coordination and is 
observed between 3337 and 3333 cm-1. The aromatic ν(C=C) absorption band is observed 
in the range 1582 – 1580 cm-1.  
Complexation is evident by the shift in the imine ν(C=N) absorption bands. Contrary to 
the trend seen in the IR spectra of the neutral cyclometalated complexes (7a – 7c and 8a 
– 8b), the ν(C=N) bands for the cationic complexes (11a – 11c and 12a – 12c) shift to 
higher wavenumbers compared to their respective ligands. In the complexes, the 
benzimidazole ν(C=N) absorption band shifts to a slightly higher wavenumber, resulting 
in the noticeable broadening of the overlapping ν(C=N) band (1609 – 1613 cm-1) for the 
benzimidazole and quinoline moieties. In addition, the pyridyl ν(C=N) band shifts to a 
significantly higher wavenumber, appearing as a shoulder in the region 1633 – 1631 cm-1, 
compared to 1592 – 1590 cm-1 in the ligand. 
 
















These shifts in bond frequencies, are indicative of cationic complexes. Previous literature 
examples have shown the effect of the net charge of a complex on π-backbonding.21, 22 
The positive charge on the metal results in decreased electron density in the metal 
molecular orbitals and thus reduces the extent to which π-back-bonding can take place. 
Less back-bonding affords weaker and lengthened metal–nitrogen bonds and 
consequently, strengthening and shortening of the C=N bonds. The extent of this effect on 
the pyridyl C=N bond is more significant than that on the benzimidazole C=N bond. 
Mass spectrometry 
The structures of cationic complexes 11a – 11c and 12a – 12c were confirmed by ESI 
mass spectrometry, where M refers to the complex cation without the 
hexafluorophosphate counter-ion. Analysed in the positive mode, base peaks 
corresponding to the protonated molecular ion [M+H]2+ fragment are observed for 
compounds 11a – 11c, at m/z 388.5986, 395.6066 and 422.5920, respectively. The 
spectra of compounds 12a and 12b display base peaks for the [M–Cl]2+ fragments at m/z 
325.5818 and 332.5899, respectively. On the other, in the mass spectrum of compound 
12c, the base peak at m/z 240.0528 corresponds to the [M–Cl+H]3+ fragment. The 
experimentally determined base peak values in the positive mode, as well as the 
calculated values are summarised in Table 4.3. In all cases, the two values are in 
agreement, confirming the complex structures. Presence of the hexafluorophosphate 
counter-ion was confirmed by mass spectral analysis in the negative mode. In the mass 
spectra of all complexes, a base peak corresponding to the [PF6]– fragment is observed 
around m/z 144.9640, corroborating what was seen in the 31P{1H} NMR spectra. 
Table 4.3 Experimentally determined base peak m/z values and corresponding calculated values 
for complexes 11a – 11c and 12a – 12c. 
Compound 
Base peak (100% abundant) 
Found m/z Calculated m/z 
11a 388.5986 [M+H]2+ 388.5986 
11b 395.6066 [M+H]2+ 395.6064 
11c 422.5920 [M+H]2+ 422.5923 
12a 325.5818 [M–Cl]2+ 325.5818 
12b 332.5899 [M–Cl]2+ 332.5896 
12c 240.0528 [M–Cl+H]3+ 240.0529 





Suitable crystals of compound 11b were obtained and the molecular structure was 
confirmed by single-crystal X-ray diffraction. Crystals were grown by slow diffusion of 
hexane into a solution of compound 11b in acetone, forming red block crystals in a 
monoclinic crystal system with the P21/n space group. The molecular structure of 
compound 11b is shown in Figure 4.9. There are two molecules of compound 11b and 
three and a half molecules of acetone in the asymmetric unit.  
The molecular structure shown in Figure 4.9 confirms the desired structure of compound 
11b, with the 2-pyridylbenzimidazole ligand coordinating in the bidentate-chelating 
mode, through the benzimidazole- and pyridyl-nitrogen atoms. In addition, preparation 
of the N^N-chelated Ir(III) complex results in a cationic species, which is confirmed by 
the presence of the hexafluorophosphate counter-ion in the molecular structure. The 
complex adopts a pseudo-tetrahedral geometry around the iridium metal centre, as seen 
in Figure 4.9. This three-dimensional shape, described as a ‘piano-stool’ geometry, is 
commonly adopted by half-sandwich complexes. 
 
 
Figure 4.9 Molecular structure of compound 11b, with ellipsoidal models drawn at the 40% 
probability level. 
 




Selected bond lengths and angles are listed in Table 4.4 and crystallographic data in 
Table 4.5, respectively. The Ir–Cp* bond distances range between 1.339 and 1.467 Å. The 
Cl–Ir–N1 and Cl–Ir–N2 bond angles are comparable, at the near orthogonal 86.06 and 
85.88°, respectively, while the N–Ir–N bond angle is 75.72°, significantly smaller than the 
former. These bond angles are in agreement with structurally similar N^N-coordinated 
Ir(III),23 Rh(III)23, 24 and Ru(II)23-25 complexes in the literature. The Ir–Cl and Ir–Npyr bond 
lengths are comparable, with distances of 1.594 and 1.587 Å, respectively. The Ir–Nimine 
bond length is shorter, measuring at 1.349 Å. Although the geometry and bond angles 
about the metal centre correlate well with analogous complexes in the literature, the 
metal-ligand bond lengths in the molecular structure of complex 11b are shorter than 
corresponding bond lengths reported. Analogous M–Nimine/pyr  lengths are approximately 
2.1 Å, while M–Cl lengths are approximately 2.4 Å in the literature.23, 25 
 
Table 4.4 Selected bond lengths and angles of compound 11b 
 11b 
Bond lengths (Å)  
Ir(1A) – Cl(1A) 1.594(4) 
Ir(1A) – N(1A) 1.587(4) 
Ir(1A) – N(2A) 1.349(6) 
Ir(1A) – C(26A) 1.357(6) 
Ir(1A) – C(27A) 1.392(6) 
Ir(1A) – C(28A) 1.339(5) 
Ir(1A) – C(29A) 1.398(6) 
Ir(1A) – C(30A) 1.467(5) 
Bond angles (°)  
Cl(1A) – Ir(1A) – N(1A) 86.06(12)    
Cl(1A) – Ir(1A) – N(2A) 85.88(12)    











Table 4.5 Crystallographic data for compound 11b 
 11b 
Chemical formula  C35H37Cl2IrN5F6P   
Formula weight 935.80 
Crystal system  Monoclinic 
Space group P21/n 
Crystal size (mm) 0.10 × 0.14 × 0.15 
a, b, c (Å) 14.8624(11), 23.0137(18), 26.002(2) 
α, β, γ (°) 90, 102.009(2), 90 





Scan range/° 1.2 < θ < 27.5   
Unique reflections  19922 
Reflections used [I > 2σ(I)]  14511 
Rint  0.097 
R indices (all data) R 0.0400, wR2 0.0929, S 1.01 
Goodness-of-fit 1.01 
Max, Min Δρ/e Å  -1.22, 1.94 
 
4.2.2.2 N^N-coordinated Rh(III) 2-phenylpyridyl (ppy) complexes (13a – 13c) 
Synthesis 
Cationic N^N-coordinated Rh(III) 2-phenylpyridyl (ppy) complexes were prepared via 
successive bridge-splitting and counter-ion exchange reactions as depicted in 
Scheme 4.5. In a one-pot synthesis similar to that for complexes 11a – 11c and 12a – 12c, 
the pyridyl aminoquinoline-benzimidazole ligands (6a – 6c) were reacted with 
dichlorotetrakis(2-(2-pyridinyl)phenyl)dirhodium(III)26 in dichloromethane and 
methanol at 65 °C. This was followed by subsequent anion exchange of the chloride ion 
using ammonium hexafluorophosphate in dichloromethane and ethanol at room 
temperature. The desired cationic Rh(III) complexes (13a – 13c) were isolated as either 




dark orange crystals, pale-yellow or beige powders in moderate to high 
yields (71 – 89%).  These complexes are soluble in a range of organic solvents such as 
dichloromethane, methanol and acetone, and are sparingly soluble in ethanol and ethyl 
acetate. 
 
Scheme 4.5 Preparation of cationic Rh(III)-ppy complexes. Reagents and 
conditions (i) [Rh(ppy)2Cl]2 / DCM:MeOH / 65 °C / 24 h; (ii) NH4PF6 / 25 °C / 2 h. 
Characterisation 
The structures of the cationic rhodium-ppy complexes (13a – 13c) were confirmed using 
NMR (1H, 13C{1H}, 31P{1H}, COSY and HSQC) and IR spectroscopy, and high-resolution ESI 
mass spectrometry.  
NMR spectroscopy 
As seen for the previous cationic complexes (11a – 11c and 12a – 12c, Section 4.2.2.1), 
in the spectra of complexes 13a – 13c, most signals shift downfield compared to their 
respective ligands. This deshielding effect results from the presence of the electron-
deficient rhodium centre, which draws electron density from the ligands, and thus 
provides evidence of successful coordination. The 1H NMR spectra of compounds 
13a – 13c all display similar trends, with slight chemical shift differences in the aromatic 
proton signals based on the electron-withdrawing or -donating effect of the 5-position 
substituent (H, CH3 or CF3). The 1H NMR spectrum of compound 13b is shown in Figure 
4.10, depicting the proton assignments.  
The methylene protons of the propyl linker give rise to three multiplets at 5.00, 3.64 and 
2.38 ppm, respectively. The increased multiplicity/splitting of the signals for H-13, H-12 




and H-11 (Figure 4.10, zoomed in with the water signal suppressed) suggests 
diasterotopicity of these methylene protons. This effect is the result of the chirality of the 
coordinated metal centre, and thus confirms successful complexation of the bidentate 




Figure 4.10 1H NMR spectrum of complex 13b in DMSO-d6. 
Signals between 8.6 and 5.8 ppm integrate for twenty-eight aromatic protons collectively, 
for the quinoline, benzimidazole and phenyl moieties, as well as the two 2-phenylpyridine 
ligands. There is great overlap of signals in this region and proton assignments were 
made with the aid of 2D correlation spectroscopy (COSY). The protons of the two identical 
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2-phenylpyridyl ligands do not experience identical chemical environments, with each 
proton resonating individually in the spectrum. Corresponding proton pairs resonate 
close together with similar multiplicities and coupling constants. In Figure 4.10, proton 
pairs H-41/H-30 and H-44/H-33 provide an excellent example of this trend. Contrary to 
the trend of signals shifting downfield compared to that in the ligand, aromatic proton 
H-18 (4-position of the benzimidazole, adjacent to the methyl substituent) shifts 
significantly upfield upon complexation, from 7.52 ppm in ligand 6b to 5.85 ppm in 
compound 13b. Similarly, in the spectrum of compound 13c, the aromatic proton at the 
4-position of the benzimidazole shifts upfield, from 8.11 ppm in ligand 6c to 6.44 ppm in 
compound 13c. In addition, the protons of the methyl substituent of compound 13b 
are observed as a singlet at 2.03 ppm, shifted upfield compared to that of the 
ligand (2.44 ppm). 
In the 31P{1H} NMR spectra of compounds 13a – 13c, a septet is observed around -144 
ppm, corresponding to the phosphorous atom of the hexafluorophosphate counter-ion. 
Furthermore, the 13C{1H} NMR spectra of compounds 13a – 13c were also recorded. 
Compared to the spectra of the respective ligands, the additional signals in the aromatic 
region attest to the incorporation of the two 2-phenylpyridyl ligands, confirming 
successful complexation. For all complexes, the forty-three aromatic carbon atoms, as 
well as the trifluoromethyl carbon atom of compound 13c, resonate between 168.9 and 
99.0 ppm. The methyl carbon atom of compound 13b gives rise to a signal at 21.5 ppm. 
In addition, the methylene carbon atoms of the propyl linker give rise to three signals 
around 43.8, 40.5 and 28.3 ppm, respectively. 
Infrared spectroscopy 
Infrared spectral analysis of compounds 13a – 13c were carried out using ATR. The shifts 
of some absorption bands compared to the ligands, and the appearance of new bands 
confirms the desired structures. The absorption bands for compounds 13a – 13c are 
summarised in Table 4.6. The secondary amine ν(N-H) and aromatic ν(C=C) stretching 
frequencies are retained in the spectra at 3345 and 1580 – 1581 cm-1, respectively. The 
newly-introduced 2-phenylpyridyl moieties gives rise to a sharp ν(C=N) absorption band 
in the region 1604 – 1606 cm-1, confirming successful complexation.  




Coordination of the metal is also evidenced in the shifts of the ν(C=N) absorption bands 
corresponding to the pyridyl and benzimidazole moieties. As mentioned for complexes 
11a – 11c and 12a – 12c (Section 4.2.3.1, Figure 4.8), the cationic nature of the rhodium 
metal centre of complexes 13a – 13c results in decreased back-donation and 
consequently weakened rhodium-ligand bonds and strengthened C=N bonds. The shorter 
C=N bond in the complex compared to the ligand is evident by the shift of the ν(C=N) 
bands to higher wavenumbers in the IR spectra. The pyridyl ν(C=N) band shifts from 
1590 – 1592 cm-1 in the ligands to 1629 cm-1 in the complexes, while the benzimidazole 
ν(C=N) band only shifts slightly from 1609 – 1613 cm-1 in the ligands to 1615 cm-1 in the 
complexes, appearing as a shoulder. The quinoline ν(C=N) band is also retained in the 
spectra, overlapping with the benzimidazole and ppy ν(C=N) bands, resulting in the 
absorption band broadening. 
Table 4.6 Infrared absorbances for compounds 13a – 13c. 
Compound 
ν (cm-1) 
N-H C=Npyr (sh)a,b C=Nbenz/quin (sh)b,c C=Nppyd C=C 
13a 3345 1629 1615 1604 1581 
13b 3345 1629 1615 1604 1580 
13c 3345 1629 1615 1606 1581 
apyr = pyridyl, bsh = shoulder, cbenz/quin = benzimidazole/quinoline, dppy = 2-phenylpyridyl  
 
Mass spectrometry 
The correct structures of complexes 13a – 13c, and the presence of the 
hexafluorophosphate counter-ion was confirmed using ESI mass spectrometry, where M 
refers to the complex cation excluding the PF6– counter-ion. The exact molecular masses 
of the cationic complexes 13a – 13c, without the hexafluorophosphate ion, are 824.1776, 
838.1932 and 892.1650 g.mol-1, respectively. Peaks corresponding to the molecular ion 
[M]+ fragments are observed at m/z 824.1747, 838.1908 and 892.1625 in the mass 
spectra, respectively. The mass spectra also reveal interesting fragmentation patterns for 
these complexes, with the aminoquinoline-benzimidazole ligands (6a – 6c) cleaving from 
the metal under the applied analysis conditions. Peaks corresponding to the [Rh(ppy)2]+ 
fragment (m/z 411.0366) and the protonated ligand [L+H]+ fragment are observed in the 




spectra of complexes 13a – 13c. The mass spectrum (positive mode) of complex 13b is 
displayed in Figure 4.11, showing the fragments observed. 
 
Figure 4.11 Mass spectrum (positive mode) of compound 13b. 
In addition, analysis of compounds 13a – 13c in the negative mode confirmed the 
presence of the hexafluorophosphate anion. In the mass spectra of all three complexes, a 
base peak corresponding to the [PF6]– fragment is observed around m/z 144, further 





































Based on their superior antiplasmodium and antimycobacterial activities, as well as 
favourable resistance indices and low cytotoxicity, 2-phenyl hybrid ligands 4a – 4c and 
2-pyridyl hybrid ligands 6a – 6c were selected for complexation with various Platinum 
Group Metal dimers. Cyclometalated (C^N-coordinated) iridium(III)- and rhodium(III) 
complexes 7a – 7c and 8a – 8b were prepared via C-H activation reactions. Two 
equivalents of ligands 4a – 4c were reacted with one equivalent of the iridium dimer 
[Ir(Cp*)(Cl)2]2 or rhodium dimer [Rh(Cp*)(Cl)2] in the presence of sodium acetate. 
Successful synthesis of complexes 7a – 7c required only mild conditions, proceeding at 
room temperature, while complexes 8a – 8b required elevated temperatures for 
successful synthesis. The decreased reactivity of the Rh(III) is in line with the proposed 
electrophilic mechanism of C-H activation during cyclometalation. In addition, quinoline 
N-coordinated iridium(III) and rhodium(III)  complexes 9a – 9c and 10a – 10c complexes 
were synthesised, as a result of their selective formation under certain reaction 
conditions. These eleven new neutral complexes were fully characterised using 1H and 
13C{1H} NMR spectroscopy, IR spectroscopy and high-resolution ESI mass spectrometry. 
The 1H NMR spectra of compounds 7a – 7c and 8a – 8b each revealed the presence of two 
conformational isomers, which convert to the proposed more stable of the two isomers 
upon heating of the NMR sample or extended periods of time in solution.   
Furthermore, two sets of cationic N^N-coordinated complexes were also prepared. Two 
equivalents of ligands 6a – 6c were reacted with one of either the iridium dimer 
[Ir(Cp*)(Cl)2]2 or rhodium dimer [Rh(Cp*)(Cl)2]2, via bridge-splitting reactions to afford 
the cationic complexes as chloride salts, which were not isolated. This was followed by 
counter-ion exchange with ammonium hexafluorophosphate to yield the desired cationic 
Ir(III)- and Rh(III)-Cp* complexes (11a – 11c and 12a – 12c) as hexafluorophosphate 
salts. In a similar way, cationic Rh(III)-ppy complexes 13a – 13c were synthesised by 
reaction of ligands 6a – 6c with a rhodium dimer [Rh(ppy)2Cl]2, via bridge-splitting 
reactions, followed by counter-ion exchange with ammonium hexafluorophosphate. The 
initial bridge-splitting step to form complexes 11a – 11c and 12a – 12c were performed 
at room temperature, while that for complexes 13a – 13c required elevated 
temperatures due to limited solubility of the [Rh(ppy)2Cl]2 dimer. These nine new 




cationic complexes were fully characterised using NMR (1H, 13C{1H}, 31P{1H}, COSY and 
HSQC) and IR spectroscopy, and high-resolution ESI mass spectrometry. 
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Pharmacological evaluation of PGM-containing 
aminoquinoline-benzimidazole hybrid complexes 
 
5.1 Introduction 
A special consideration in the process of drug development is the mechanism of action, 
the way in which the ‘drug’ will exert its pharmacological effect. Metal-based compounds 
have demonstrated a number of different modes of action in various diseases, including 
DNA interaction,1 enzyme inhibition,2 generation of reactive oxygen species (ROS)3 and 
induction of apoptosis.4 Some compounds are known to target the survival mechanisms 
of the microbe of interest. The latter is of particular importance with regards to tackling 
Plasmodium falciparum parasites. The haem degradation pathway is a prominent target 
in the parasite life cycle, in which drugs are aimed at inhibiting haemozoin formation.  
The detergent-mediated Nonidet P-40 (NP-40) β-haematin inhibition assay, developed 
by Sandlin et al.,5 is a high throughput screen used to identify potential inhibitors of 
haemozoin formation, and was used to evaluate the compounds herein. The neutral 
NP-40 detergent provides a lipophilic environment, mimicking lipids in the parasite 
digestive vacuole, which mediates the formation of β-haematin (synthetic haemozoin).5 
The pyridine ferrohaemochrome method, developed by Egan et al.,6 is often used to 
measure the inhibition activity. In this quantification method, pyridine forms a complex 
with haematin (β-haematin precursor) only, in mixtures of both haematin and β-
haematin. Its absorbance correlates with, and is a measure of, the β-haematin inhibition 
activity of a compound.6 
In addition to the aforementioned mechanisms of action, metal-based compounds 
provide novel ways to overcome or evade resistance, by taking advantage of their 
catalytic properties. In contrast to stoichiometric reactions, intracellular catalysis by 
catalytic metallodrugs may only require low dosages to be administered in order for 
transformations to take place.7, 8 This may reduce toxicity, unwanted side-reactions and 





undesirable side-effects. Transfer hydrogenation is a versatile reduction process, which 
has demonstrated applicability in aqueous media, using sodium formate as the hydride 
source.9 This bodes well for its application in biological media/systems using 
biomolecules.   
With regards to transformations of biomolecules, transfer hydrogenation reactions 
involving the NAD+/NADH couple, utilising metal-based catalysts, have been explored.10, 
11 The coenzymes, NAD+ and NADH, take part in redox reactions essential to the 
metabolism of living organisms, and thus their interconversion may represent an 
important target intracellularly. Sadler and co-workers have previously reported on the 
NAD+/NADH transfer hydrogenation activity of ruthenium-containing complexes in 
cancer cells, using sodium formate as a hydride source.8, 12 
Most relevant to the study at hand, Stringer et al. investigated the transfer hydrogenation 
of NAD+ by iridium- and rhodium-containing complexes, in the context of Plasmodium 
parasites.13  The transfer hydrogenation activity of half-sandwich Ir(III) and Rh(III) 
complexes, in the presence of sodium formate, was demonstrated in a cell-free 
environment.13 The principle of the cell-free assay is depicted in Figure 5.1, and is 
modified from the Plasmodium lactate dehydrogenase (pLDH) assay. In this case, NADH 
reduces the tetrazolium dye to formazan, which is quantified using absorption 
spectroscopy and serves as a measure of activity. Furthermore, an investigation of the K1 
strain parasite viability suggested that co-administration of the Ir(III) complex and 
sodium formate lead to transfer hydrogenation in the parasite.13 
 
Figure 5.1 Principle of cell-free transfer hydrogenation assay.  





5.2 Pharmacological evaluation of Ir(III) and Rh(III) aminoquinoline-
benzimidazole hybrid complexes 
The pharmacological activities of the neutral and cationic Ir(III) and Rh(III) complexes 
(7 – 8 and 11 – 13, Figure 5.2), described in Chapter 4, were evaluated. The complexes 
were screened in vitro against the chloroquine-sensitive NF54 and multidrug-resistant 
K1 strains of Plasmodium falciparum. Their cytotoxicity was determined against the non-
tumorigenic Chinese hamster ovarian (CHO) cell-line. Mechanistic studies were 
performed on selected complexes, probing their β-haematin inhibition activity and their 
ability to catalyse transfer hydrogenation reactions. In addition, the in vitro 
antimycobacterial activity of all complexes was determined against the H37Rv strain of 
Mycobacterium tuberculosis. 
 
Figure 5.2 Pharmacologically screened PGM-containing aminoquinoline-benzimidazole hybrid 
complexes (7 – 8 and 11 – 13). 
The neutral quinoline N-coordinated Ir(III) and Rh(III) complexes (9 – 10) were not 
evaluated for their biological activity as a result of their instability in dimethyl sulfoxide 
(DMSO), the solvent used to prepare stock solutions for biological screenings. DMSO-
based stock solutions are required for the in vitro antiplasmodium, cytotoxicity and 





antimycobacterial assays, as well as the β-haematin inhibition mechanistic study. 
Gasser et al. investigated the DMSO-mediated ligand dissociation of a range of 
N-heterocyclic-[Ru(η6-arene)Cl2] complexes.14 It was observed, visually and by 1H NMR 
spectroscopy, that the N-coordinated complex readily undergoes a ligand exchange 
reaction in DMSO.14 The 1H NMR spectrum of the proposed complex in DMSO-d6, displays 
signals corresponding to a physical mixture of the N-heterocyclic ligand and the 
[Ru(η6-arene)(DMSO)Cl2] complex.14 This ligand exchange was revealed to have 
implications on the outcomes of the biological evaluation.14 
The stability of these quinoline N-coordinated complexes (9a – 9c and 10a – 10c) in 
DMSO-d6 was monitored by 1H NMR spectroscopy. The stacked 1H NMR spectra of 
compounds 9b, 4b and [Ir(Cl2)(Cp*)]2 in DMSO-d6 are depicted in Figure 5.3. The 
spectrum of the proposed complex shows signals corresponding to the protons of the 
aminoquinoline-benzimidazole and Cp* ligand, with no differences in chemical shifts 
compared to the starting materials. This trend is consistent for all of the Ir(III) and Rh(III) 
quinoline N-coordinated complexes. 
 
Figure 5.3 Stacked 1H NMR spectra of complex 9b, ligand 4b and [Ir(Cl2)(Cp*)]2 in DMSO-d6. 
[Ir(Cl2)(Cp*)]2 in DMSO-d6 





The proposed ligand exchange reaction which takes place in solution is shown in Scheme 
5.1. We speculate that this ligand dissociation and exchange occurs at varying rates for 
the different analogues (M = Ir or Rh and X = H, CH3 or CF3). The spectra of compounds 
9a – 9c and 10a – 10c initially display downfield shifts in selected proton signals, 
consistent with metal-coordination, which after some time shift upfield as a result of 
DMSO-mediated ligand dissociation. Further evidence of metal-ligand bond dissociation 
was provided using single crystal X-ray diffraction. Crystals grown from a DMSO-d6 
solution of complex 9b were determined to be that of ligand 4b alone, with no metal 
coordination. 
 
Scheme 5.1 The proposed ligand exchange reaction taking place in solution. 
 
 
5.2.1 In vitro antiplasmodium activity and cytotoxicity 
The C^N-coordinated (7 – 8) and N^N-coordinated (11 – 13) Ir(III) and Rh(III) 
complexes were evaluated for their in vitro antiplasmodium activity using the 
Plasmodium lactate dehydrogenase (pLDH) assay,15 described in Chapter 3 (Section 3.1). 
All complexes were screened against the CQS NF54 strain of P. falciparum and selected 
complexes, which were sufficiently active in this strain (IC50 ≤ 2 µM), were screened 
against the MDR K1 strain. Chloroquine (CQ) was used as the control drug in the 
screening. The IC50 values and resistance indices (RI) are summarised in Table 5.1. In 
general, most of the PGM-containing aminoquinoline-benzimidazole hybrid complexes 
display good antiplasmodium activity, with IC50 values in the low micromolar and sub-
micromolar range. 
 





Table 5.1 In vitro antiplasmodium data for compounds 7 – 8, 11 – 13 and CQ. 
   IC50 (µM) ± SE  
Compound M X NF54 K1 RIa 
7a Ir H 2.007 ± 0.075 2.844 ± 0.030 1.417 
7b Ir CH3 1.676 ± 0.171 2.181 ± 0.025 1.301 
7c Ir CF3 0.488 ± 0.062 0.688 ± 0.032 1.410 
8a Rh H 1.073 ± 0.028 2.217 ± 0.167 2.066 
8b Rh CH3 1.327 ± 0.255 1.810 ± 0.176 1.364 
11a Ir H > 10 NDb – 
11b Ir CH3 > 10 NDb – 
11c Ir CF3 1.454 ± 0.043 > 10 – 
12a Rh H 2.001 ± 0.148 > 10 – 
12b Rh CH3 1.867 ± 0.562 > 10 – 
12c Rh CF3 0.194 ± 0.066 > 10 – 
13a Rh H 0.326 ± 0.002 0.844 ± 0.144 2.589 
13b Rh CH3 0.313 ± 0.005 0.228 ± 0.003 0.728 
13c Rh CF3 0.404 ± 0.010 1.302 ± 0.494 3.223 
CQ – – 0.0160 ± 0.0005 0.164 ± 0.018 10.250 
aRI = IC50(K1) / IC50(NF54); 
bND = not determined 
The IC50 values obtained against the CQS NF54 strain are graphically depicted in Figure 
5.4. With regards to the neutral cyclometalated complexes, the unsubstituted Rh(III) 
complex 8a (1.073 µM) is more active than the corresponding Ir(III) complex 7a (2.007 
µM), while the methyl-substituted complexes 8b and 7b have comparable activity (1.327 
and 1.676 µM). Interestingly, the activity of the Ir(III) complexes appears to increase with 
increasing hydrophobicity of the 5-position benzimidazole substituent (X). The 
unsubstituted and methyl-substituted compounds 7a and 7b are 3- to 4-fold less active 
than the trifluoromethyl-substituted analogue 7c. Compound 7c is the most active of the 
neutral compounds in the CQS NF54 strain, with the lowest IC50 value of 0.488 µM. This 
may suggest a correlation between antiplasmodium activity and hydrophobicity, as well 
as the closely-related property of lipophilicity. However, this trend is not observed for 
the Rh(III) complexes.   



















Figure 5.4 IC50 values of compounds 7 – 8 and 11 – 13 against the CQS NF54 strain of 
P. falciparum. 
For the cationic pentamethylcyclopentadienyl (Cp*) series, the unsubstituted and 
methyl-substituted Ir(III) complexes 11a and 11b were inactive (IC50 > 10 µM) against 
the NF54 strain at the tested concentration. The trifluoromethyl-substituted compound 
11c, however, displays good activity in the low micromolar range. The Rh(III) complexes 
12a – 12c display significantly enhanced activity compared to their corresponding Ir(III) 
complexes 11a – 11c. In addition, the analogues with the more hydrophobic 
trifluoromethyl group (11c and 12c) are the most active of the Ir(III) and Rh(III) 
complexes, giving rise to IC50 values of 1.454 and 0.194 µM, respectively. Comparing the 
activity of the neutral and cationic M-Cp* series, the neutral Ir(III) and Rh(III) complexes 
(7 – 8) generally outperformed their corresponding cationic complexes (11 – 12).  
The potent sub-micromolar activity of the cationic Rh(III) phenylpyridyl (ppy) complexes 
(13a – 13c) reiterates the favourable antiplasmodium properties attributed to the 
rhodium metal centre. Compounds 13a, 13b and 13c have comparable activity against 
the NF54 strain, displaying IC50 values of 0.326, 0.313 and 0.404 µM, respectively. The 
general superior activity of these Rh(III)-ppy complexes, compared to the M-Cp* 
complexes, may be related to the planarity of the ppy ligands. A cationic platinum 
complex of 1,10-phenanthroline, reported by Egan et al., demonstrated a strong 














inhibition ability.16 The strong interaction with ferriprotoporphyrin IX was attributed in 
part to the presence of an extended planar phenanthroline ring system with delocalized 
electrons.16 Considering haemozoin inhibition as a possible mechanism of action for 
these hybrid complexes, the planar ppy ligand system of complexes 13a – 13c may have 
greater interaction with ferriprotoporphyrin IX, which may have implications on their 
potential haemozoin inhibition ability. 
Selected hybrid complexes were evaluated in the MDR K1 strain of P. falciparum. The 
cationic Ir(III)-Cp* complexes, 11a and 11b, were not screened as a result of their 
inactivity in the CQS NF54 strain. In addition, the remaining cationic M-Cp* complexes 
(11c and 12a – 12c) were inactive against K1 parasites (IC50 > 10 µM) at the tested 
concentration. With the exception of the aforementioned compounds, all tested 
compounds displayed good antiplasmodium activity in the low to sub-micromolar range. 

















Figure 5.5 IC50 values of compounds 7 – 8 and 11 – 13 against the MDR K1 strain of 
P. falciparum. 
In the resistant K1 strain, the neutral iridium and rhodium complexes are comparably 
active. The unsubstituted and methyl-substituted Ir(III) complexes (7a and 7b) and their 
corresponding Rh(III) analogues (8a and 8b) give rise to IC50 values in the range 2.844 – 
1.810 µM. Once again, the activity of the analogue with the more hydrophobic X 
substituent is enhanced. The most active neutral complex against the K1 strain is the 





trifluoromethyl-substituted Ir(III) complex 7c, displaying an IC50 value of 0.688 µM. In 
contrast, the CF3-substituted Rh(III)-ppy complex 13c (1.302 µM) was the least active of 
its series. Cationic complexes 13a and 13b are the most active unsubstituted and methyl-
substituted analogues overall, giving rise to sub-micromolar IC50 values of 0.844 and 
0.228 µM, respectively.  
When comparing the activity of the compounds in the CQS NF54 and MDR K1 strains, it 
can be seen that in general, most of the compounds have comparable or decreased 
activity in the resistant strain. Compounds 7a – 7c, 8a – 8b, 13a and 13c all display 
resistance indices in the range 1.3 – 3.2 (RI ≥ 1), significantly lower than that of CQ. The 
compounds with RI values close to one may be applicable in both sensitive and resistant 
strains of P. falciparum. Compound 13b provides an exception in this regard, displaying 
enhanced activity in the resistant strain compared to the sensitive strain. The cationic 
Rh(III)-ppy complex 13b has a RI value of 0.728 (RI < 1), suggesting that it is not 
susceptible to cross-resistance and indicating a potential to overcome parasite resistance. 
With regards to the effect of organometallic derivatisation on the antiplasmodium 
activity, the activity of the PGM-containing complexes (7 – 8 and 11 – 13) was compared 
to that of the corresponding ligands (described in Chapter 3). Contrasting trends are 
revealed across the different series and P. falciparum strains. In the NF54 strain, the 
neutral unsubstituted Ir(III) and Rh(III) complexes, 7a and 8a, are almost 3- and 5-fold 
more potent than the ligand 4a (5.553 µM). Cationic complexes 12b, 12c, 13a and 13b 
are more active than their respective ligands 6a (1.089 µM), 6b (4.984 µM) and 
6c (0.410 µM). Trifluoromethyl-substituted complexes 7c and 13c maintained 
comparable activity to their respective ligands 4c (0.431 µM) and 6c. Interestingly, in the 
K1 strain, the coordination of the [Rh(ppy)2] moiety to the inactive ligands, 6a and 
6c (> 20 µM), resulted in potent sub-micromolar activity in complexes 13a and 13c. In all 
other cases, higher IC50 values were observed for the complexes compared to the ligands, 










The C^N-coordinated Ir(III) and Rh(III) complexes (7a – 7c and 8a – 8b) and selected 
N^N-coordinated Rh(III) complexes (13a – 13c) were screened against the non-
tumorigenic CHO cell-line, to determine their cytotoxicity and to evaluate selectivity. The 
compounds were evaluated using the MTT assay17, 18 and emetine was used as the control 
drug. The cytotoxicity of the N^N-coordinated Ir(III)-Cp* and Rh(III)-Cp* complexes 
(11a – 11c and 12a – 12c) was not determined as a result of their inactivity in the NF54 
strain (11a and 11b) and the K1 strain (11c and 12a – 12c) of P. falciparum. In general, 
all tested compounds displayed low or no cytotoxicity against the non-tumorigenic cells. 
The IC50 values and selectivity indices (SI) of the screened compounds are reported in 
Table 5.2. 
Table 5.2 Cytotoxicity data and selectivity indices for selected compounds (7 – 8 and 13) and the 
control, emetine. 
Compound CHO IC50 (µM) SI1a SI2b 
7a > 50 – – 
7b > 50 – – 
7c 14.14 28.98 20.55 
8a 133.30 124.23 60.13 
8b 78.89 59.45 43.59 
13a 91.52 280.74 108.44 
13b 106.36 339.81 466.49 
13c 60.63 150.07 46.57 
Emetine 0.0181 - - 
aSI1 = IC50(CHO) / IC50(NF54); 
bSI2 = IC50(CHO) / IC50(K1) 
Compound 7c displayed low toxicity towards the CHO cells, giving rise to a moderate 
micromolar IC50 value of 14.14 µM. Compounds 7a – 7b, 8a – 8b and 13a – 13c were non-
cytotoxic at the highest concentration tested, with IC50 values greater than 50 µM. The 
selectivity indices (SI) were determined to gauge the selectivity of the tested compounds 
for the sensitive and resistant Plasmodium strains compared to the CHO cell-line. The SI 
values were calculated to be greater than 28 and 20 for the sensitive NF54 (SI1) and 
resistant K1 (SI2) strains, respectively. These values, which are significantly greater than 





one, suggest that these Ir(III) and Rh(III)-containing hybrid complexes are selective 
toward parasite strains. In addition, it may also imply that the antiplasmodium properties 
of these complexes are the result of mechanisms other than general cytotoxicity. 
 
5.2.2 Mechanistic studies 
5.2.2.1 β-haematin inhibition 
Selected active complexes from each series were evaluated for a potential mechanism of 
action which takes place in the Plasmodium digestive vacuole. The detergent-mediated 
NP-40 assay5 and subsequent colorimetric pyridine ferrihaemochrome method6 were 
used to assess the β-haematin (synthetic haemozoin) inhibition ability of the iridium and 
rhodium complexes of interest. Compounds 7a, 7c, 8a, 8b, 11c, 12c and 13b were tested, 
and CQ was used as the positive control. The IC50 values obtained are listed in Table 5.3.  
Table 5.3 β-haematin inhibition activity of compounds 7a, 7c, 8a, 8b, 11c, 12c and 13b. 
Compound IC50 (µM) [95% confidence interval] 
7a 13.88 [12.13 to 15.88] 
7c 16.03 [14.43 to 17.81] 
8a 31.05 [30.03 to 32.09] 
8b 36.34 [33.63 to 39.28] 
11c 5.46 [5.01 to 5.95] 
12c 8.39 [7.83 to 8.99] 
13b 11.68 [10.50 to 12.99] 
CQ 73.98 [71.14 to 76.94] 
 
In general, all of the tested compounds are potent inhibitors of β-haematin formation in 
the cell-free assay, at least 2-fold more active than CQ (74 µM). The IC50 values are 
graphically represented in Figure 5.6, displaying the trends observed. The X substituent 
appears to have no significant effect on the β-haematin inhibition activity. The 
unsubstituted and trifluoromethyl-substituted Ir(III) complexes (7a and 7c) have 
comparable IC50 values, as do the unsubstituted and methyl-substituted Rh(III) 
complexes (8a and 8b). The cationic N^N-coordinated complexes (11 – 13), 
outperformed the neutral C^N-coordinated complexes (7 – 8), giving rise to IC50 values 





in the range 5.46 – 11.68 µM, compared to 13.88 – 36.34 µM for complexes 7 – 8.  The 
superior activity of the cationic compounds may be the result of their enhanced solubility 
in the assay medium over time, compared to the neutral compounds. This may allow 
greater interaction with the haematin species, thus leading to greater inhibition of 
β-haematin formation.  














Figure 5.6 IC50 values compounds 7a, 7c, 8a, 8b, 11c, 12c and 13b towards 
β-haematin inhibition. 
In addition, the effect of the different metals on β-haematin inhibition activity is clearly 
seen in Figure 5.6. Across the neutral and cationic M-Cp* series, the Ir(III)-containing 
complexes display enhanced activity compared to the Rh(III)-containing analogues. For 
the neutral M-Cp* complexes, the Ir(III) complexes 7a and 7c (13.88 – 16.03 µM) have 
IC50 values approximately two-fold lower than the Rh(III) complexes 8a and 8b (31.05 – 
36.34 µM). For the cationic M-Cp* complexes, Ir(III) complex 11c (5.46 µM) displays an 
IC50 value about 1.5-fold lower than Rh(III) complex 12c (8.39 µM). This difference in 
activity may be the result of differences in lipophilicity, as observed for the 2-phenyl, 2-
ferrocenyl and 2-pyridyl aminoquinoline-benzimidazole hybrids in Chapter 3 (Section 
3.2.4.1).  Although logP values of these aminoquinoline-benzimidazole hybrid Ir(III) and 
Rh(III) complexes have not been determined, previous literature reports higher logP 
values (and thus greater lipophilicity) for a d6 low-spin Ir(III) half-sandwich complex 
compared to the isostructural Rh(III) complex.19 Furthermore, there is no discernable 





correlation between β-haematin inhibition activity and the in vitro antiplasmodium 
activity (NF54/K1), reported in Section 5.2.1. 
 
5.2.2.2 Transfer hydrogenation 
As discussed in Section 5.1, the catalytic activities of metal-based compounds can be 
utilised to establish novel modes of antimicrobial action. Selected compounds (7a and 
8a) were evaluated for their ability to catalyse the transfer hydrogenation of β-
nicotinamide adenine dinucleotide (NAD+) to form β-nicotinamide adenine dinucleotide 
reduced (NADH) in the presence of sodium formate as the hydride source.  
As a preliminary study, neutral cyclometalated complexes 7a and 8a were subjected to a 
qualitative screening of their ability to reduce NAD+ to NADH using sodium formate, by 
means of 1H NMR spectroscopic experiments. Compound 7a or 8a, sodium formate and 
NAD+ were combined and the 1H NMR spectra of the mixtures were recorded over a 
period of one hour. In order to mimic biological or assay conditions, the samples were 
maintained at a temperature of 310 K (37 °C). The 1H NMR spectra, recorded five minutes 
after sample preparation, after thirty minutes and one hour for each compound (7a and 
8a), are shown in Figure 5.7.  
The regioselective reduction of NAD+ to form 1,4-NADH is confirmed by differences in the 
spectra. The conversion effected by each catalyst takes place at varying rates, as 
demonstrated by the appearance of 1,4-NADH at different times. For Ir(III) complex 7a, 
a considerable amount of 1,4-NADH had already formed immediately after sample 
preparation, and complete conversion had taken place after thirty minutes. On the other 
hand, for Rh(III) complex 8a, only trace amounts of 1,4-NADH was formed immediately 
after sample preparation. After thirty minutes, only trace amounts of NAD+ remained, 
with complete conversion taking place by one hour.  






Figure 5.7 Stacked 1H NMR spectra of a mixture of compound 7a or 8a, NAD+ and sodium 
formate in D2O/MeOD at 310K over time. * = signals for NAD+ and * = signals for 1,4-NADH. 
The transfer hydrogenation ability of the hybrid complexes in a cell-free environment 
was then monitored using a method described by Stringer et al.,13 based on the pLDH 
assay (Chapter 3, Section 3.1).15, 20 In the modified assay, the complex of interest catalyses 
the conversion of NAD+ to NADH, using sodium formate as the hydrogen source. In an 
analogous way to APADH in the pLDH/MalstatTM assay,20, 21 the NADH formed reduces 
the nitroblue tetrazolium (NBT) to formazan.13 The conversion of the yellow NBT to blue 
formazan, quantified by absorption spectroscopy, serves as a measure of the transfer 
hydrogenation activity of the complex. Different concentrations of the complex (7a or 8a) 
were incubated (37 °C, pH 7.4) with NAD+ and sodium formate for six hours, allowing the 
complex to catalyse the reduction, followed by addition of NBT and further incubation. 
NAD+ 
1,4-NADH 
7a at t = 0 h 
7a at t = 0.5 h 
 
8a at t = 0 h 
8a at t = 0.5 h 
 
8a at t = 1 h 
* 
* * 


























The 96-well plate setup for complexes 7a and 8a is shown in Figure 5.8. Visually, the 
presence of the blue colour (formazan) in the wells is indicative of the conversion of NAD+ 
to NADH. Based on the development of formazan, it seems as though complex 8a has 
greater catalytic activity than complex 7a, as formazan is present at lower concentrations 
of complex 8a.  
 
Figure 5.8 Plate layout of cell-free transfer hydrogenation experiment after 16-hour incubation. 
The absorbance values, recorded at 600 nm, are proportional to the amount of the 
formazan present, and thus indicates transfer activity. The absorbance values of 
complexes 7a and 8a at the varying concentrations (2250 – 4 µM) are graphically 
depicted in Figure 5.9.  


































For both complexes 7a and 8a, there is a concentration-dependent increase in the 
amount of formazan formed. This indicates that, under the given conditions (37 °C and 
pH = 7.4), both complexes catalyse the transfer hydrogenation of NAD+ to NADH in a 
concentration-dependent manner. The Rh(III) complex 8a is significantly more active 
than the Ir(III) complex 7a, consistently achieving greater conversion at every 
concentration. This is in agreement with the visual result (Figure 5.8). In contrast, in the 
study by Stringer et al., the Ir(III) complex was found to be slightly more active than the 
corresponding Rh(III) complex.13 
The coenzyme NAD+ provides a unique and important target within Plasmodium 
parasites. Previous studies have demonstrated elevated levels of NAD+ during the asexual 
erythrocytic stage of the life cycle of various Plasmodium species.22-26 NAD+ is essential 
for the glycolytic pathway, and has been identified as an enzyme substrate in other 
cellular processes such as DNA repair27 and calcium signalling.28 In this way, the 
regulation of NAD+ by a therapeutic agent may have significant implications for the 
parasite. With this in mind, the in vitro antiplasmodium activity of the Ir(III) complex 7a 
was screened against the CQS NF54 strain of P. falciparum, in the presence of varying 
concentrations of sodium formate. 
The percentage parasite viability for two concentrations of complex 7a (2500 and 
1250 ng/ml), co-administered with sodium formate (0, 5, 10 and 20 mM), is depicted in 
Figure 5.10. As expected, treatment with a greater concentration of complex 7a results in 
lower parasite viability. In the absence of sodium formate (0 mM), 52 and 86% parasite 
viability were observed for 2500 and 1250 ng/ml of complex 7a, respectively. For both 
concentrations of complex 7a, there is a stepwise decrease in the parasite viability with 
increasing concentrations of sodium formate. Comparing 0 mM to 20 mM sodium formate 
at 2500 and 1250 ng/ml of complex 7a, there is an 11% and 9% difference in parasite 
viability, respectively. These differences were found to be statistically insignificant using 
a two-tailed t-test at the 95% confidence interval. Therefore, the effect of co-
administration of sodium formate with complex 7a on parasite viability is not significant 
and may suggest that complex 7a does not have significant transfer hydrogenation 
activity in the parasite. 



























Figure 5.10 Parasite viability observed in the NF54 strain of P. falciparum, when complex 7a 
(2500 and 1250 ng/ml) was incubated with sodium formate (0, 5, 10 and 20 mM). 
 
 
5.2.3 In vitro antimycobacterial activity 
To our knowledge, literature reports exploring the antimycobacterial properties of PGM-
containing hybrid complexes are limited. An example of antimycobacterial iridium(III)- 
and rhodium(III)-containing hybrid complexes29 was briefly discussed in Chapter 3 
(Section 3.1). With this in mind, the C^N-coordinated and N^N-coordinated Ir(III) and 
Rh(III) complexes (7 – 8 and 11 – 13) were evaluated for their in vitro activity against the 
H37Rv strain of  M. tuberculosis. Using the broth micro dilution method,30 minimum 
inhibitory concentration (MIC) values were determined. The 7-day MIC90 values for the 
complexes as well as the control, rifampicin, are summarised in Table 5.4. The 
compounds were screened using two different growth media, the glucose-based 
Middlebrook 7H9-ADC (albumin-dextrose complex) and 7H9-CAS (casitone). Similar 
trends in activity were observed in both media, however, general higher activity (lower 
MIC90 values) was exhibited in the 7H9-CAS medium. 
 





Table 5.4 Antimycobacterial activity of compounds 7 – 8 and 11 – 13. 
Compound Day 7 MIC90 (µM)  
[media: 7H9 GLU CAS] 
Day 7 MIC90 (µM)  
[media: 7H9 GLU ADC] 
7a 0.488 4.244 
7b 1.490 7.813 
7c 1.100 3.652 
8a 8.778 15.309 
8b 8.183 15.800 
11a 62.500 > 125 
11b 39.218 > 125 
11c 31.250 31.250 
12a 31.250 62.500 
12b 19.215 47.679 
12c 17.994 31.250 
13a 4.495 1.161 
13b 4.233 0.889 
13c 7.141 2.085 
Rifampicin 0.026 0.002 
 
The MIC90 values determined in the 7H9-CAS medium are graphically represented in 
Figure 5.11. Most of the compounds displayed moderate to good antimycobacterial 
activity in the range 0.488 – 62.5 µM. These PGM-containing aminoquinoline-
benzimidazole hybrid complexes are significantly less active than the positive control, 
displaying MIC90 values at least twenty-fold higher than the antibiotic 
rifampicin (0.026 µM). With regards to the neutral complexes, the Ir(III) complexes 7a – 
7c are significantly more active than the Rh(III) complexes 8a – 8b. Compounds 7a – 7c 
gave rise to MIC90 values between 0.488 and 1.490 µM, about 5-fold lower than that for 
compounds 8a – 8b (8.778 and 8.183 µM). For these cyclometalated complexes, there is 
no discernable trend with regards to the antimycobacterial activity and the substituent 
(X) at the 5-position of the benzimidazole.   
 






















Figure 5.11 MIC90 values of compounds 7 – 8 and 11 – 13 against the H37Rv stain of M. 
tuberculosis. 
Considering the cationic Ir(III)- and Rh(III)-Cp* complexes, 11 – 12, an interesting trend 
is observed with regards to the 5-position substituent (X). For both the Ir(III) complexes 
(11a – 11c) and the Rh(III) complexes (12a – 12c), the antimycobacterial activity 
increases with incorporation of the hydrophobic substituents (CH3 and CF3). The 
unsubstituted Ir(III) and Rh(III) complexes (11a and 12a) are the least active in the 
series, with MIC90 values of 62.5 and 31.25 µM, respectively. Substitution of the 
hydrophobic methyl group (11b and 12b) enhances the activity, giving decreased MIC90 
values of 39.219 and 19.215 µM, respectively. The analogues with the more hydrophobic 
trifluoromethyl group (11c and 12c) have the lowest MIC90 values of 31.25 and 17.994 
µM, respectively. This trend in activity suggests a correlation between hydrophobicity 
and the antimycobacterial activity.  
The link between hydrophobicity and the antimycobacterial activity suggests a possible 
relationship between lipophilicity and the activity. A positive correlation was observed 
for the antimycobacterial activity of 2-phenyl and 2-ferrocenyl hybrid compounds, 
reported in Chapter 3. These findings are supported by recent studies, which have 
reported on the relationship between lipophilicity and antimycobacterial properties.31-33 
Contrary to what was observed for the neutral M-Cp* complexes, for the cationic M-Cp* 
complexes, the Ir(III) complexes 11a – 11c are consistently less active than their 





corresponding Rh(III) analogues 12a – 12c. Each Rh(III) complex is almost 2-fold more 
active than its corresponding Ir(III) complex, as is evident in Figure 5.11. Considering 
the two M-Cp* series, the neutral complexes 7 – 8 significantly outperformed their 
corresponding cationic complexes 11 – 12. 
The cationic Rh(III)-ppy complexes, 13a – 13c, display good activity against M. 
tuberculosis H37Rv, with MIC90 values in the range 4.233 – 7.141 µM. The unsubstituted 
13a (4.495 µM) and methyl-substituted 13b (4.233 µM) had comparable activity, while 
the trifluoromethyl-substituted 13c (7.141 µM) was slightly less active. Comparing the 
two series of cationic compounds, the Rh(III)-ppy complexes are significantly more active 
than the Ir(III)- and Rh(III)-Cp* complexes. Once again, these differences in activity may 
be attributed to differences in hydrophobicity. Compounds 11 – 12 have a hydrophobic 
Cp* ligand, while compounds 13a – 13c each have two 2-phenylpyridyl ligands, which 
contributes greater hydrophobicity, and thus may confer greater antimycobacterial 
activity.  
With regards to the strategy of organometallic derivatisation, the antimycobacterial 
activity of the PGM-containing complexes was compared to that of the respective ligands 
(described in Chapter 3). The graphs in Figure 5.12 show the comparison of the MIC90 
values of the ligands (4 and 6) and the neutral (7 – 8) and cationic (11 – 13) complexes. 
In all cases, introduction of the Ir(III) and Rh(III) moieties resulted in enhanced 
antimycobacterial activity compared to the ligands. The 2-phenyl hybrid ligands (4a – 4c) 
display moderate micromolar MIC90 values (15.8 – 50.6 µM) and coordination of the 
metal moiety results in low micromolar and even sub-micromolar MIC90 values for the 
neutral cyclometalated complexes (7a – 7c and 8a – 8b). While the 2-pyridyl hybrid 
ligands (6a – 6c) are inactive against M. tuberculosis (MIC90 > 125 µM), coordination of 
the metal gave rise to cationic complexes (11a – 11c, 12a – 12c and 13a – 13c) which 
are active in the moderate and low micromolar range. 
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Figure 5.12 Comparison of (I) MIC90 values of the 2-phenyl hybrid ligands (4) and the neutral 
cyclometalated complexes (7 and 8); (II) MIC90 values of the 2-pyridyl hybrids (6) and the 




The neutral C^N-coordinated and cationic N^N-coordinated iridium and rhodium 
complexes (7 – 8 and 11 – 13) were screened for their potential antiparasitic properties 
against the CQS NF54 strain and MDR K1 strain of Plasmodium falciparum. In the NF54 
strain, most compounds displayed good activity with IC50 values in the low to sub-
micromolar range. However, within the cationic M-Cp* series, the unsubstituted and 
methyl-substituted Ir(III) analogues (11a and 11b) were inactive at the concentration 
tested. When selected compounds were evaluated against the K1 strain, the 
neutral M-Cp* complexes and cationic Rh-ppy complexes were potent, once again 
displaying low to sub-micromolar IC50 values. In this case, the cationic M-Cp* complexes 
(11c and 12a – 12c) proved inactive at the test concentration. Most compounds had 
resistance indices equal to or above one (RI ≥ 1), indicating comparable or decreased 
activity in the resistant strain compared to the sensitive strain. The lower RI values 





















However, the methyl-substituted Rh(III)-ppy complex 13b provides an exception, with a 
RI value of 0.728 (RI < 1), indicating enhanced activity in the resistant strain.  
Selected active compounds were also screened against the non-tumorigenic Chinese 
hamster ovarian (CHO) cell line, in order to evaluate their cytotoxicity. The 
trifluoromethyl-substituted Ir(III)-Cp* complex 7c displayed low cytotoxicity compared 
to the control (emetine), with a moderate micromolar IC50 value of 14.14 µM. All 
remaining compounds (7a – 7b, 8a – 8b and 13a – 13c) were non-cytotoxic against the 
CHO cells, displaying IC50 values greater than 50 µM. All of the tested hybrid complexes 
showed selectivity toward the parasitic strains, compared to the CHO cell-line. 
Selected compounds with favourable antiplasmodium and cytotoxic properties were 
subjected to further mechanistic studies. Active compounds from each series were 
screened for their β-haematin inhibition ability. In the cell-free assay, all of the evaluated 
compounds (7a, 7c, 8a, 8b, 11c, 12c and 13b) were determined to be good to potent 
inhibitors of β-haematin formation. All compounds displayed improved inhibitory effects 
(IC50 values) compared to the control, CQ. In addition, NMR spectroscopic and cell-free 
experiments were utilised in order to gain insight into the transfer hydrogenation ability 
of selected hybrid complexes (7a and 8a). Both the Ir(III) complex 7a and Rh(III) complex 
8a demonstrated the ability to catalyse the conversion of NAD+ to NADH under biological 
or assay conditions. The co-administration of complex 7a and sodium formate did not 
have a significant effect on NF54 parasite viability in vitro. 
Furthermore, all of the hybrid complexes were also evaluated for activity against the 
H37Rv strain of Mycobacterium tuberculosis. Overall, all compounds displayed moderate 
to good antimycobacterial activity. The neutral M-Cp* complexes (7a – 7c and 8a – 8b) 
and the cationic Rh(III)-ppy complexes (13a – 13c) were most active, displaying low 
micromolar MIC90 values. Moderate micromolar MIC90 values were observed for the less 
active cationic M-Cp* complexes (11a – 11c and 12a – 12c). The activity of the cationic 
M-Cp* complexes showed a positive correlation with the hydrophobicity of the 5-position 
substituent (X), suggesting a further link between antimycobacterial activity and 
lipophilicity. 
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Conclusions and Future Outlook 
 
6.1 Conclusions 
The overall aim of this project was to develop aminoquinoline-benzimidazole hybrid 
compounds and their organometallic complexes as antimicrobial agents. Initially, a series 
of 2-phenyl (4a – 4e), 2-ferrocenyl (5a – 5e) and 2-pyridyl (6a – 6e) aminoquinoline-
benzimidazole hybrids were synthesised through successive nucleophilic aromatic 
substitution, reduction and cyclo-condensation reactions. Subsequently, the most 
pharmacologically active 2-phenyl hybrid ligands were reacted with Platinum 
Group Metal dimers, [Ir(Cp*)Cl2]2 and [Rh(Cp*)Cl2]2. This afforded neutral C^N-
coordinated M-Cp* complexes (7a – 7c and 8a – 8b) via C-H activation reactions, as well 
as quinoline N-coordinated M-Cp* complexes (9a – 9c and 10a – 10c). Furthermore, the 
2-pyridyl hybrid ligands were reacted with [Ir(Cp*)Cl2]2 and [Rh(Cp*)Cl2]2, as well as 
[Rh(ppy)2Cl]2  to yield cationic N^N-coordinated M-Cp* (11a – 11c and 12a – 12c) and 
Rh(III)-ppy (13a – 13c) complexes, respectively. The proposed compound structures 
were confirmed through characterisation using 1H and 13C{1H} NMR spectroscopy, IR 
spectroscopy and mass spectrometry.   
The 2-phenyl, 2-ferrocenyl and 2-pyridyl hybrid compounds were evaluated for their in 
vitro activity against the chloroquine-sensitive (CQS) NF54 and multidrug-resistant 
(MDR) K1 strains of Plasmodium falciparum. The organic and ferrocenyl hybrids 
displayed good activity against the NF54 strain, with IC50 values in the low to sub-
micromolar range (5.553 – 0.329 µM). In general, the phenyl and ferrocenyl hybrid 
compounds were more potent in the resistant K1 strain, with most mostly sub-
micromolar IC50 values (0.658 – 0.151 µM). For most of the hybrids, the resistance indices 
were less than one (RI < 1), indicating the absence of cross-resistance with CQ, and 
suggesting greater applicability in resistant strains. In contrast, the methylsulfonyl-
substituted phenyl hybrid (4d) and pyridyl hybrids (6a and 6c) were comparatively less 
active in the K1 strain (RI > 1). These hybrids are among the least lipophilic in the series. 




The effect of ferrocenyl derivatisation on the antiplasmodium activity was inconsistent 
across the two strains. In some cases, the ferrocenyl hybrids (5a – 5e) were more active 
than the phenyl analogues (4a – 4e), and in others not. The most active phenyl, ferrocenyl 
and pyridyl hybrids overall were compounds 4c (CF3), 5b (CH3) and 6c (CF3), 
respectively. These all contain hydrophobic substituents, suggesting a correlation 
between hydrophobicity and antiplasmodium activity. In general, the antiplasmodium 
activity of these hybrids can be summarised as seen below:   
2-phenyl hybrids ≈ 2-ferrocenyl hybrids > 2-pyridyl hybrids 
The individual aminoquinoline (B1) and benzimidazole (B2) components of the general 
hybrid structure were also screened in order to assess their efficacy compared to that of 
the hybrid. Most significantly, hybrid 4a was more potent than either of the individual 
components in the resistant K1 strain. This result indicates that the combination of the 
two components allows the hybrid to overcome or evade resistance in K1 parasites, 
rather than the enhanced K1 activity being attributed to the influence of either 
component. Combination studies in the sensitive NF54 strain revealed that an equimolar 
physical mixture of components (B1+B2) was more active than hybrid 4a, indicating that 
in this case, a ‘combination therapy’ was more efficacious than the corresponding ‘hybrid 
therapy’. Furthermore, isobologram analysis of the individual components in the NF54 
strain revealed additive and antagonistic relationships for the co-administration of 
components B1 and B2 in different relative concentrations. In combination, the 
aminoquinoline confers activity, while the benzimidazole has no enhancing effect or 
decreases activity, indicating that this combination is not ideal as a physical mixture 
against the NF54 strain. This conclusion does not hold for the aminoquinoline-
benzimidazole hybrid in the resistant K1 strain.  
The phenyl and ferrocenyl hybrids were evaluated for their cytotoxicity against the non-
tumorigenic Chinese Hamster Ovarian (CHO) cell line. All of the hybrid compounds were 
non-cytotoxic and selectivity indices indicated selectivity toward the P. falciparum 
strains (SI > 1). Based on their favourable in vitro antiplasmodium activity and non-
cytotoxicity, the most active 2-phenyl hybrid (4c) and 2-ferrocenyl hybrid (5b) were 
evaluated in vivo against Plasmodium berghei in mice. Oral administration (4 × 50 mg/kg) 
with ferrocenyl hybrid 5b resulted in 92% reduction in parasitemia, while phenyl hybrid 




4c resulted in 58% reduction. The organometallic hybrid was a significantly more potent 
inhibitor than the organic hybrid in vivo. 
The most active phenyl, ferrocenyl and pyridyl hybrids (4c, 5b and 6c) were subjected to 
a β-haematin inhibition assay and were all found to be good to potent inhibitors of 
synthetic haemozoin formation under the cell-free assay conditions. The β-haematin 
inhibition activity correlated well with lipophilicity, where hybrids 4c and 5b, with 
higher logP values were significantly more active than hybrid 6c, which has a lower logP 
value. To confirm this mechanism of action in the parasite, a cellular haem fractionation 
assay was performed using ferrocenyl hybrid 5b, which confirmed that it is a bona fide 
haemozoin inhibitor in the parasite. In the interest of exploring a possible multifaceted 
mode of action of these hybrids, reactive oxygen species (ROS) generation of the 
ferrocenyl hybrids was investigated by means of a DNA-cleavage assay. However, hybrid 
5b displayed insignificant ROS-generating ability in this preliminary study.   
In addition, all organic and ferrocenyl aminoquinoline-benzimidazole hybrids were 
screened for their in vitro activity against the H37Rv strain of Mycobacterium tuberculosis. 
The substituent at the 5-position of the benzimidazole played a pivotal role in tuning the 
antimycobacterial activity. Substitution with the less hydrophobic groups (SO2CH3 and 
CN) resulted in hybrids (4d – 4e and 5d – 5e) which were inactive at the maximum tested 
concentration. On the other hand, substitution with the more hydrophobic groups 
(CH3 and CF3) gave hybrids (4b – 4c and 5b – 5c) with moderate to good activity 
(32.7 – 10.8 µM). The 5-position substituent of the hybrid significantly affected logP 
values, revealing a positive correlation between lipophilicity and antimycobacterial 
activity. It is worth noting that the more lipophilic ferrocenyl hybrids were consistently 
more potent than their corresponding less lipophilic phenyl analogues, while the least 
lipophilic pyridyl hybrids were inactive (MIC90 > 125 µM).  
2-ferrocenyl hybrids > 2-phenyl hybrids > 2-pyridyl hybrids 
Furthermore, when evaluated against the H37Rv strain, the individual aminoquinoline 
(B1) and benzimidazole (B2) components, administered individually, proved less active 
than the corresponding hybrid (4a) against the H37Rv strain. The results of the 




individual component studies and aforementioned combination studies reveal merit in 
the development of hybrid antimicrobial agents.  
The C^N- and N^N-coordinated PGM hybrid complexes were also evaluated against the 
CQS NF54 and MDR K1 strains of P. falciparum. In the sensitive NF54 strain, the hybrid 
complexes generally displayed good activity in the low to sub-micromolar range (2.007 – 
0.194 µM). When tested in the resistant K1 strain, the cationic M-Cp* complexes (11c, 
12a – 12c) did not retain activity, proving inactive at the tested concentration. The 
remaining neutral M-Cp* and cationic Rh(III)-ppy complexes retained activity in the K1 
strain, displaying comparable or slightly higher IC50 values (2.844 – 0.228 µM) compared 
to that in the NF54 strain. Resistance indices for these complexes were greater than or 
equal to one (RI = 1 – 3), significantly lower than that of CQ. The lower RI values bode 
well for their application against both sensitive and resistant strains. Overall, the cationic 
Rh(III)-ppy complexes were most potent across both strains, with complex 13b being the 
most active and the only compound in the series demonstrating enhanced activity in the 
resistant K1 strain (RI < 1). Within this series of PGM-containing hybrids, the 
antiplasmodium activity can be summarised as follows: 
cationic Rh(III)-ppy > neutral Ir(III)/Rh(III)-Cp* > cationic Ir(III)/Rh(III)-Cp* 
When considering the effect of organometallic derivatisation on the antiplasmodium 
activity, contrasting trends were observed. However, the cationic Rh(III)-ppy complexes 
(13a – 13c) consistently displayed enhanced activity compared to the ligands (6a – 6c) 
across both strains of P. falciparum. Selected hybrid complexes were evaluated against 
non-tumorigenic CHO cells, displaying non-cytotoxicity overall. SI values indicate great 
selectivity toward P. falciparum and suggest that the antiplasmodium activity of these 
complexes may be attributed to mechanisms other than general cytotoxicity. Once again, 
β-haematin inhibition was explored as a possible mechanism of action. The selected PGM-
containing hybrid complexes (7a, 7c, 8a, 8b, 11c, 12c and 13b) displayed potent 
inhibition of β-haematin formation, with the Ir(III)-Cp* complexes consistently 
outperforming the Rh(III)-Cp* complexes.  
In a bid to explore a potentially novel mode of antiplasmodium action, the transfer 
hydrogenation catalytic ability of Ir(III) and Rh(III) C^N-coordinated hybrid complexes 




(7a and 8a) was investigated. The hybrid complexes were used to effect the reduction of 
NAD+ to NADH, in the presence of sodium formate as the hydride source. In 1H NMR 
experiments and under cell-free assay conditions, both complexes demonstrated the 
ability to catalyse the conversion. However, in the in vitro antiplasmodium assay, co-
administration of Ir(III) complex 7a with sodium formate did not have a significant effect 
on parasite viability (NF54). This suggests that the extent of transfer hydrogenation is 
not significant within the parasite. 
Furthermore, the C^N- and N^N-coordinated PGM hybrid complexes (7 – 8 and 11 – 13) 
generally displayed moderate to good activity when screened against M. tuberculosis 
H37Rv. The neutral M-Cp* and cationic Rh(III)-ppy complexes displayed low micromolar 
MIC90 values (8.78 – 0.488 µM), significantly outperforming the cationic M-Cp* complexes 
(62.50 – 17.99 µM). Overall, the Ir(III) C^N-coordinated complexes were most potent, 
displaying MIC90 values in the low to sub-micromolar range (1.490 – 0.488 µM). It is 
interesting to note that with regards to antimycobacterial activity, the PGM-containing 
hybrid complexes were consistently more active than the corresponding ligands. In the 
case of complex 7a, metal coordination resulted in a 100-fold increase in activity 
compared to ligand 4a. It can thus be concluded that in this study, incorporation of PGMs 
into organic hybrid scaffolds results in significantly enhanced antimycobacterial activity.  








6.2 Future outlook 
The aminoquinoline-benzimidazole hybrids and their PGM-containing complexes studied 
herein display promising pharmacological properties. These results do, however, raise a 
few further questions and new ideas, which can be addressed through structural 
modifications of the hybrids, as well as further pharmacological and mechanistic studies. 
An important question to be answered is with regards to what happens to the hybrid 
compound once it has been administered to a living organism. Pharmacokinetics refers 
to the study of how a drug is absorbed, distributed, metabolised and excreted (ADME). In 
our study of the in vivo efficacy of selected hybrid compounds in P. berghei-infected mice 
ferrocenyl hybrid 5b displayed significantly enhanced inhibition compared to phenyl 
hybrid 4c. An evaluation of the pharmacokinetics may help to understand why there is a 
vast difference in activity at the in vivo level, compared to similar activity in vitro. 
Furthermore, a study of all four properties may also aid in rationalizing why mice treated 
with either hybrid compound had the same mean survival time, despite the 
aforementioned more potent inhibition exhibited by hybrid 5b.   
Another question which arises, is whether or not these hybrids maintain the same 
mechanism of action in both sensitive and resistant strains of P. falciparum. The organic 
and organometallic hybrids displayed potent β-haematin inhibition activity and the 
ferrocenyl hybrid 5b was confirmed to inhibit haemozoin formation in sensitive NF54 
parasites. With this in mind, cellular haem fractionation experiments on these hybrids 
could be conducted using resistant K1 parasites, in order to confirm that the mechanism 
of action is maintained. Furthermore, hybrid agents are speculated to act via dual or 
multiple modes of action. Therefore, additional mechanistic studies could be undertaken 
to elucidate the possible additional modes of action which are coupled to haemozoin 
inhibition for these hybrids. The inhibition of enzymes, such as cysteine protease and 
dihydroorotate dehydrogenase, could be investigated in this regard. 
Modifications, based on the outcomes of this study, can be made to the hybrid structure 
in order to enhance pharmacological properties. The preparation of an optimised 
ferrocenyl hybrid is proposed for enhanced antimalarial activity. It is clear from the 
potent activity of ferroquine, as well as the ferrocenyl hybrids in this study, that 




incorporation of the ferrocenyl moiety often results in enhanced activity in resistant 
strains of P. falciparum (RI < 1). The improved activity of the ferrocenyl analogues may 
be the result of a number of factors including increased lipophilicity and redox 
accessibility. In some instances, highly lipophilic compounds may have decreased cellular 
uptake due to strong interactions with cell membranes. To counteract this effect, a water-
soluble substituent can be incorporated at the 5-position of the benzimidazole, which 
may also improve the overall solubility of the hybrid. An additional secondary amine 
could also be incorporated into the linker, which may enhance accumulation in the 
digestive vacuole through pH trapping, thus leading to enhanced activity. The proposed 









Figure 6.1 Structural modifications for a new potential antimalarial hybrid. 
This study revealed the use of organometallic hybrid compounds against M. tuberculosis 
to be a promising endeavor. Incorporation of the ferrocenyl or PGM moieties significantly 
enhanced antimycobacterial activity compared to their corresponding organic analogues. 
The neutral Ir(III)-Cp* hybrid complexes (7a – 7c) displayed low to sub-micromolar 
MIC90 values against the susceptible H37Rv strain. These hybrid complexes should be 
further evaluated against MDR-TB strains, in order to gauge whether or not they retain 
their potent activity. Furthermore, structural modifications can be made to the hybrids at 
Lipophilic ferrocenyl moiety to 
overcome resistance and lower RI 
values, enhance in vivo activity. 
Additional secondary amine to 
enhance accumulation in digestive 
vacuole, improve activity 
Water-soluble group to 
counteract lipophilicity and 
improve overall solubility 




hand, to improve their antimycobacterial properties. We propose an organometallic 
hybrid incorporating the highly lipophilic ferrocenyl moiety as well as an Ir(III)-Cp* 
entity. This can be achieved through the cyclometalation of a ferrocenyl hybrid with an 
Ir(III)-Cp* moiety, to afford the neutral heterobimetallic complex shown in Figure 6.2. 
This modification would ideally combine the favourable effects of the two moieties, 







Figure 6.2 Structural modification for a new potential antimycobacterial hybrid. 
 
 
Ferrocenyl moiety increases 
lipophilicity, leading to 
significantly enhanced 
activity. 
Cyclometalation to Ir(III)-Cp* 










7.1 General remarks 
All reagents and solvents were purchased from commercial sources (Sigma Aldrich, 
Combi-blocks, Kimix and Merck). The aminoquinoline precursor, N1-(7-chloroquinolin-
4-yl)-propane-1,3-diamine (1),1 and the metal dimers, [Ir(Cp*)Cl2]2,2 [Rh(Cp*)Cl2]2,2 and 
[Rh(ppy)2Cl]2,3 were prepared using modified literature methods. 
Infrared (IR) absorptions were measured on a Perkin-Elmer Spectrum 100 FT-IR 
spectrometer using Attenuated Total Reflectance (ATR). Nuclear Magnetic Resonance 
(NMR) spectra were recorded on a Varian Mercury XR300 MHz (1H at 300.08 MHz), a 
Bruker 400 Biospin GmbH (1H at 400.22 MHz, 13C{1H} at 100.65 MHz, 31P{1H} at 161.80 
MHz) or a Bruker 600 FT spectrometer (1H at 600.10 MHz, 13C{1H} at 150.60 MHz) 
spectrometer at 30 °C. Chemical shifts are reported using tetramethylsilane (TMS) as the 
internal standard. Mass spectrometry determinations were carried out using Electron 
Impact (EI) on a JEOL GC Matell instrument or Electrospray Ionisation (ESI) on a Waters 
API Quattro Micro triple quadrupole mass spectrometer with data recorded using both 
the positive and negative modes. Melting points were determined using a Büchi Melting 
Point Apparatus B-540.  
Purity was determined using an analytical Agilent HPLC 1260 equipped with an Agilent 
DAD 1260 UV/vis detector and a X Bridge C18 column (2.5 μM, 50 mm × 3 mm). The 
compounds were eluted using a mixture of solvent A (10 mM NH4OAc/H2O) and solvent 
B (10 mM NH4OAc/MeOH) at a flow rate of 0.9 mL/min (4a – 4e and 6a – 6c) or 
0.5 mL/min (5a – 5e). The gradient elution conditions for compounds 4a – 4e and 6a – 
6c were as follows: 15% solvent B between 0 and 0.5 min, 15–100% solvent B between 
0.5 and 1.2 min, 100% solvent B between 1.2 and 4.5 min. The gradient elution conditions 
for compounds 5a – 5e were as follows: 10% solvent B between 0 and 2 min, 10–90% 
solvent B between 2 and 8 min, 90% solvent B between 8 and 9 min. Purity was 
determined at 280 nm. All compounds were confirmed to have >97% purity.  




Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-Kα radiation (χ = 0.71073 Å). Data 
collection was carried out at 173(2) K for compounds 4b and 5c, and 100(2) K for 
compound 11b. Temperature was controlled by an Oxford Cryostream cooling system 
(Oxford Cryostat). Cell refinement and data reduction were performed using the program 
SAINT.4 The data were scaled, and absorption correction performed using SADABS.5 The 
structures were solved by direct methods using SHELXS-975 and refined by full-matrix 
least-squares methods based on F2 using SHELXL-20145 or SHELXL-20185 and using the 
graphics interface program X-Seed.6, 7 The programs X-Seed and POV-Ray8 were used to 
prepare molecular graphic images. 
 
7.2 Aminoquinoline precursors 
7.2.1 General method for synthesis of nitro-containing precursors (2a – 2e) 
A nitrobenzene derivative (1.5 eq.) was added to a stirring solution of compound 1 (1 eq.) 
in anhydrous DMF (5 ml), and the reaction mixture was stirred at room temperature 
under N2 for 24 hours. Thereafter, 1 M NaOH (50 ml) was added to basify the mixture, 
which was then extracted with DCM or EtOAc (3 × 50 ml). The organic fractions were 
collected and washed with brine (3 × 50 ml). The organic layer was collected, dried over 
anhydrous Na2SO4 and filtered by gravity. The solvent of the filtrate was removed to 
afford the crude product as a bright yellow or orange solid. The crude product was 
purified by column chromatography (silica gel) using DCM:MeOH (19:1). Subsequent 
trituration in diethyl ether afforded the desired product as a bright yellow or orange 
powder, which was collected by suction filtration. 
N1-(7-chloroquinolin-4-yl)-N3-(2-nitrophenyl)-propane-1,3-diamine (2a) 
1-Fluoro-2-nitrobenzene (1.02 ml, 9.67 mmol), 
compound 1 (1.52 g, 6.45 mmol). Product: Yellow 
powder. Yield: 1.20 g, 52.2%. Rf(DCM:MeOH, 19:1): 
0.25. M.p. 181.9 – 183.6 °C. 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) = 8.39 (d, 3JHH = 5.5 Hz, 1H, H-2), 8.25 (d, 3JHH = 9.1 Hz, 1H, H-7), 8.20 
(t, 3JHH = 5.7 Hz, 1H, H-14), 8.06 (dd, 3JHH = 8.6, 4JHH = 1.6 Hz, 1H, H-19), 7.79 (d, 3JHH = 2.3 
 




Hz, 1H, H-4), 7.50 (m, 1H, H-17), 7.45 (dd, 3JHH = 9.1, 4JHH = 2.3 Hz, 1H, H-6), 7.35 (t, 3JHH = 
5.4 Hz, 1H, H-10), 7.08 (dd, 3JHH = 8.7, 4JHH = 0.9 Hz, 1H, H-16), 6.68 (m, 1H, H-18), 6.49 (d, 
3JHH = 5.5 Hz, 1H, H-1), 3.51 (q, 3JHH = 6.6 Hz, 2H, H-13), 3.40 (q, 3J HH = 6.6 Hz, 2H, H-11), 
2.03 (p, 3JHH = 6.8 Hz, 2H, H-12). 13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 152.4, 
150.5, 149.6, 145.6, 137.0, 133.9, 131.6, 128.0, 126.8, 124.5 (2C), 118.0, 115.6, 114.9, 99.2, 
40.5, 40.4, 27.5. FT-IR (ATR, cm-1): ν = 3377 (N–H), 3306 (N–H), 1621 (C=N), 1568 (C=C), 
1530 (N–O), 1360 (N–O). EI-MS: m/z 355.95 (91.0%, [M]+), calculated 356.10. 
N1-(7-chloroquinolin-4-yl)-N3-(4-methyl-2-nitrophenyl)propane-1,3-diamine (2b) 
4-Fluoro-3-nitrotoluene (0.992 g, 6.40 mmol), 
compound 1 (1.00 g, 4.24 mmol). Product: Orange 
powder. Yield: 0.688 g, 43.7%. Rf(DCM:MeOH, 19:1): 
0.23. M.p. 198.1 – 199.9 °C. 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) = 8.39 (d, 3JHH = 5.5 Hz, 1H, H-2), 
8.26 (d, 3JHH = 9.0 Hz, 1H, H-7), 8.12 (t, 3JHH = 5.7 Hz, 1H, H-14), 7.87 (m, 1H, H-19), 7.79 
(d, 4JHH = 2.3 Hz, 1H, H-4), 7.45 (dd, 3JHH = 9.0, 2.3 Hz, 1H, H-6), 7.38 – 7.32 (overlapping 
m, 2H, H-10/17), 7.01 (d, 3JHH = 9.0 Hz, 1H, H-16), 6.49 (d, 3JHH = 5.5 Hz, 1H, H-1), 3.49 (q, 
3JHH = 6.6 Hz, 2H, H-13), 3.39 (q, 3JHH = 6.6 Hz, 3H, H-11), 2.22 (s, 3H, H-18’), 2.01 (p, 3JHH 
= 6.8 Hz, 2H, H-12). 13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 152.4, 150.5, 149.6, 
144.0, 138.5, 133.9, 131.1, 128.0, 125.7, 124.7, 124.5 (2C), 118.0, 115.0, 99.2, 40.5, 40.4, 
27.6, 19.9. FT-IR (ATR, cm-1): ν = 3417 (N–H), 3361 (N–H), 1609 (C=N), 1570 (C=C), 
1520 (N–O), 1350 (N–O). EI-MS: m/z 370.04 (100%, [M]+), calculated 370.12. 
N1-(7-chloroquinolin-4-yl)-N3-(2-nitro-4-(trifluoromethyl)phenyl)propane-1,3-
diamine (2c) 
4-Chloro-3-nitrobenzotrifluoride (01.43 ml, 9.58 
mmol), compound 1 (1.51 g, 6.41 mmol). Product: 
Yellow powder. Yield: 1.54 g, 56.6%. Rf(DCM:MeOH, 
19:1): 0.21. M.p. 210.4 – 212.8 °C. 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) = 8.56 (t, 3JHH = 5.8 Hz, 1H, H-14), 
8.39 (d, 3JHH = 5.5 Hz, 1H, H-2), 8.30 (dd, 3JHH = 2.3, 4JHH = 0.9 Hz, 1H, H-19), 8.24 (d, 3JHH = 
9.1 Hz, 1H, H-7), 7.79 (d, 4JHH = 2.3 Hz, 1H, H-4), 7.75 (dd, 3JHH = 9.2, 4JHH = 2.3 Hz, 1H, H-17), 
7.45 (dd, 3JHH = 9.0, 4JHH =  2.3 Hz, 1H, H-6), 7.34 (t, 3JHH = 5.4 Hz, 1H, H-10), 7.28 (d, 3JHH = 
 
 




9.2 Hz, 1H, H-16), 6.50 (d, 3JHH = 5.5 Hz, 1H, H-1), 3.58 (q, 3JHH = 6.6 Hz, 2H, H-13), 3.40 (q, 
3JHH = 6.6 Hz, 2H, H-11), 2.02 (p, 3JHH = 6.7 Hz, 2H, H-12). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ (ppm) = 152.4, 150.5, 149.6, 147.2, 133.9, 132.3, 130.7, 128.0, 124.6, 
124.5 (2C), 123.0 118.0, 116.4, 115.5, 99.2, 40.8, 40.3, 27.3. FT-IR (ATR, cm-1): ν = 3361 
(N–H), 3218 (N–H), 1609 (C=N), 1568 (C=C), 1536 (N–O), 1366 (N–O), 1324 (C–F). 
EI-MS: m/z 423.99 (94%, [M]+), calculated 424.09. 
N1-(7-chloroquinolin-4-yl)-N3-(4-(methylsulfonyl)-2-nitrophenyl)propane-1,3-
diamine (2d) 
1-Fluoro-4-methanesulfonyl-2-nitrobenzene (0.848 g, 
3.87 mmol), compound 1 (0.625 g, 2.65 mmol). Product: 
Yellow powder. Yield: 0.516 g, 46.0%. Rf(DCM:MeOH, 
19:1): 0.17. M.p. 202.0 – 204.4 °C. 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) = 8.69 (t, 3JHH = 5.9 Hz, 1H, H-14), 
8.50 (d, 4JHH = 2.3 Hz, 1H, H-19), 8.40 (d, 3JHH = 5.4 Hz, 
1H, H-2), 8.24 (d, 3JHH = 9.1 Hz, 1H, H-7), 7.89 (dd, 3JHH = 9.1, 4JHH = 2.2 Hz, 1H, H-17), 7.79 
(d, 4JHH = 2.2 Hz, 1H, H-4), 7.46 (dd, 3JHH = 9.0, 4JHH = 2.3 Hz, 1H, H-6), 7.34 (t, 3JHH = 5.4 Hz, 
1H, H-10), 7.30 (d, 3JHH = 9.3 Hz, 1H, H-16), 6.51 (d, 3JHH = 5.5 Hz, 1H, H-1), 3.61 (q, 3JHH = 
6.5 Hz, 2H, H-13), 3.39 (q, 3JHH = 6.5 Hz, 2H, H-11), 3.20 (s, 3H, H-18’)  2.03 (p, 3JHH = 6.7 
Hz, 2H, H-12). 13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 152.4, 150.5, 149.5, 147.8, 
133.9 (2C), 130.5, 128.0, 127.5, 126.7, 124.5 (2C), 118.0, 116.1, 99.2, 44.3, 40.9, 40.3, 27.2. 
FT-IR (ATR, cm-1): ν = 3381 (N–H), 3218 (N–H), 1617 (C=N), 1570 (C=C), 1520 (N–O), 
1368 (S=O), 1350(N–O), 1136 (S=O). EI-MS: m/z 433.97 (38.5%, [M]+), calculated 434.08. 
4-((3-((7-chloroquinolin-4-yl)amino)propyl)amino)-3-nitrobenzonitrile (2e) 
4-Chloro-3-nitrobenzonitrile (0.587 g, 3.22 mmol), 
compound 1 (0.513 g, 2.18 mmol). Product: Yellow 
powder. Yield: 0.415 g, 51.8%. Rf(DCM:MeOH, 19:1): 
0.19. M.p. 205.7 – 207.9 °C. 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) = 8.66 (t, 3JHH = 5.8 Hz, 1H, H-14), 
8.50 (d, 4JHH = 2.0 Hz, 1H, H-19), 8.39 (d, 3JHH = 5.5 Hz, 1H, H-2), 8.23 (d, 3JHH = 9.1 Hz, 1H, 
H-7), 7.80 – 7.77 (overlapping m, 2H, H-4/17), 7.45 (dd, 3JHH = 9.1, 4JHH = 2.3 Hz, 1H, H-6), 
7.33 (t, 3JHH = 5.4 Hz, 1H, H-10), 7.23 (d, 3JHH = 9.2 Hz, 1H, H-16), 6.50 (d, 3JHH = 5.5 Hz, 1H, 
 
 




H-1), 3.58 (q, 3JHH = 6.6 Hz, 2H, H-13), 3.39 (q, 3JHH = 6.6 Hz, 2H, H-11), 2.01 (p, 3JHH = 6.7 
Hz, 2H, H-12). 13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 152.4, 150.4, 149.5, 147.3, 
138.1, 133.9, 132.4, 131.3, 128.0, 124.5 (2C), 118.7, 118.0, 116.2, 99.2, 96.8, 40.8, 40.3, 
27.2. FT-IR (ATR, cm-1): ν = 3369 (N–H), 3306 (N–H), 2222 (C≡N), 1621 (C=N), 1578 
(C=C), 1522 (N–O), 1367 (N–O). EI-MS: m/z 381.02 (74.4%, [M]+), calculated 381.10. 
 
7.2.2 General method for synthesis of 1,2-diamine precursors (3a – 3e) 
Ammonium chloride (10 eq.) was added to a stirring mixture of the appropriate nitro-
containing aminoquinoline precursor (2a – 2e) (1 eq.) in anhydrous methanol (100 ml) 
and the yellow mixture was stirred under N2 for 15 min. Zinc powder (20 eq.) was then 
added, and the resulting grey mixture was stirred vigorously at room temperature under 
N2 for 24 hours. Thereafter, 1 M NaOH (20 ml) was added to basify the mixture, which 
was then filtered through Celite®. The MeOH was removed under reduced pressure, and 
the aqueous mixture extracted using DCM (3 × 50 ml). The organic fractions were 
collected and washed with brine (2 × 50 ml), followed by water (1 × 50 ml). The organic 
layer was collected, dried over anhydrous Na2SO4 and filtered by gravity. The solvent of 
the filtrate was removed to afford the desired product as a brown, beige, pink or purple 
powder. 
N1-(3-((7-chloroquinolin-4-yl)amino)propyl)benzene-1,2-diamine (3a) 
Ammonium chloride (0.757 g, 14.2 mmol), compound 
2a (0.503 g, 1.41 mmol), zinc powder (1.87 g, 28.6 
mmol). Product: Brown powder. Yield: 0.440 g, 95.5%. 
M.p. 169.1 – 170.8 °C. 1H NMR (400 MHz, DMSO-d6): 
δ (ppm) = 8.40 (d, 3JHH = 5.4 Hz, 1H, H-2), 8.30 (d, 3JHH = 9.0 Hz, 1H, H-7), 7.80 (d, 4JHH = 2.2 
Hz, 1H, H-4), 7.44 (dd, 3JHH = 9.0, 4JHH = 2.3 Hz, 1H, H-6), 7.33 (t, 3JHH = 5.3 Hz, 1H, H-10), 
6.57-6.40 (m, 5H, H-1/16/17/18/19), 4.49 (m, 2H, H-21), 4.44 (m, 1H, H-14), 3.42 (q, 3JHH 
= 6.8 Hz, 2H, H-11), 3.18 (q, 3JHH = 6.8 Hz, 2H, H-13), 2.01 (p, 3JHH = 6.8 Hz, 2H, H-12). 
13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 152.4, 150.6, 149.6, 136.4, 135.8, 133.8, 
128.0, 124.6, 124.5, 118.1, 118.0, 117.4, 114.6, 110.5, 99.2, 41.7, 41.1, 28.0. FT-IR (ATR, 
 




cm-1): ν = 3413 (N–H), 3349 (N–H), 1611 (C=N), 1580 (C=C). EI-MS: m/z 326.10 (94.4%, 
[M]+), calculated 326.13. 
N1-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-methylbenzene-1,2-diamine (3b) 
Ammonium chloride (0.953 g, 17.8 mmol), compound 
2b (0.655 g, 1.75 mmol), zinc powder (2.29 g, 35.0 
mmol). Product: Purple powder. Yield: 0.589 g, 97.8%. 
M.p. 134.7 – 138.7 °C. 1H NMR (400 MHz, DMSO-d6): δ 
(ppm) = 8.39 (d, 3JHH = 5.4 Hz, 1H, H-2), 8.29 (d, 3JHH = 
9.0 Hz, 1H, H-7), 7.79 (d, 4JHH = 2.3 Hz, 1H, H-4), 7.44 (dd, 3JHH = 9.0, 4JHH = 2.3 Hz, 1H, H-6), 
7.34 (t, 3JHH = 5.2 Hz, 1H, H-10), 6.50 (d, 3JHH = 5.5 Hz, 1H, H-1), 6.40 (d, 4JHH = 1.7 Hz, 1H, 
H-19), 6.36 (d, 3JHH = 7.9 Hz, 1H, H-16), 6.29 (dd, 3JHH = 7.9, 4JHH = 1.7 Hz, 1H, H-17), 4.44 
(br s, 2H, H-21), 4.25 (m, 1H, H-14), 3.40 (q, 3JHH = 6.8 Hz, 2H, H-11), 3.13 (q, 3JHH = 6.8 Hz, 
2H, H-13), 2.09 (s, 3H, H-18’), 1.98 (p, 3JHH = 6.8 Hz, 2H, H-12). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ (ppm) = 152.4, 150.6, 149.6, 136.0, 134.1, 133.8, 128.0, 125.9, 124.6, 
124.5, 118.3, 118.0, 115.6, 110.9, 99.2, 42.1, 41.1, 28.0, 20.9. FT-IR (ATR, cm-1): ν = 3349 
(br, N–H), 1607 (C=N), 1578 (C=C). EI-MS: m/z 340.15 (62.5%, [M]+), calculated 340.15. 
N1-(3-((7-chloroquinolin-4-yl)amino)propyl)-4-(trifluoromethyl)benzene-1,2-diamine (3c) 
Ammonium chloride (0.953 g, 17.8 mmol), compound 
2c (0.755 g, 1.78 mmol), zinc powder (2.42 g, 37.0 
mmol). Product: Purple powder. Yield: 0.674 g, 96.1%. 
M.p. 174.9 – 176.0 °C. 1H NMR (400 MHz, DMSO-d6): δ 
(ppm) = 8.39 (d, 3JHH = 5.4 Hz, 1H, H-2), 8.29 (d, 3JHH = 
9.1 Hz, 1H, H-7), 7.79 (d, 4JHH = 2.3 Hz, 1H, H-4), 7.45 (dd, 3JHH = 9.0, 4JHH = 2.3 Hz, 1H, H-6), 
7.33 (t, 3JHH = 5.3 Hz, 1H, H-10), 6.82 (d, 4JHH = 2.1 Hz, 1H, H-19), 6.79 (dd, 3JHH = 8.7 Hz, 
4JHH = 2.1 Hz 1H, H-17), 6.53-6.50 (overlapping m, 2H, H-1/16), 5.10 (t, 3JHH = 5.3 Hz, 1H, 
H-14), 4.94 (s, 2H, H-21), 3.41 (q, 3JHH = 6.8 Hz, 2H, H-11), 3.25 (q, 3JHH = 6.8 Hz, 2H, H-13), 
2.01 (p, 3JHH = 6.8 Hz, 2H, H-12). 13C{1H NMR (101 MHz, DMSO-d6): δ (ppm) = 152.4, 
150.6, 149.6, 139.3, 135.6, 133.9, 128.0, 127.4, 124.6, 124.5, 118.0, 116.7, 115.0, 109.8, 
108.7, 99.2, 41.3, 40.9, 27.6. FT-IR (ATR, cm-1): ν = 3377 (br, N–H), 1611 (C=N), 1581 
(C=C), 1328 (C–F). EI-MS: m/z 394.11 (56.6%, [M]+), calculated 394.12. 
 
 





Ammonium chloride (0.242 g, 4.52 mmol), compound 
2d (0.192 g, 0.454 mmol), zinc powder (0.592 g, 9.05 
mmol). Product: Brown powder. Yield: 0.148 g, 80.5%. 
M.p. 227.2 – 229.5 °C. 1H NMR (400 MHz, DMSO-d6): δ 
(ppm) = 8.40 (d, 3JHH = 5.5 Hz, 1H, H-2), 8.29 (d, 3JHH = 
9.1 Hz, 1H, H-7), 7.79 (d, 4JHH = 2.3 Hz, 1H, H-4), 7.45 (dd, 
3JHH = 9.1, 4JHH = 2.3 Hz, 1H, H-6), 7.34 (t, 3JHH = 5.2 Hz, 1H, H-10), 7.02 (overlapping m, 2H, 
H-17/19), 6.56 (d, 3JHH = 8.9 Hz, 1H, H-16), 6.51 (d, 3JHH = 5.5 Hz, 1H, H-1), 5.38 (t, 3JHH = 
5.3 Hz, 1H, H-14), 5.03 (br s, 2H, H-21), 3.41 (q, 3JHH = 6.8 Hz, 2H, H-11), 3.29 (q, 3JHH = 6.8 
Hz, 2H, H-13), 2.99 (s, 3H, H-18’), 2.02 (p, 3JHH = 6.8 Hz, 2H, H-12). 13C{1H} NMR (101 
MHz, DMSO-d6): δ (ppm) = 152.4, 150.6, 149.6, 140.5, 135.4, 133.9, 128.0, 127.5, 124.6, 
124.5, 118.0 (2C), 111.4, 108.3, 99.3, 45.1, 41.2, 40.8, 27.6. FT-IR (ATR, cm-1): ν = 3401 
(N–H), 3345 (N–H), 1611 (C=N), 1580 (C=C), 1370 (S=O), 1124 (S=O). EI-MS: m/z 405.12 
(100%, [M+H]+), calculated 405.11. 
3-Amino-4-((3-((7-chloroquinolin-4-yl)amino)propyl)amino)benzonitrile (3e)  
Ammonium chloride (0.592 g, 11.1 mmol), compound 
2e (0.406 g, 1.10 mmol), zinc powder (1.45 g, 22.2 
mmol). Product: Pink powder. Yield: 0.294 g, 75.7%. 
M.p. 250.1 – 253.4 °C. 1H NMR (400 MHz, DMSO-d6): δ 
(ppm) = 8.38 (d, 3JHH = 5.4 Hz, 1H, H-2), 8.27 (d, 3JHH = 
9.1 Hz, 1H, H-7), 7.77 (d, 4JHH = 2.3 Hz, 1H, H-4), 7.43 (dd, 3JHH = 9.1, 4JHH = 2.3 Hz, 1H, ArH), 
7.29 (t, 3JHH = 5.1 Hz, 1H, H-10), 6.89 (dd, 3JHH = 8.2, 4JHH = 2.0 Hz, 1H, H-17), 6.78 (d, 4JHH 
= 2.0 Hz, 1H, H-19), 6.49-6.47 (overlapping m, 2H, H-1/16), 5.42 (t, 3JHH = 5.1 Hz, 2H, 
H-14), 4.97 (s, 2H, H-21), 3.38 (q, 3JHH = 6.8 Hz, 2H, H-11), 3.26 (m, 2H, H-13), 1.99 (p, 3JHH 
= 6.8 Hz, 2H, H-12). 13C{1H} NMR (101 MHz, DMSO-d6) δ 152.4, 150.6, 149.6, 140.5, 
135.7, 133.8, 128.0, 124.6, 124.5, 123.3, 121.5, 118.0, 115.4, 109.2, 99.3, 97.1, 41.0, 40.8, 
27.6. FT-IR (ATR, cm-1): ν = 3417 (N–H), 3393 (N–H), 2202 (C≡N), 1609 (C=N), 1580 








7.3 Aminoquinoline-benzimidazole hybrids 
7.3.1 General method for synthesis of 2-phenyl hybrids (4a – 4e) 
A 1,2-diamine aminoquinoline precursor (3a – 3e) (1 eq.), benzaldehyde (1.5 eq.) and 
TFA (0.1 eq.) were dissolved in ethanol (25 ml). Anhydrous MgSO4 (5 eq.) was added and 
the brown reaction mixture was refluxed for 24 hours. Thereafter, the resulting brown 
mixture was filtered by gravity and the solvent of the filtrate was removed to give a brown 
residue. To this crude residue, 1 M NaOH (50 ml) was added and the mixture was 
extracted using DCM (3 × 50 ml). The organic fractions were collected and washed with 
brine (2 × 50 ml), followed by water (1 × 30 ml). The organic layer was collected, dried 
over anhydrous Na2SO4 and filtered by gravity. The solvent of the filtrate was removed to 
afford the crude product as a dark orange residue. The crude product was purified by 
column chromatography (silica gel) using EtOAc (100%). Subsequent precipitation from 
DCM/pet. ether (40 – 60 °C) afforded the desired product as a white, pale-yellow or beige 
powder, which was collected by suction filtration and dried in vacuo.  
7-Chloro-N-(3-(2-phenyl-1H-benzo[d]imidazole-1-yl)propyl)quinolin-4-amine (4a) 
Compound 3a (0.502 g, 1.54 mmol), benzaldehyde 
(0.235 ml, 2.31 mmol), TFA (11.7 µl, 0.153 mmol) and 
anhydrous MgSO4 (0.927 g, 7.70 mmol). Product: Pale-
yellow powder. Yield: 0.407 g, 64.2%. Rf(EtOAc, 
100%): 0.15. M.p. 180.9 – 182.5 °C. 1H NMR (300 
MHz, DMSO-d6): δ (ppm) = 8.35 (d, 3JHH = 5.5 Hz, 1H, 
H-2), 8.13 (d, 3JHH = 9.1, 1H, H-7), 7.80 (d, 4JHH = 2.2 Hz, 1H, H-4), 7.75 – 7.61 (m, 4H, 
H-15/18/22), 7.44 (dd, 3JHH = 9.1, 4JHH = 2.2 Hz, 1H, H-6), 7.40 – 7.24 (m, 5H, 
H-16/17/23/24), 7.21 (t, 3JHH = 4.8 Hz, 1H, H-10) 6.30 (d, 3JHH = 5.5 Hz, 1H, H-1), 4.47 (t, 
3JHH = 7.4 Hz, 2H, H-13), 3.19 (m, 2H, H-11), 2.13 (m, 2H, H-12).13C{1H} NMR (101 MHz, 
DMSO-d6): δ 153.4, 152.3, 150.3, 149.5, 143.1, 136.1, 133.9, 130.8, 129.9, 129.4 (2C), 
129.0 (2C), 127.9, 124.5 (2C), 122.9, 122.5, 119.7, 118.0, 111.3, 99.1, 42.5, 39.8, 28.4. 
FT-IR (ATR, cm-1): ν = 3433 (N–H), 1611 (C=Nbenz/quin), 1578 (C=C). ESI-MS: 
m/z 413.1534 (100%, [M+H]+), calculated 413.1528. HPLC purity >99% (tR = 2.30 min).  
 






Compound 3b (0.405 g, 1.19 mmol), benzaldehyde 
(0.181 ml, 1.78 mmol), TFA (8.98 µl, 0.119 mmol) and 
anhydrous MgSO4 (0.716 g, 5.95 mmol). Product: Pale-
yellow powder. Yield: 0.307 g, 60.5%. Rf(EtOAc, 
100%): 0.14. M.p. 248.2 – 250.2 °C. 1H NMR (300 
MHz, DMSO-d6): δ (ppm) = 8.35 (d, 3JHH = 5.4 Hz, 1H, 
H-2), 8.13 (d, 3JHH = 9.1 Hz, 1H, H-7), 7.80 (d, 4JHH = 2.2 
Hz, 1H, H-4), 7.71 – 7.63 (m, 2H, H-22), 7.57 (d, 3JHH = 8.3 Hz, 1H, H-15), 7.48 (m, 1H, H-18), 
7.43 (dd, 3JHH = 9.1, 4JHH = 2.2 Hz, 1H, H-6), 7.39 – 7.26 (overlapping m, 3H, H-23/24), 7.21 
(t, 3JHH = 5.2 Hz, 1H, H-10), 7.10 (d, 3JHH = 8.3 Hz, 1H, H-16), 6.29 (d, 3JHH = 5.4 Hz, 1H, H-1), 
4.44 (t, 3JHH = 7.3 Hz, 1H, H-13), 3.18 (m, 2H, H-11), 2.43 (s, 3H, H-17’) 2.11 (m, 2H, H-12). 
13C{1H} NMR (101 MHz, DMSO-d6): δ 153.3, 152.3, 150.3, 149.5, 143.5, 134.3, 133.9, 
131.5, 130.9, 129.8, 129.4 (2C), 128.9 (2C), 127.9, 124.5 (2C), 124.3, 119.4, 118.0, 110.9, 
99.1, 42.5, 39.9, 28.4, 21.6. FT-IR (ATR, cm-1): ν = 3250 (N–H), 1609 (C=Nbenz/quin), 1578 
(C=C). ESI-MS: m/z 214.0882 (100%, [M+2H]2+), calculated 214.0878; m/z 427.1690 
(30%, [M+H]+), calculated 427.1684. HPLC purity >99% (tR = 2.37 min). 
7-Chloro-N-(3-(5-(trifluoromethyl)-2-phenyl-1H-benzo[d]imidazol-1-yl)propyl)quinolin-4-
amine (4c) 
Compound 3c (0.250 g, 0.633 mmol), benzaldehyde 
(0.0965 ml, 0.950 mmol), TFA (4.84 µl, 0.0633 mmol) 
and anhydrous MgSO4 (0.381 g, 3.17 mmol). Product: 
White powder. Yield: 0.248 g, 81.4%. Rf(EtOAc, 
100%): 0.26. M.p. 197.8 – 199.6 °C. 1H NMR (300 
MHz, DMSO-d6): δ (ppm) = 8.35 (d, 3JHH = 5.4 Hz, 1H, 
H-2), 8.10 (d, 3JHH = 9.1 Hz, 1H, H-7), 8.06 (m, 1H, H-18) 
7.97 (d, 3JHH = 8.6 Hz, 1H, H-15), 7.80 (d, 4JHH = 2.2 Hz, 1H, H-4), 7.74 – 7.67 (m, 2H, H-22), 
7.61 (dd, 3JHH = 8.6, 4JHH = 1.1 Hz, 1H, H-16), 7.43 (dd, 3JHH = 9.1, 4JHH = 2.2 Hz, 1H, H-6), 
7.40 – 7.28 (overlapping m, 3H, H-23/24), 7.19 (t, 3JHH = 5.1 Hz, 1H, H-10), 6.30 (d, 3JHH = 
5.4 Hz, 1H, H-1), 4.54 (t, 3JHH = 7.4 Hz, 1H, H-13), 3.20 (m, 2H, H-11), 2.13 (m, 1H, H-12). 
 
 




13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 155.8, 152.3, 150.3, 149.5, 142.5, 138.4, 
133.9, 130.4, 130.1, 129.5 (2C), 129.1 (2C), 127.9, 126.8, 124.5 (2C), 123.3, 119.5, 118.0, 
117.0, 112.5, 99.2, 42.9, 39.7, 28.2. FT-IR (ATR, cm-1): ν = 3278 (N–H), 1611 
(C=Nbenz/quin), 1578 (C=C), 1326 (C–F). ESI-MS: m/z 481.1410 (100%, [M+H]+), calculated 
481.1401. HPLC purity 99% (tR = 2.44 min). 
7-Chloro-N-(3-(5-(methylsulfonyl)-2-phenyl-1H-benzo[d]imidazol-1-yl)propyl)quinolin-4-
amine (4d)  
Compound 3d (0.0600 g, 0.148 mmol), benzaldehyde 
(0.0226 g, 0.222 mmol), TFA (1.13 µl, 0.0148 mmol) 
and anhydrous MgSO4 (0.0891 g, 0.740 mmol). 
Product: Beige powder. Yield: 0.0453 g, 62.3%. 
Rf(EtOAc, 100%): 0.06. M.p. 94.1 – 96.5 °C. 1H NMR 
(300 MHz, DMSO-d6): δ (ppm) = 8.35 (d, 3JHH = 5.5 Hz, 
1H, H-2), 8.24 (d, 4JHH = 1.6 Hz, 1H, H-18), 8.11 (d, 3JHH 
= 9.1 Hz, 1H, H-7), 8.00 (d, 3JHH = 8.6 Hz, 1H, H-15), 7.83 
(dd, 3JHH = 8.6, 4JHH = 1.6 Hz, 1H, H-16), 7.80 (d, 4JHH = 2.2 Hz, 1H, H-4), 7.73 – 7.69 (m, 2H, 
H-22), 7.44 (dd, 3JHH = 9.1, 4JHH = 2.2 Hz, 1H, H-6), 7.42 – 7.30 (overlapping m, 3H, 
H-23/24), 7.20 (t, 3JHH = 5.3 Hz, 1H, H-10), 6.31 (d, 3JHH = 5.5 Hz, 1H, H-1), 4.55 (t, 3JHH = 
7.3 Hz, 1H, H-13), 3.24 (s, 3H, H-17’), 3.20 (m, 2H, H-11), 2.13 (m, 2H, H-12). 13C{1H} NMR 
(101 MHz, DMSO-d6): δ (ppm) = 156.3, 152.3, 150.3, 149.5, 142.4, 139.2, 135.2, 133.9, 
130.5, 129.9, 129.5 (2C), 129.1 (2C), 127.9, 124.5 (2C), 121.4, 119.3, 118.0, 112.4, 99.2, 
44.7, 42.9, 39.8, 28.2. FT-IR (ATR, cm-1): ν = 3397 (N–H), 1609 (C=Nbenz/quin), 1578 (C=C), 
1368 (S=O), 1136 (S=O). ESI-MS: m/z 246.0693 (100%, [M+2H]2+), calculated 246.0688; 












Compound 3e (0.141 g, 0.401 mmol), benzaldehyde 
(0.0607 ml, 0.597 mmol), TFA (3.04 µl, 0.0397 mmol) 
and anhydrous MgSO4 (0.244 g, 1.99 mmol).  Product: 
Beige powder. Yield: 0.115 g, 65.5%. Rf(EtOAc, 100%): 
0.12. M.p. 228.8 – 230.5 °C. 1H NMR (300 MHz, 
DMSO-d6): δ (ppm) = 8.35 (d, 3JHH = 5.5 Hz, 1H, H-2), 
8.25 (d, 4JHH = 1.0 Hz, 1H, H-18), 8.10 (d, 3JHH = 9.1 Hz, 
1H, H-7), 7.97 (d, 3JHH = 8.4 Hz, 1H, H-15), 7.80 (d, 4JHH = 2.2 Hz, 1H, H-4), 7.72 – 7.69 
(overlapping m, 3H, H-16/22), 7.44 (dd, 3JHH = 9.1, 4JHH = 2.2 Hz, 1H, H-6), 7.40 – 7.27 
(overlapping m, 3H, H-23/24), 7.21 (t, 3JHH = 5.1 Hz, 1H, H-10), 6.30 (d, 3JHH = 5.5 Hz, 1H, 
H-1), 4.53 (t, 3JHH = 7.3 Hz, 2H, H-13), 3.19 (m, 2H, H-11), 2.11 (m, 2H, H-12). 13C{1H} NMR 
(101 MHz, DMSO-d6): δ (ppm) = 156.1, 152.3, 150.2, 149.5, 142.6, 139.1, 133.9, 130.5, 
129.8, 129.5 (2C), 129.1 (2C), 128.0, 126.3, 124.6, 124.5 (2C), 120.3, 118.0, 113.0, 104.8, 
99.2, 42.9, 39.7, 28.2. FT-IR (ATR, cm-1): ν = 3175 (N–H), 1611 (C=Nbenz/quin), 1580 (C=C), 
2214 (C≡N). ESI-MS: m/z 219.5773 (100%, [M+2H]2+), calculated 219.5776; m/z 
438.1470 (90%, [M+H]+), calculated 438.1480. HPLC purity >99% (tR = 2.30 min). 
 
7.3.2 General method for synthesis of 2-ferrocenyl hybrids (5a – 5e)  
A 1,2-diamine aminoquinoline precursor (3a – 3e) (1 eq.), ferrocenecarboxaldehyde 
(1.5 eq.) and TFA (0.1 eq.) were dissolved in EtOH (25 ml). Anhydrous MgSO4 (5 eq.) was 
added and the dark red reaction mixture was refluxed for 48 hours. Thereafter, the 
resulting dark red mixture was filtered by gravity and the solvent of the filtrate was 
removed to give a red residue. To this crude residue, 1 M NaOH (50 ml) was added and 
the mixture was extracted using DCM (3 × 50 ml). The organic fractions were collected 
and washed with brine (2 × 50 ml), followed by water (1 × 30 ml). The organic layer was 
collected, dried over anhydrous Na2SO4 and filtered by gravity. The solvent of the filtrate 
was removed to afford the crude product as a red residue. The crude product was purified 
by column chromatography (silica gel) using EtOAc (100%). Compounds 5a – 5e were 
isolated as orange powders and dried in vacuo. 
 





Compound 3a (0.102 g, 0.312 mmol), 
ferrocenecarboxaldehyde (0.100 g, 0.467 mmol), 
TFA (2.50 µl, 0.0327 mmol) and anhydrous MgSO4 
(0.184 g, 1.53 mmol). Product: Orange powder. 
Yield: 0.0742 g, 45.6%. Rf(EtOAc, 100%): 0.26. 
M.p. 227.0 – 228.3 °C. 1H NMR (300 MHz, 
DMSO-d6): δ (ppm) = 8.44 (d, 3JHH = 5.5 Hz, 1H, H-2), 8.37 (d, 3JHH = 9.1 Hz, 1H, H-7), 7.87 
(d, 4JHH = 2.2 Hz, 1H, H-4), 7.69 – 7.57 (overlapping m, 3H, H-10/15/18), 7.56 (d, 4JHH = 2.2 
Hz, 1H, H-6), 7.25 – 7.14 (overlapping m, 2H, H-16/17), 6.63 (d, 3JHH = 5.5 Hz, 1H, H-1), 
4.75 (t, 3JHH = 1.8 Hz, 2H, H-22), 4.62 (m, 2H, H-13), 4.14 (t, 3JHH = 1.8 Hz, 2H, H-23), 3.99 
(s, 5H, H-24), 3.60 (q, 3JHH = 5.7 Hz, 2H, H-11), 2.23 (m, 2H, H-12). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ (ppm) = 152.5, 152.5, 150.4, 149.8, 143.2, 136.5, 134.0, 128.1, 124.7, 124.6, 
122.1 (2C), 118.7, 118.1, 110.3, 99.5, 74.1, 70.1 (2C), 69.7 (5C), 69.1 (2C), 42.3, 39.5, 29.1. 
FT-IR (ATR, cm-1): ν = 3437 (N–H), 1609 (C=Nbenz/quin), 1574 (C=C). ESI-MS: m/z 
521.1207 (100%, [M+H]+), calculated 521.1190. HPLC purity >99% (tR = 6.75 min). 
7-Chloro-N-(3-(5-(methyl)-2-ferrocenyl-1H-benzo[d]imidazol-1-yl)propyl)quinolin-4-
amine (5b) 
Compound 3b (0.0813 g, 0.239 mmol), 
ferrocenecarboxaldehyde (0.0774 g, 0.362 mmol), 
TFA (2.30 µl, 0.0301 mmol) and anhydrous MgSO4 
(0.146 g, 1.21 mmol). Product: Orange powder. 
Yield: 0.0718 g, 56.3%. Rf(EtOAc, 100%): 0.29. 
M.p. 114.2 – 115.9 °C. 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) = 8.44 (d, 3JHH = 5.5 Hz, 1H, 
H-2), 8.37 (d, 3JHH = 9.1 Hz, 1H, H-7), 7.87 (d, 4JHH = 2.3 Hz, 1H, H-4), 7.65 (t, 3JHH = 5.5 Hz, 
1H, H-10), 7.57 (dd, 3JHH = 9.1, 4JHH = 2.3 Hz, 1H, H-6), 7.49 (d, 3JHH = 8.3 Hz, 1H, H-15), 7.36 
(m, 1H, H-18), 7.03 (dd, 3JHH = 8.3, 4JHH = 1.2 Hz, 1H, H-16), 6.62 (d, 3JHH = 5.5 Hz, 1H, H-1), 
4.74 (t, 3JHH = 1.9 Hz, 2H, H-22), 4.58 (m, 2H, H-13), 4.13 (t, 3JHH = 1.9 Hz, 2H, H-23), 3.98 
(s, 5H, H-24) 3.58 (q, 3JHH = 6.0 Hz, 2H, H-11), 2.41 (s, 3H, H-17’), 2.21 (m, 2H, H-12). 
13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 152.5, 152.3, 150.4, 149.8, 143.6, 134.7, 
 
 




134.0, 131.1, 128.1, 124.7, 124.6, 123.4, 118.5, 118.1, 109.8, 99.5, 74.3, 70.0 (2C), 69.7 
(5C), 69.0 (2C), 42.3, 39.7, 29.1, 21.7. FT-IR (ATR, cm-1): ν = 3254 (N–H), 1609 
(C=Nbenz/quin), 1580 (C=C). ESI-MS: m/z 268.0718 (100%, [M+2H]2+), calculated 
268.0710; m/z 535.1367 (23%, [M+H]+), calculated 535.1346. HPLC purity 99% 
(tR = 6.98 min). 
7-Chloro-N-(3-(5-(trifluoromethyl)-2-ferrocenyl-1H-benzo[d]imidazol-1-
yl)propyl)quinolin-4-amine (5c) 
Compound 3c (0.140 g, 0.355 mmol), 
ferrocenecarboxaldehyde (0.117 g, 0.547 mmol), 
TFA (3.43 µl, 0.0355 mmol) and anhydrous MgSO4 
(0.214 g, 1.78 mmol). Product: Orange powder. 
Yield: 0.107 g, 51.2%. Rf(EtOAc, 100%): 0.39. 
M.p. 184.2 – 185.7 °C. 1H NMR (400 MHz, 
DMSO-d6): δ (ppm) = 8.44 (d, 3JHH = 5.3 Hz, 1H, H-
2), 8.36 (d, 3JHH = 9.0 Hz, 1H, H-7), 7.92 (m, 1H, H-18), 7.90 – 7.85 (overlapping m, 2H, H-
4/15), 7.67 (t, 3JHH = 5.2 Hz, 1H, H-10), 7.58 (dd, 3JHH = 9.0, 4JHH = 2.0 Hz, 1H, H-6), 7.54 (d, 
3JHH = 8.7 Hz, 1H, H-16), 6.64 (d, 3JHH = 5.3 Hz, 1H, H-1), 4.79 (m, 2H, H-22), 4.67 (m, 2H, 
H-13), 4.16 (m, 2H, H-23), 4.00 (s, 5H, H-24), 3.61 (m, 2H, H-11), 2.24 (m, 2H, H-12). 
13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 155.5, 152.5, 150.4, 149.8, 142.7, 138.9, 
134.0, 128.1, 127.0, 124.7, 124.5, 123.0, 118.7, 118.1, 115.9, 111.3, 99.5, 73.0, 70.5 (2C), 
69.9 (5C), 69.3 (2C), 42.7, 39.6, 29.0. FT-IR (ATR, cm-1): ν = 3266 (N–H), 1611 
(C=Nbenz/quin), 1582 (C=C), 1328 (C–F). ESI-MS: m/z 295.0572 (100%, [M+2H]2+), 
calculated 295.0568; m/z 589.1068 (32%, [M+H]+), calculated 589.1064. HPLC purity 













Compound 3d (0.159 g, 0.393 mmol), 
ferrocenecarboxaldehyde (0.130 g, 0.607 mmol), 
TFA (3.01 µl, 0.0393 mmol) and anhydrous MgSO4 
(0.239 g, 1.99 mmol). Product: Orange powder. 
Yield: 0.128 g, 54.4%. Rf(EtOAc, 100%): 0.10. 
M.p  164.0 – 166.0 °C. 1H NMR (300 MHz, 
DMSO-d6): δ (ppm) = 8.45 (d, 3JHH = 5.5 Hz, 1H, H-
2), 8.37 (d, 3JHH = 9.0 Hz, 1H, H-7), 8.10 (d, 4JHH = 1.5 Hz, 1H, H-18), 7.92 (d, 3JHH = 8.5 Hz, 
1H, H-15), 7.87 (d, 4JHH = 2.1 Hz, 1H, H-4), 7.76 (dd, 3JHH = 8.5, 4JHH = 1.5 Hz, 1H, H-16), 7.68 
(t, 3JHH = 5.4 Hz, 1H, H-10), 7.58 (dd, 3JHH = 9.0, 4JHH = 2.1 Hz, 1H, H-6), 6.65 (d, 3JHH = 5.5 
Hz, 1H, H-1), 4.80 (m, 2H, H-22), 4.68 (m, 2H, H-13), 4.18 (m, 2H, H-23), 4.00 (s, 5H, H-24), 
3.62 (m, 2H, H-11), 3.22 (s, 3H, H-17’), 2.24 (m, 2H, H-12). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ (ppm) = 156.5, 156.2, 152.5, 150.4, 142.6, 139.7, 134.9, 134.0, 128.2, 124.7 
(2C), 124.6, 120.6, 118.0, 111.2, 99.6, 72.8, 70.6 (2C), 69.9 (5C), 69.4 (2C), 44.7, 42.8, 39.6, 
29.0. FT-IR (ATR, cm-1): ν = 3242 (N–H), 1609 (C=Nbenz/quin), 1580 (C=C), 1366 (S=O), 
1136 (S=O). ESI-MS: m/z 599.0969 (100%, [M+H]+), calculated 599.0965. HPLC purity 
97% (tR = 7.55 min). 
1-(3-((7-Chloroquinolin-4-yl)amino)propyl)-2-ferrocenyl-1H-benzo[d]imidazole-5-
carbonitrile (5e) 
Compound 3e (0.141 g, 0.398 mmol), 
ferrocenecarboxaldehyde (0.131 g, 0.614 mmol), 
TFA (3.04 µl, 0.0398 mmol) and anhydrous MgSO4 
(0.240 g, 1.99 mmol). Product: Orange powder. 
Yield: 0.0954 g, 43.9%. Rf(EtOAc, 100%): 0.21. 
M.p. 222.9 – 224.4 °C. 1H NMR (300 MHz, 
DMSO-d6): δ (ppm) = 8.44 (d, 3JHH = 5.4 Hz, 1H, 
H-2), 8.37 (d, 3JHH = 9.1 Hz, 1H, H-7), 8.09 (m, 1H, H-18), 7.91 – 7.85 (overlapping m, 2H, 
H-4/15), 7.71 (t, 3JHH = 5.2 Hz, 1H, H-10), 7.66 – 7.56 (overlapping m, 2H, H-6/16), 6.64 
(d, 3JHH = 5.4 Hz, 1H, H-1), 4.77 (m, 2H, H-22), 4.66 (m, 2H, H-13), 4.15 (m, 2H, H-23), 4.00 
 
 




(s, 5H, H-24), 3.61 (m, 2H, H-11), 2.21 (m, 2H, H-12). 13C{1H} NMR (101 MHz, DMSO-d6): 
δ (ppm) = 156.0, 152.5, 150.4, 149.8, 142.7, 139.6, 134.0, 128.1, 125.6, 124.7, 124.5, 123.2, 
120.5, 118.1, 111.9, 104.3, 99.5, 72.7, 70.7 (2C), 69.9 (5C), 69.4 (2C), 42.7, 39.5, 29.0. 
FT-IR (ATR, cm-1): ν = 3242 (N–H), 1609 (C=Nbenz/quin), 1580 (C=C), 2222 (C≡N). 
ESI-MS: m/z 273.5657 (100%, [M+2H]2+), calculated 273.5608; m/z 546.1166 (47%, 
[M+H]+), calculated 546.1142. HPLC purity 97% (tR = 8.02 min). 
 
7.3.3 General method for synthesis of 2-pyridyl hybrids (6a – 6c) 
Compound 3a, 3b or 3c (1 eq.), 2-pyridinecarboxaldehyde (1.5 eq.) and TFA (0.1 eq.) 
were dissolved in ethanol (25 ml). Anhydrous MgSO4 (5 eq.) was added and the brown 
reaction mixture was refluxed for 24 hours. Thereafter, the resulting brown mixture was 
filtered by gravity and the solvent of the filtrate was removed to give a brown residue. To 
this crude residue, 1 M NaOH (50 ml) was added and the mixture was extracted using 
DCM (3 x 50 ml). The organic fractions were combined and washed with brine (2 x 50 ml). 
the organic layer was collected, dried over anhydrous Na2SO4, filtered by gravity and the 
solvent of the filtrate was removed to afford a dull orange/brown solid. The crude 
product was purified by column chromatography (silica gel) using EtOAc (100%). 
Compounds 6a – 6c were isolated as pale-yellow or beige powders and dried in vacuo. 
7-chloro-N-(3-(2-(pyridin-2-yl)-1H-benzo[d]imidazol-1-yl)propyl)quinolin-4-amine (6a) 
Compound 3a (0.222 g, 0.680 mmol), 
2-pyridinecarboxaldehyde (0.0971 ml, 1.02 mmol), 
TFA (0.00520 ml, 0.0680 mmol) and anhydrous MgSO4 
(0.409 g, 3.40 mmol). Product: Pale-yellow powder. 
Yield: 0.166 g, 59.1%. M.p. 201.9 – 203.0 °C. 1H NMR 
(400 MHz, DMSO-d6): δ 8.47 (ddd, 3JHH = 4.8, 4JHH = 1.8, 
5JHH = 0.9 Hz, 1H, H-25), 8.34 (d, 3JHH = 5.5 Hz, 1H, H-2), 8.27 (dt, 3JHH = 8.0, 1.2 Hz, 1H, 
H-22), 8.21 (d, 3JHH = 9.1 Hz, 1H, H-7), 7.90 (td, 3JHH = 7.8, 4JHH = 1.8 Hz, 1H, H-23), 7.79 (d, 
4JHH = 2.3 Hz, 1H, H-4), 7.76 – 7.71 (overlapping m, 2H, H-15/18), 7.44 (dd, 3JHH = 9.1, 4JHH 
= 2.3 Hz, 1H, H-6), 7.36 (ddd, 3JHH = 7.6, 3JHH = 4.8, 4JHH = 1.2 Hz, 1H, H-24), 7.33 – 7.25 
(overlapping m, 3H, H-10/16/17), 6.34 (d, 3JHH = 5.5 Hz, 1H, H-1), 4.99 (t, 3JHH = 7.3 Hz, 
 




2H, H-13), 3.29 (m, 2H, H-11), 2.23 (m, 2H, H-12). 13C{1H} NMR (101 MHz, DMSO-d6): δ 
152.3, 150.4 (2C), 149.9, 149.6, 149.1, 142.6, 137.7, 136.9, 133.8, 128.0, 124.8, 124.5 (3C), 
123.6, 122.9, 120.1, 118.0, 111.3, 99.1, 43.3, 40.1, 29.0. IR (ATR, cm-1): ν = 3194 (N–H), 
1609 (C=Nbenz/quin), 1592 (C=Npyr), 1580 (C=C). ESI-MS: m/z 414.1485 (100%, [M+H]+), 
calculated 414.1480. HPLC purity 99% (tR = 2.62 min). 
7-chloro-N-(3-(5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazol-1-yl)propyl)quinolin-4-
amine (6b) 
Compound 3b (0.186 g, 0.545 mmol), 
2-pyridinecarboxaldehyde (0.0777 ml, 0.817 mmol), 
TFA (0.00417 ml, 0.0545 mmol) and anhydrous 
MgSO4 (0.331 g, 2.75 mmol). Product: Beige powder. 
Yield: 0.146 g, 62.4%. M.p. 216.0 – 217.5 °C. 1H NMR 
(300 MHz, DMSO-d6): δ 8.46 (d, 3JHH = 4.8 Hz, 4JHH = 
1.7 Hz, 5JHH = 0.9 Hz 1H, H-25), 8.34 (d, 3JHH = 5.5 Hz, 
1H, H-2), 8.25 (dt, 3JHH = 8.0 Hz, 4JHH = 1.0 Hz, 1H, H-22), 8.21 (d, 3JHH = 9.1 Hz, 1H, H-7), 
7.89 (td, 3JHH = 7.8, 4JHH = 1.8 Hz, 1H, H-23), 7.79 (d, 4JHH = 2.3 Hz, 1H, H-4), 7.60 (d, 3JHH = 
8.3 Hz, 1H, H-15), 7.52 (m, 1H, H-18), 7.44 (dd, 3JHH = 9.1, 4JHH = 2.3 Hz, 1H, H-6), 7.35 (ddd, 
3JHH = 7.6, 3JHH = 4.8, 4JHH = 1.2 Hz, 1H, H-24), 7.28 (t, 3JHH = 5.5 Hz, 1H, H-10), 7.13 (dd, 3JHH 
= 8.3, 4JHH = 1.2 Hz, 1H, H-16), 6.33 (d, 3JHH = 5.5 Hz, 1H, H-1), 4.95 (t, 3JHH = 7.1 Hz, 2H, 
H-13), 3.28 (m, 2H, H-11), 2.44 (s, 3H, H-17’), 2.20 (m, 2H, H-12). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ 152.2, 150.4, 149.7, 149.4, 149.1, 142.9, 137.6, 135.0, 133.9, 132.0, 127.9, 
125.2, 124.7, 124.5, 124.5 (2C), 124.4, 119.6, 118.0, 110.8, 99.1, 43.3, 40.1, 29.0, 21.6. 
FT-IR (ATR, cm-1): ν = 3171 (N–H), 1611 (C=Nbenz/quin), 1592 (C=Npyr), 1580 (C=C). 
ESI-MS: m/z 428.1644 (100%, [M+H]+), calculated 428.1637. HPLC purity >99% 












Compound 3c (0.402 g, 1.02 mmol), 2-
pyridinecarboxaldehyde (0.145 ml, 1.53 mmol), TFA 
(0.00781 ml, 0.102 mmol), anhydrous MgSO4 (0.616 
g, 5.12 mmol). Product: Beige powder. Yield: 0.298 g, 
60.7%. M.p. 200.0 – 201.0 °C. 1H NMR (400 MHz, 
DMSO-d6): δ 8.45 (ddd, 3JHH = 4.8, 4JHH = 1.6, 5JHH = 0.8 
Hz, 1H, H-25), 8.31 (d, 3JHH = 5.5 Hz, 1H, H-2), 8.24 (dt, 
3JHH = 8.0, 4JHH = 1.2 Hz, 1H, H-22), 8.15 (d, 3JHH = 9.1 Hz, 1H, H-7), 8.08 (m, 1H, H-18), 7.95 
(d, 3JHH = 8.7 Hz, 1H, H-15), 7.91 (td, 3JHH = 7.8, 4JHH = 1.6 Hz, 1H, H-23), 7.77 (d, 4JHH = 2.3 
Hz, 1H, H-4), 7.60 (dd, 3JHH = 8.7, 4JHH = 1.6 Hz, 1H, H-16), 7.41 (dd, 3JHH = 9.1, 4JHH = 2.3 Hz, 
1H, H-6), 7.37 (ddd, 3JHH = 7.6, 3JHH = 4.8, 4JHH = 1.2 Hz, 1H, H-24), 7.25 (t, 3JHH = 5.2 Hz, 1H, 
H-10), 6.33 (d, 3JHH = 5.5 Hz, 1H, H-1), 5.01 (t, 3JHH = 7.2 Hz, 2H, H-13), 3.28 (m, 2H, H-11), 
2.21 (m, 2H, H-12). 13C{1H} NMR (101 MHz, DMSO-d6): δ 152.2 (2C), 150.4, 149.7, 149.4, 
149.2, 141.9, 139.1, 137.9, 133.9, 127.9, 126.8, 125.1 (2C), 124.5 (2C), 124.0, 120.1, 118.0, 
117.4, 112.6, 99.1, 43.8, 40.1, 28.9. FT-IR (ATR, cm-1): ν = 3179 (N–H), 1613 
(C=Nbenz/quin), 1590 (C=Npyr), 1580 (C=C), 1330 (C–F). ESI-MS: m/z 482.1353 (100%, 
[M+H]+), calculated 482.1354. HPLC purity 99% (tR = 2.41 min). 
 
7.4 Neutral iridium(III) and rhodium(III) hybrid complexes 
7.4.1 General method for synthesis of C^N-coordinated Ir(III)-Cp* complexes 
(7a – 7c) 
Sodium acetate (1.5 eq.) was added to a stirring solution of ligand 4a, 4b or 4c (1 eq.) in 
dry DCM (10 ml) and EtOH (2 ml), and the yellow solution was stirred under N2 for 1.5 
hours. A solution of pentamethylcyclopentadienyliridium(III) chloride (0.5 eq.) in DCM 
(20 ml) was added dropwise over 30 minutes and the orange solution was stirred for a 
further 24 hours. The resulting cloudy orange reaction mixture was filtered through 
Celite® and the solvent of the filtrate was removed to afford an orange residue. This crude 
product was purified by column chromatography (aluminium oxide) using CHCl3:MeOH 
 




(97:3) for compounds 7a or 7b, and CHCl3 (100%) for compound 7c. Subsequent 
precipitation from DCM/pentane afforded the desired product as a dull yellow powder, 
which was collected by suction filtration and dried in vacuo. 
Unsubstituted cyclometalated Ir(III)-Cp* complex (7a) 
Sodium acetate (0.0182 g, 0.222 mmol), 
compound 4a (0.0581 g, 0.141 mmol), 
[Ir(Cp*)Cl2]2 (0.0560 g, 0.0703 mmol). 
Product: Dull yellow powder. Yield: 0.0687 g, 
63.0%. M.p. 204.0 – 206.3 °C.  1H NMR (300 
MHz, DMSO-d6): δ 8.40 (d, 3JHH = 9.1 Hz, 1H, 
H-7), 8.35 (d, 3JHH = 5.4 Hz, 1H, H-2), 8.00 (m, 2H, H-22/25), 7.83 (d, 3JHH = 7.5 Hz, 1H, 
H-15), 7.80 (d, 4JHH = 2.2 Hz, 1H, H-4), 7.70 (t, 3JHH = 5.1 Hz, 1H, H-10), 7.59 – 7.47 
(overlapping m, 3H, H-16/17/18), 7.45 (dd, 3JHH = 9.0, 4JHH = 2.2 Hz, 1H, H-6), 7.27 (t, 3JHH 
= 7.5 Hz, 1H, H-23), 6.98 (t, 3JHH = 7.5 Hz, 1H, H-24), 6.42 (d, 3JHH = 5.4 Hz, 1H, H-1), 4.99 
(m, 2H, H-13), 3.49 (m, 2H, H-11), 2.31 (m, 2H, H-12), 1.72 (s, 15H, H-27’). 13C{1H} NMR 
(151 MHz, DMSO-d6): δ 161.7, 154.5, 152.3, 150.4, 149.6, 138.3, 137.5, 136.0, 134.3, 
133.9, 131.5, 127.9, 126.4, 125.0, 124.9 (2C), 124.9, 124.6, 118.1, 116.0, 113.0, 99.1, 96.3 
(5C), 43.2, 40.5, 28.3, 9.2 (5C). FT-IR (ATR, cm-1): ν = 3254 (N–H), 1609 (C=Nquin), 1580 
(C=C/C=Nbenz). ESI-MS: m/z 370.1120 (100%, [M–Cl+H]2+), calculated 370.1129; m/z 
773.1756 (60%, [M–H]–), calculated 773.1795.  
Methyl-substituted cyclometalated Ir(III)-Cp* complex (7b) 
Sodium acetate (0.0182 g, 0.222 mmol), 
compound 4b (0.0599 g, 0.140 mmol), 
[Ir(Cp*)Cl2]2 (0.0559 g, 0.0702 mmol). 
Product: Dull yellow powder. Yield: 0.0689 g, 
62.6%. M.p. 204.4 – 207.2 °C. 1H NMR (400 
MHz, DMSO-d6): δ 8.38-8.35 (overlapping m, 
2H, H-2/7), 7.93 (d, 3JHH = 7.8 Hz, 1H, H-25), 
7.89 (d, 3JHH = 8.5 Hz, 1H, H-15), 7.80 (m, 2H, H-4/22), 7.72 (t, 3JHH = 4.4 Hz, 1H, H-10), 
7.47 (dd, 3JHH = 9.0, 4JHH = 2.2 Hz, 1H, H-6), 7.33 (d, 3JHH = 8.5 Hz, 1H, H-16), 7.27 – 7.23 
(overlapping m, 2H, H-18/23), 6.90 (t, 3JHH = 7.3 Hz, 1H, H-24), 6.44 (d, 3JHH = 5.5 Hz, 1H, 
 
 




H-1), 4.94 (m, 2H, H-13), 3.47 (m, 2H, H-11), 2.56 (s, 3H, H-17’), 2.25 (m, 2H, H-12), 1.72 
(s, 15H, H-27’). 13C{1H} NMR (101 MHz, DMSO-d6): δ 161.4, 154.2, 152.3, 150.4, 149.6, 
138.6, 137.4, 134.7, 134.3, 134.2, 133.9, 131.4, 127.9, 126.3, 126.2, 124.9, 124.7, 124.6, 
118.0, 115.4, 112.7, 99.1, 96.3 (5C), 43.1, 40.3, 28.4, 21.7, 9.2 (5C). FT-IR (ATR, cm-1): 
ν = 3274 (N–H), 1611 (C=Nquin), 1584 (C=C/C=Nbenz). ESI-MS: m/z 370.1207 (100%, 
[M-Cl+H]2+), calculated 377.1207; m/z 787.1949 (50%, [M–H]–), calculated 787.1952.  
Trifluoromethyl-substituted cyclometalated Ir(III)-Cp* complex (7c) 
Sodium acetate (0.0259 g, 0.316 mmol), 
compound 4c (0.0754 g, 0.157 mmol), 
[Ir(Cp*)Cl2]2 (0.0624 g, 0.0784 mmol). 
Product: Yellow powder. Yield: 0.0683 g, 
51.7%. M.p. 201.1 – 203.1 °C.1H NMR (600 
MHz, DMSO-d6): δ 8.38 (d, 3JHH = 9.0 Hz, 1H, 
H-7), 8.35 (d, 3JHH = 5.5 Hz, 1H, H-2), 8.32 (d, 
3JHH = 8.6 Hz, 1H, H-15), 7.99 (d, 3JHH = 7.8 Hz, 1H, H-25), 7.85 – 7.82 (overlapping m, 2H, 
H-16/22), 7.79 (d, 4JHH = 2.3 Hz, 1H, H-4), 7.75 (t, 3JHH = 5.5 Hz, 1H, H-10), 7.69 (m, 1H, 
H-18), 7.45 (dd, 3JHH = 9.0, 4JHH = 2.3 Hz, 1H, H-6), 7.29 (td, 3JHH = 7.8, 4JHH = 1.1 Hz, 1H, 
H-23), 6.89 (td, 3JHH = 7.8, 4JHH = 1.1 Hz, 1H, H-24), 6.47 (d, 3JHH = 5.5 Hz, 1H, H-1), 5.02 (m, 
2H, H-13), 3.52 (m, 2H, H-11), 2.29 (m, 2H, H-12), 1.70 (s, 15H, H-27’). 13C{1H} NMR (151 
MHz, DMSO-d6): δ 164.3, 155.6, 152.3, 150.4, 149.6, 138.7, 138.2, 137.3, 133.9, 133.6, 
132.3, 127.9, 127.52, 127.1, 125.3, 125.0, 124.8, 124.6, 121.4, 118.0, 114.6, 112.8, 99.2, 
96.4 (5C), 43.8, 40.5, 28.2, 9.2 (5C). FT-IR (ATR, cm-1): ν = 3274 (N–H), 1611 (C=Nquin), 
1584 (C=C/C=Nbenz), 1326 (C–F). ESI-MS: m/z 404.1064 (100%, [M–Cl+H]2+), calculated 
404.1066; m/z 807.2033 (70%, [M–Cl]–), calculated 807.2053; m/z 841.1702 (100%, 








7.4.2 General method for synthesis of C^N-coordinated Rh(III)-Cp* complexes 
(8a – 8b) 
Sodium acetate (2 eq.) was added to a stirring solution of ligand 4a or 4b (1 eq.) in dry 
methanol (15 ml) and the pale-yellow solution was stirred under N2 for 30 minutes. 
Thereafter, a solution of pentamethylcyclopentadienylrhodium(III) chloride dimer 
(0.5 eq.) in dry DCM (20 ml) was added dropwise over 10 minutes and the red solution 
was refluxed under N2 for 96 hours. The resulting red solution was cooled to room 
temperature and the solvent was removed to afford a red residue. This crude residue was 
purified by column chromatography (aluminium oxide) using CHCl3:MeOH (19:1). 
Precipitation from DCM/pentane afforded the desired product as a dull orange powder, 
which was collected by suction filtration and dried in vacuo. 
Unsubstituted cyclometalated Rh(III)-Cp* complex (8a) 
Sodium acetate (0.0217 g, 0.264 mmol), 
compound 4a (0.0514 g, 0.124 mmol), 
[Rh(Cp*)Cl2]2 (0.0382 g, 0.0618 mmol). 
Product: Dull orange powder. Yield: 0.0304 g, 
35.9%. M.p. 186.8 °C (Decomp. w/o melting). 
1H NMR (300 MHz, DMSO-d6): δ 8.39 – 8.32 
(overlapping m, 2H, H-2/7), 8.01 (dd, 3JHH = 6.9, 4JHH = 1.9 Hz, 1H, H-25), 7.93 (d, 3JHH = 7.5 
Hz, 1H, H-22), 7.83 – 7.79 (overlapping m, 2H, H-4/15), 7.66 – 7.59 (overlapping m, 2H, 
H-10/18), 7.54 – 7.43 (overlapping m, 3H, H-6/16/17), 7.32 (t, 3JHH = 7.4 Hz, 1H, H-23), 
6.90 (t, 3JHH = 7.2 Hz, 1H, H-24), 6.45 (d, 3JHH = 5.5 Hz, 1H, H-1), 4.92 (m, 2H, H-13), 3.47 
(m, 2H, H-11), 2.26 (m, 2H, H-12), 1.64 (s, 15H, H-27’). 13C{1H} NMR (151 MHz, 
DMSO-d6): δ 158.4, 152.7, 151.1, 149.5, 139.2, 138.2, 136.8, 135.1, 134.8, 131.7, 128.0, 
126.7, 126.0, 125.4, 125.3 (2C), 124.9 (2C), 118.3, 116.8, 113.2, 102.5 (2C), 102.4 (3C), 
99.7, 43.7, 40.5, 28.6, 9.9 (5C). FT-IR (ATR, cm-1): ν = 3266 (N–H), 1611 (C=Nquin), 1580 
(C=C/C=Nbenz). ESI-MS: m/z 325.0846 (100%, [M–Cl+H]2+), calculated 325.0842; 








Methyl-substituted cyclometalated Rh(III)-Cp* complex (8b) 
Sodium acetate (0.0320 g, 0.390 mmol), 
compound 4b (0.0801 g, 0.188 mmol), 
[Rh(Cp*)Cl2]2 (0.0580 g, 0.0938 mmol). 
Product: Dull orange powder. Yield: 0.0613 g, 
46.8%. M.p. 194.2 °C (Decomp. w/o melting). 
1H NMR (600 MHz, DMSO-d6): δ 8.39 (d, 3JHH = 
9.1 Hz, 1H, H-7), 8.34 (d, 3JHH = 5.4 Hz, 1H, H-2), 
7.92 – 7.87 (overlapping m, 2H, H-15/25), 7.82 – 7.77 (overlapping m, 2H, H-4/22), 7.68 
(t, 3JHH = 5.4 Hz, 1H, H-10), 7.47 (dd, 3JHH = 9.0, 4JHH = 2.3 Hz, 1H, H-6), 7.34 (m, 1H, H-18), 
7.33 – 7.26 (m, 2H, H-16/23), 6.89 (td, 3JHH = 7.8, 4JHH = 1.0 Hz, 1H, H-24), 6.43 (d, 3JHH = 
5.5 Hz, 1H, H-1), 4.88 (m, 2H, H-13), 3.46 (m, 2H, H-11), 2.54 (s, 3H, H-17’), 2.23 (m, 2H, 
H-12), 1.63 (s, 15H, H-27’). 13C{1H} NMR (151 MHz, DMSO-d6): δ 157.7, 152.3, 150.4, 
149.6, 139.2, 137.6, 134.7, 134.6, 134.4, 133.9, 131.0, 127.9, 126.2, 126.1, 125.4, 124.8 
(2C), 124.6, 118.0, 115.8, 112.6, 101.9 (3C), 101.8 (2C), 99.1, 43.3, 40.5, 28.3, 21.6, 9.5 
(5C). FT-IR (ATR, cm-1): ν = 3258 (N–H), 1611 (C=Nquin), 1580 (C=C/C=Nbenz). ESI-MS: 
m/z 332.0920 (100%, [M–Cl+H]2+), calculated 332.0920; m/z 663.1749 (28%, [M–Cl]+), 
calculated 663.1761.  
 
7.4.3 General method for synthesis of quinoline N-coordinated Ir(III)- and Rh(III)-
Cp* complexes (9a – 9c and 10a – 10c) 
Pentamethylcyclopentadienyliridium(III) chloride dimer (0.5 eq.) or pentamethyl-
cyclopentadienylrhodium(III) chloride dimer (0.5 eq.) suspended in anhydrous MeOH 
(15 ml) was added dropwise to a stirring solution of ligand 4a, 4b or 4c (1 eq.) in 
anhydrous methanol (5 ml) and the orange or red solution was stirred under N2 at room 
temperature for 24 hours. The desired product precipitated as a yellow or orange 
powder, which was collected by suction filtration and washed with cold methanol, 








Unsubstituted quinoline N-coordinated Ir(III)-Cp* complex (9a) 
Compound 4a (0.0509 g, 0.122 mmol), [Ir(Cp*)Cl2]2 
(0.0482 g, 0.0605 mmol). Product: Yellow powder. 
Yield: 0.0902 g, 91.9%. M.p. 241.8 °C (Decomp. with 
melting). 1H NMR (300 MHz, DMSO-d6): δ 8.41 (d, J = 
6.1 Hz, 1H, H-2), 8.23 (d, 3JHH = 9.1 Hz, 1H, H-7), 7.97 (t, 
3JHH = 5.5 Hz, 1H, H-10), 7.85 (d, 4JHH = 2.1 Hz, 1H, H-4), 
7.75 – 7.63 (overlapping m, 4H, H-15/18/22), 7.58 
(dd, 3JHH = 9.1, 4JHH = 2.2 Hz, 1H, H-6), 7.34 – 7.21 
(overlapping m, 5H, H-16/17/23/24), 6.46 (d, 3JHH = 6.1 Hz, 1H, H-1), 4.49 (t, 3JHH = 7.3 
Hz, 2H, H-13), 3.28 (m, 2H, H-11), 2.1 (m, 2H, H-12), 1.63 (s, 15H, H-25’). 13C{1H} NMR 
(151 MHz, DMSO-d6): δ 153.8, 153.1, 148.6, 144.9, 143.2, 136.5, 136.2, 130.7, 130.3, 
129.7 (2C), 129.3 (2C), 126.2, 125.4, 124.3, 123.5, 123.1, 120.0, 117.3, 111.7, 99.5, 93.0 
(5C), 42.5, 40.5, 28.3, 9.0 (5C). FT-IR (ATR, cm-1): ν = 3317 (N–H), 1613 (C=N), 1590 
(C=C). ESI-MS: m/z 811.1723 ([M+H]+), calculated 811.1708; m/z 775.1938 ([M–Cl]+), 
calculated 775.1946.  
Methyl-substituted quinoline N-coordinated Ir(III)-Cp* complex (9b) 
Compound 4b (0.0521 g, 0.122 mmol), [Ir(Cp*)Cl2]2 
(0.0469 g, 0.0589 mmol). Product: Yellow powder. 
Yield: 0.0834 g, 96.2%. M.p. 253.6 °C (Decomp. with 
melting). 1H NMR (300 MHz, DMSO-d6): δ 8.35 (d, 
3JHH = 5.5 Hz, 1H, H-2), 8.13 (d, 3JHH = 9.0 Hz, 1H, H-7), 
7.79 (d, 3JHH = 2.1 Hz, 1H, H-4), 7.67 (m, 2H, H-22), 7.57 
(d, 3JHH = 8.2 Hz, 1H, H-15), 7.48 (m, 1H, H-18), 7.43 
(dd, 3JHH = 9.0, 4JHH = 2.2 Hz, 1H, H-6), 7.40 – 7.27 
(overlapping m, 3H, H-23/24), 7.21 (t, 3JHH = 5.2 Hz, 1H, H-10), 7.10 (d, 3JHH = 8.2 Hz, 1H, 
H-16), 6.29 (d, 3JHH = 5.5 Hz, 1H, H-1), 4.44 (t, 3JHH = 7.3 Hz, 2H, H-13), 3.18 (m, 2H, H-11), 
2.44 (s, 3H, H-17’), 2.11 (m, 2H, H-12), 1.63 (s, 15H, H-25’). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ 153.2, 152.2, 150.2, 149.4, 143.4, 134.2, 133.8, 131.4, 130.8, 129.7 (2C), 
129.3 (2C), 128.9, 127.9, 124.4 (2C), 124.2, 119.3, 117.9, 110.8, 99.1, 92.5 (5C), 42.5, 40.5, 
28.3, 21.6, 8.6 (5C). FT-IR (ATR, cm-1) ν = 3317 (N–H), 1611 (C=N), 1590 (C=C). 
 
 




ESI-MS: m/z 789.2087 ([M–Cl]+), calculated 789.2102; m/z 825.1714 ([M+H]+), 
calculated 825.1864.  
Trifluoromethyl-substituted quinoline N-coordinated Ir(III)-Cp* complex (9c) 
Compound 4c (0.0508 g, 0.106 mmol), [Ir(Cp*)Cl2]2 
(0.0411 g, 0.0516 mmol). Product: Yellow powder. 
Yield: 0.0834 g, 88.6%. M.p. 267.4 °C (Decomp. with 
melting). 1H NMR (600 MHz, DMSO-d6): δ 8.30 (d, 
3JHH = 5.4 Hz, 1H, H-2), 8.04 (d, 3JHH = 9.1 Hz, 1H, H-7), 
8.03 (m, 1H, H-18), 7.92 (d, 3JHH = 8.5 Hz, 1H, H-15), 
7.79 (d, 3JHH = 2.2 Hz, 1H, H-4), 7.65 (m, 2H, H-22), 7.59 
(dd, 3JHH = 8.6, 4JHH = 1.3 Hz, 1H, H-16), 7.41 (dd, 3JHH = 
9.0, 4JHH = 2.2 Hz, 1H, H-6), 7.36 – 7.27 (overlapping m, 3H, H-23/24), 7.21 (t, 3JHH = 5.2 
Hz, 1H, H-10), 6.27 (d, 3JHH = 5.4 Hz, 1H, H-1), 4.51 (t, 3JHH = 7.4 Hz, 2H, H-13), 3.18 (m, 2H, 
H-11), 2.11 (m, 2H, H-12), 1.61 (s, 15H, H-25’). 13C{1H} NMR (151 MHz, DMSO-d6): δ 
156.1, 152.4, 150.8, 149.3, 142.6, 138.6, 134.4, 130.7, 130.1, 129.7, 129.4, 128.0, 127.8, 
125.0 (2C), 124.7 (2C), 124.0, 119.9, 118.1, 117.2, 112.8, 99.4, 93.0 (5C), 43.1, 40.5, 28.3, 
9.0 (5C). FT-IR (ATR, cm-1): ν = 3321 (N–H), 1613 (C=N), 1590 (C=C), 1328 (C-F). 
ESI-MS: m/z 879.1503 ([M+H]+), calculated 879.1582, m/z 843.1803 ([M–Cl]+), 
calculated 843.1820.  
Unsubstituted quinoline N-coordinated Rh(III)-Cp* complex (10a) 
Compound 4a (0.0521 g, 0.122 mmol), [Rh(Cp*)Cl2]2 
(0.0469 g, 0.0589 mmol). Product: Orange powder. 
Yield: 0.0786 g, 89.9%. M.p. 261.7 °C (Decomp. with 
melting). 1H NMR (300 MHz, DMSO-d6): δ 8.42 (d, 
3JHH = 6.1 Hz, 1H, H-2), 8.23 (d, 3JHH = 9.1 Hz, 1H, H-7), 
8.04 (t, 3JHH = 5.5 Hz, 1H, H-10), 7.85 (d, 3JHH = 2.1 Hz, 
1H, H-4), 7.77 – 7.63 (overlapping m, 4H, H-
15/18/22), 7.59 (dd, 3JHH = 9.0, 4JHH = 2.1 Hz, 1H, H-6), 
7.36 – 7.16 (overlapping m, 5H, H-16/17/23/24), 6.48 (d, 3JHH = 6.2 Hz, 1H, H-1), 4.49 (t, 
3JHH = 7.3 Hz, 2H, H-13), 3.29 (m, 2H, H-11), 2.13 (m, 2H, H-12), 1.63 (s, 15H, H-25’). 
13C{1H} NMR (151 MHz, DMSO-d6): δ 153.9, 153.5, 148.3, 144.5, 143.2, 136.8, 136.2, 
 
 




130.7, 130.4, 129.8 (2C), 129.4 (2C), 126.5, 125.5, 124.1, 123.7, 123.3, 120.0, 117.3, 111.8, 
100.0 (3C), 99.9 (2C), 99.5, 42.6, 40.5, 28.3, 9.5 (5C). FT-IR (ATR, cm-1): ν = 3313 (N–H), 
1613 (C=N), 1588 (C=C). ESI-MS: m/z 721.1142 ([M+H]+), calculated 721.1134; m/z 
685.1360 ([M–Cl]+), calculated 685.1372.  
Methyl-substituted quinoline N-coordinated Rh(III)-Cp* complex (10b) 
Compound 4b (0.0516 g, 0.121 mmol), [Rh(Cp*)Cl2]2 
(0.0364 g, 0.0589 mmol). Product: Orange powder. 
Yield: 0.0692 g, 71.2%. M.p. 278.6 °C (Decomp. with 
melting). 1H NMR (300 MHz, DMSO-d6): δ 8.35 (d, 
3JHH = 5.4 Hz, 1H, H-2), 8.13 (d, 3JHH = 9.1 Hz, 1H, H-7), 
7.79 (d, 3JHH = 1.9 Hz, 1H, H-4), 7.67 (m, 2H, H-22), 7.57 
(d, 3JHH = 8.3 Hz, 1H, H-15), 7.48 (m, 1H, H-18), 7.43 
(dd, 3JHH = 9.0, 4JHH = 2.1 Hz, 1H, H-6), 7.40 – 7.27 
(overlapping m, 3H, H-23/24), 7.20 (t, 3JHH = 4.5 Hz, 1H, H-10), 7.10 (d, 3JHH = 7.3 Hz, 1H, 
H-16), 6.30 (d, 3JHH = 5.4 Hz, 1H, H-1), 4.44 (t, 3JHH = 7.3 Hz, 2H, H-13), 3.18 (m, 2H, H-11), 
2.44 (s, 3H, H-17’), 2.11 (m, 2H, H-12), 1.63 (s, 15H, H-25’). 13C{1H} NMR (101 MHz, 
DMSO-d6): δ 153.3, 152.2, 150.3, 149.4, 143.4, 134.2, 133.8, 131.5, 130.8, 129.8 (2C), 
129.3 (2C), 128.9, 127.8, 124.5, 124.4, 124.3, 119.4, 117.9, 110.8, 99.3 (2C), 99.2 (3C), 
99.1, 42.5, 28.3, 21.6, 9.0 (5C). FT-IR (ATR, cm-1): ν = 3306 (N-H), 1611 (C=N), 1588 
(C=C). ESI-MS: m/z 735.1277 ([M+H]+), calculated 735.1290; m/z 699.1505 ([M–Cl]+), 
calculated 699.1528.  
Trifluoromethyl-substituted quinoline N-coordinated Rh(III)-Cp* complex (10c) 
Compound 4c (0.0513 g, 0.107 mmol), [Rh(Cp*)Cl2]2 
(0.0326 g, 0.0527 mmol). Product: Orange powder. 
Yield: 0.0544 g, 65.4%. M.p. 285.4 °C (Decomp. with 
melting). 1H NMR (300 MHz, DMSO-d6): δ 8.31 (d, 
3JHH = 5.5 Hz, 1H, H-2), 8.06 (d, 3JHH = 9.1 Hz, 1H, H-7), 
8.03 (m, 1H, H-18), 7.92 (d, 3JHH = 8.5 Hz, 1H, H-15), 
7.80 (d, 4JHH = 2.2 Hz, 1H, H-4), 7.65 (m, 2H, H-22), 7.59 
(dd, 3JHH = 8.6 Hz, 4JHH = 1.5 Hz, 1H, H-16), 7.43 (dd, 3JHH 
= 9.1 Hz, 4JHH = 2.2 Hz, 1H, H-6), 7.36 – 7.27 (overlapping m, 4H, H-10/23/24), 6.29 (d, 
 
 




3JHH = 5.2 Hz, 1H, H-1), 4.52 (t, J = 3JHH = 7.4 Hz, 2H, H-13), 3.19 (m, 2H, H-11), 2.11 (m, 2H, 
H-12), 1.61 (s, 15H, H-25’). 13C{1H} NMR (151 MHz, DMSO-d6): δ 156.1, 151.9, 151.0, 
148.8, 142.6, 138.5, 134.6, 130.7, 130.1, 129.7, 129.3, 128.4, 127.4, 125.1, 124.7, 123.9, 
119.9, 118.0, 117.2, 112.8, 99.7 (3C), 99.6 (2C), 99.4, 43.1, 40.5, 28.3, 9.3 (5C). FT-IR 
(ATR, cm-1): ν = 3310 (N-H), 1613 (C=N), 1588 (C=C). ESI-MS: m/z 789.1037 ([M+H]+), 
calculated 789.1007; m/z 753.1227 ([M–Cl]+), calculated 753.1245.  
 
7.5 Cationic iridium(III) and rhodium(III) hybrid complexes 
7.5.1 General method for synthesis of N^N-coordinated Ir(III)- and Rh(III)-Cp* 
complexes (11a – 11c and 12a – 12c) 
Pentamethylcyclopentadienyliridium(III) chloride dimer (0.5 eq.) or pentamethyl-
cyclopentadienylrhodium(III) chloride dimer (0.5 eq.) dissolved in DCM (10 ml) was 
added dropwise to a stirring solution of ligand 6a, 6b or 6c (1 eq.) in EtOH (10 ml) and 
the orange solution was stirred at room temperature under N2 for 16 – 24 hours. The 
DCM was then removed, NH4PF6 (1.2 eq.) was added and the solution was stirred at 0 °C 
for 2 hours, resulting in the precipitation of the product as a yellow or orange solid. 
Thereafter, the solvent was reduced and the mixture placed in the fridge overnight. The 
resulting precipitate was collected by suction filtration and washed with cold ethanol, 
followed by diethyl ether and dried in vacuo. 
Unsubstituted N^N-coordinated Ir(III)-Cp* complex (11a) 
[Ir(Cp*)Cl2]2 (0.0494 g, 0.0620 mmol), 
compound 6a (0.0512 g, 0.124 mmol) 
and NH4PF6 (0.0255 g, 0.156 mmol). 
Product: Yellow powder. Yield: 0.0759 
g, 66.4%. M.p. 189.3 – 192.3 °C. 1H 
NMR (400 MHz, DMSO-d6): δ 9.12 
(dd, 3JHH = 5.6 Hz, 4JHH = 1.0 Hz, 1H, H-25), 8.56 (d, 3JHH = 8.2 Hz, 1H, H-22), 8.40 (d, 3JHH = 
5.7 Hz, 1H, H-2), 8.26 (d, 3JHH = 9.1 Hz, 1H, H-7), 8.11 – 8.06 (overlapping m, 2H, H-10/23), 
7.86 – 7.82 (overlapping m, 2H, H-4/24), 7.76 (m, 1H, H-15), 7.66 – 7.58 (overlapping m, 
3H, H-16/17/18), 7.53 (dd, 3JHH = 9.1, 4JHH = 2.2 Hz, 1H, H-6), 6.50 (d, 3JHH = 5.7 Hz, 1H, 
 




H-1), 5.08 (m, 2H, H-13), 3.50 (m, 2H, H-11), 2.31 (m, 2H, H-12), 1.69 (s, 15H, H-26’). 
13C{1H} NMR (101 MHz, DMSO-d6): δ 154.3, 151.2, 151.0, 150.9, 148.0, 145.6, 140.8, 
137.7, 136.4, 134.6, 129.1, 126.9, 126.7, 126.0, 125.1, 125.0, 124.6, 117.8, 117.6, 113.4, 
99.2, 89.1 (5C), 43.7, 40.5, 28.4, 9.3 (5C). 31P{1H} NMR (162 MHz, DMSO-d6): δ -144.2 
(sep, 1J = 711.2 Hz, PF6–). FT-IR (ATR, cm-1): ν = 3333 (N-H), 1633 (sh, C=Npyr), 1609 
(C=Nbenz/quin), 1580 (C=C). ESI-MS: m/z 388.5986 ([M+H]2+), calculated 388.5986.  
Methyl-substituted N^N-coordinated Ir(III)-Cp* complex (11b) 
[Ir(Cp*)Cl2]2 (0.0485 g, 0.0609 mmol), 
compound 6b (0.0521 g, 0.122 mmol) 
and NH4PF6 (0.0255 g, 0.156 mmol). 
Product: Yellow powder. Yield: 0.0805 
g, 70.7%. M.p. 200.8 – 202.5 °C. 1H 
NMR (600 MHz, DMSO-d6): δ 9.10 
(dd, 3JHH = 5.6, 4JHH = 1.3 Hz, 1H, H-25), 
8.54 (d, 3JHH = 8.2 Hz, 1H, H-22), 8.43 (d, 3JHH = 6.0 Hz, 1H, H-2), 8.26 (d, 3JHH = 9.1 Hz, 1H, 
H-7), 8.11 (td, 3JHH = 8.2, 4JHH = 1.3 Hz, 1H, H-23), 7.99 (m, 1H, H-10), 7.95 (d, 3JHH = 8.6 Hz, 
1H, H-15), 7.85 – 7.81 (overlapping m, 2H, H-4/24), 7.57 (dd, 3JHH = 9.1, 4JHH = 2.2 Hz, 1H, 
H-6),  7.45 (m, 1H, H-18), 7.43 (dd, 3JHH = 8.6, 4JHH = 1.1 Hz, 1H, H-16), 6.57 (d, 3JHH = 6.0 
Hz, 1H, H-1), 5.04 (m, 2H, H-13), 3.52 (m, 2H, H-11), 2.56 (s, 3H, H-17’), 2.29 (m, 2H, H-12), 
1.68 (s, 15H, H-26’). 13C{1H} NMR (151 MHz, DMSO-d6): δ 154.3, 152.1, 150.7, 149.6, 
146.0, 145.7, 140.9, 138.0, 135.9, 135.5, 134.7, 129.1, 128.4, 125.6, 125.3, 124.9, 124.8, 
117.3, 116.9, 113.2, 99.2, 89.1 (5C), 43.7, 40.5, 28.4, 21.6, 9.4 (5C). 31P{1H} NMR (162 
MHz, DMSO-d6): δ -144.2 (sep, 1J = 711.2 Hz, PF6–). FT-IR (ATR, cm-1): ν = 3337 (N-H), 
1633 (sh, C=Npyr), 1613 (C=Nbenz/quin), 1580 (C=C). ESI-MS: m/z 395.6066 ([M+H]2+), 










Trifluoromethyl-substituted N^N-coordinated Ir(III)-Cp* complex (11c) 
[Ir(Cp*)Cl2]2 (0.0436 g, 0.0547 mmol), 
compound 6c (0.0526 g, 0.109 mmol) 
and NH4PF6 (0.0236 g, 0.145 mmol). 
Product: Yellow powder. Yield: 
0.0573 g, 53.0%. M.p. 244.5 – 247.2 
°C. 1H NMR (400 MHz, DMSO-d6): δ 
9.16 (dd, 3JHH = 5.6, 4JHH = 1.1 Hz, 1H, 
H-25), 8.63 (d, 3JHH = 8.2 Hz, 1H, H-22), 8.41 (d, 3JHH = 5.6 Hz, 1H, H-2), 8.35 (d, 3JHH = 9.2 
Hz, 1H, H-15), 8.18 – 8.09 (overlapping m, 2H, H-7/23), 7.97 – 7.87 (overlapping m, 3H, 
H-16/18/24), 7.81 (d, 4JHH = 2.2 Hz, 1H, H-4), 7.60 (t, 3JHH = 5.5 Hz, 1H, H-10), 7.49 (dd, 
3JHH = 9.0, 4JHH = 2.2 Hz, 1H, H-6), 6.52 (d, 3JHH = 5.7 Hz, 1H, H-1), 5.14 (m, 2H, H-13), 3.53 
(m, 2H, H-11), 2.36 (m, 2H, H-12), 1.69 (s, 15H, H-26’). 13C{1H} NMR (151 MHz, 
DMSO-d6): δ 154.4, 153.7, 151.1, 151.0, 147.8, 145.1, 141.0, 138.9, 137.1, 134.6, 129.9, 
126.1, 125.9, 125.8, 125.4, 125.1, 124.6, 123.0, 117.6, 115.5, 114.5, 99.3, 89.3 (5C), 
44.4, 40.5, 28.2, 9.4 (5C). 31P{1H} NMR (162 MHz, DMSO-d6): δ -144.2 (sep, 1J = 711.2 Hz, 
PF6–). FT-IR (ATR, cm-1): ν = 3337 (N-H), 1633 (sh, C=Npyr), 1611 (sh, C=Nbenz/quin), 1582 
(C=C), 1330 (C–F). ESI-MS: m/z 422.5920 ([M+H]2+), calculated 422.5923.  
Unsubstituted N^N-coordinated Rh(III)-Cp* complex (12a) 
[Rh(Cp*)Cl2]2 (0.0382 g, 0.0618 
mmol), compound 6a (0.0512 g, 0.124 
mmol) and NH4PF6 (0.0243 g, 0.149 
mmol). Product: Orange powder. 
Yield: 0.0723 g, 70.2%. M.p. 194.9 – 
197.0 °C. 1H NMR (400 MHz, 
DMSO-d6): δ 9.12 (dd, 3JHH = 5.4, 4JHH = 0.9 Hz, 1H, H-25), 8.48 (d, 3JHH = 8.2 Hz, 1H, H-22), 
8.41 (d, 3JHH = 5.8 Hz, 1H, H-2), 8.25 (d, 3JHH = 9.1 Hz, 1H, H-7), 8.11 – 8.04 (overlapping m, 
2H, H-15/23), 7.87 (m, 1H, H-24), 7.85 – 7.80 (overlapping m, 2H, H-4/18), 7.73 (t, 3JHH = 
5.5 Hz, 1H, H-10), 7.62 – 7.57 (overlapping m, 2H, H-16/17), 7.54 (dd, 3JHH = 9.1, 4JHH = 2.2 
Hz, 1H, H-6), 6.53 (d, 3JHH = 5.8 Hz, 1H, H-1), 5.01 (m, 2H, H-13), 3.55 (m, 2H, H-11), 2.29 
(m, 2H, H-12), 1.68 (s, 15H, H-26’). 13C{1H} NMR (101 MHz, DMSO-d6): δ 154.3, 151.4, 
 
 




150.8, 148.3, 147.5, 145.7, 140.8, 138.5, 137.0, 134.9, 128.5, 126.5, 126.4, 125.7, 125.3, 
124.9, 124.7, 118.3, 117.5, 113.3, 99.3, 97.1 (3C), 97.0 (2C), 43.8, 40.5, 28.3, 9.5 (5C). 
31P{1H} NMR (162 MHz, DMSO-d6): δ -144.2 (sep, 1J = 711.2 Hz, PF6–). FT-IR (ATR, 
cm-1): ν = 3329 (N-H), 1633 (sh, C=Npyr), 1609 (C=Nbenz/quin), 1580 (C=C). ESI-MS: m/z 
325.5818 ([M–Cl]2+), calculated 325.5818.  
Methyl-substituted N^N-coordinated Rh(III)-Cp* complex (12b) 
[Rh(Cp*)Cl2]2 (0.0372 g, 0.0602 
mmol), compound 6b (0.0515 g, 0.120 
mmol) and NH4PF6 (0.0253 g, 0.155 
mmol). Product: Orange powder. 
Yield: 0.0842 g, 82.7%. M.p. 201.1 – 
202.6 °C. 1H NMR (600 MHz, 
DMSO-d6): δ 9.10 (dd, 3JHH = 5.5, 4JHH = 
1.1 Hz, 1H, H-25), 8.45 (d, 3JHH = 7.9 Hz, 1H, H-22), 8.44 (d, 3JHH = 6.1 Hz, 1H, H-2), 8.24 (d, 
3JHH = 9.1 Hz, 1H, H-7), 8.11 (td, 3JHH = 7.9, 4JHH = 1.1 Hz, 1H, H-23), 8.01 (m, 1H, H-10), 7.93 
(d, 3JHH = 8.6 Hz, 1H, H-15), 7.86 (ddd, 3JHH = 7.9, 3JHH = 5.5, 4JHH = 1.0 Hz, 1H, H-24), 7.84 
(d, 4JHH = 2.2 Hz, 1H, H-4), 7.58 (dd, 3JHH = 9.0, 4JHH = 2.2 Hz, 1H, H-6), 7.51 (dt, 3JHH = 1.5, 
4JHH = 0.9 Hz, 1H, H-18), 7.39 (dd, 3JHH = 8.6, 4JHH = 1.5 Hz, 1H, H-16), 6.58 (d, 3JHH = 6.1 Hz, 
1H, H-1), 4.97 (m, 2H, H-13), 3.52 (m, 2H, H-11), 2.55 (s, 3H, H-17’), 2.26 (m, 2H, H-12), 
1.67 (s, 15H, H-26’). 13C{1H} NMR (151 MHz, DMSO-d6): δ 154.3, 152.3, 149.3, 148.0, 
145.8 (2C), 140.8, 138.8, 135.6, 135.4, 135.2, 128.4, 128.1, 125.7, 125.1, 124.9, 124.8, 
117.4, 117.2, 113.0, 99.2, 97.1 (2C), 97.0 (3C), 43.8, 40.5, 28.3, 21.6, 9.6 (5C). 31P{1H} NMR 
(162 MHz, DMSO-d6): δ -144.2 (sep, 1J = 711.2 Hz, PF6–). FT-IR (ATR, cm-1): ν = 3329 
(N–H), 1633 (sh, C=Npyr), 1613 (C=Nbenz/quin), 1582 (C=C). ESI-MS: m/z 332.5899 










Trifluoromethyl-substituted N^N-coordinated Rh(III)-Cp* complex (12c) 
[Rh(Cp*)Cl2]2 (0.0335 g, 0.0542 
mmol), compound 6c (0.0521 g, 0.108 
mmol) and NH4PF6 (0.0211 g, 0.129 
mmol). Product: Orange powder. 
Yield: 0.0805 g, 82.7%. M.p. 202.0 – 
204.7 °C. 1H NMR (400 MHz, 
DMSO-d6): δ 9.17 (d, 3JHH = 5.2 Hz, 1H, 
H-25), 8.56 (d, 3JHH = 7.9 Hz, 1H, H-22), 8.46 (d, 3JHH = 6.1 Hz, 1H, H-2), 8.30 (d, 3JHH = 8.8 
Hz, 1H, H-15), 8.21 (t, 3JHH = 7.9 Hz, 1H, H-23), 8.11 (d, 3JHH = 9.1 Hz, 1H, H-7), 8.04 (m, 1H, 
H-10), 8.00 – 7.92 (overlapping m, 2H, H-18/24), 7.87 – 7.82 (overlapping m, 2H, H-4/16), 
7.57 (dd, 3JHH = 9.1, 4JHH = 1.5 Hz, 1H, H-6), 6.62 (d, 3JHH = 6.1 Hz, 1H, H-1), 5.08 (m, 2H, 
H-13), 3.58 (m, 2H, H-11), 2.35 (m, 2H, H-12), 1.68 (s, 15H, H-26’). 13C{1H} NMR (101 
MHz, DMSO-d6): δ 154.4, 152.6, 151.0, 148.7, 145.2, 141.0, 139.4, 137.8, 135.9, 129.2, 
126.1, 125.9, 125.7, 125.1, 124.9, 124.4, 122.6, 116.9, 115.3, 115.0, 114.9, 99.2, 97.3 (3C), 
97.2 (2C), 44.5, 40.4, 28.0, 9.5 (5C). 31P{1H} NMR (162 MHz, DMSO-d6): δ -144.2 (sep, 
1J = 711.2 Hz, PF6–). FT-IR (ATR, cm-1): ν = 3341 (N–H), 1631 (sh, C=Npyr), 1613 
(C=Nbenz/quin), 1582 (C=C), 1330 (C–F). ESI-MS: m/z 240.0528 ([M–Cl+H]3+), calculated 
240.0529.  
 
7.5.2 General method for synthesis of N^N-coordinated Rh(III)-ppy complexes 
(13a – 13c) 
Dichlorotetrakis(2-(2-pyridinyl)phenyl)dirhodium(III) (0.5 eq.) was added to a stirring 
solution of ligand 6a, 6b or 6c (1 eq.) in dry DCM (10 ml) and MeOH (10 ml), and the 
orange mixture was refluxed under N2 for 24 hours. Thereafter, the reaction mixture was 
cooled to room temperature, NH4PF6 (1.2 eq.) was added and the mixture was stirred for 
1.5 hours. The solvent was then removed, DCM was added and the mixture was filtered 
through Celite®. The solvent of the filtrate was removed and the resulting residue was 
triturated in pentane to afford the product as a pale-yellow, beige or orange precipitate, 
which was collected by suction filtration and dried in vacuo.  
 




Unsubstituted N^N-coordinated Rh(III)-ppy complex (13a)  
[Rh(ppy)2Cl]2 (0.0587 g, 0.0657 
mmol), compound 6a (0.0544 g, 
0.131 mmol) and NH4PF6 
(0.0278 g, 0.171 mmol). 
Product: Pale-yellow powder. 
Yield: 0.107 g, 84.3%. M.p. 227.6 
– 230.0 °C. 1H NMR (600 MHz, 
DMSO-d6): δ 8.57 (overlapping m, 2H, H-10/22), 8.46 (d, 3JHH = 6.4 Hz, 1H, H-2), 8.41 (d, 
3JHH = 9.1 Hz, 1H, H-7), 8.27 (d, 3JHH = 8.2 Hz, 1H, H-44), 8.20 (d, 3JHH = 8.1 Hz, 1H, H-33), 
8.07 (td, 3JHH = 8.0, 4JHH = 1.6 Hz, 1H, H-23), 8.03 – 7.89 (overlapping m, 6H, 
H-15/25/27/34/38/45), 7.88 (d, 4JHH = 2.2 Hz, 1H, H-4), 7.71 (d, 3JHH = 5.7 Hz, 1H, H-47), 
7.69 – 7.65 (overlapping m, 2H, H-6/24), 7.61 (d, 3JHH = 5.7 Hz, 1H, H-36), 7.32 (ddd, 3JHH 
= 8.3, 3JHH = 7.3, 4JHH = 1.0 Hz, 1H, H-16), 7.18 – 7.13 (overlapping m, 2H, H-35/39/46), 
7.10 (td, 3JHH = 7.6, 4JHH = 1.2 Hz, 1H, H-28), 7.03 – 6.96 (overlapping m, 3H, H-17/29/40), 
6.64 (d, 3JHH = 6.4 Hz, 1H, H-1), 6.29 (d, 3JHH = 7.7 Hz, 1H, H-41), 6.21 (overlapping m, 2H, 
H-18/30), 5.02 (m, 2H, H-13), 3.58 (m, 2H, H-11), 2.37 (m, 2H, H-12). 13C{1H} NMR (151 
MHz, DMSO-d6): δ 168.8, 168.6, 166.1, 165.9, 164.7, 164.6, 153.7, 151.2, 150.0, 149.8, 
149.5, 147.2, 146.5, 144.7, 144.4, 140.4, 139.5, 139.3, 139.1, 137.0, 133.1, 132.5, 130.5, 
129.9, 128.4, 126.4, 125.9, 125.5, 125.4, 125.3, 125.1, 125.0, 124.3, 124.2, 123.7, 123.6, 
123.2, 120.6, 120.4, 117.8, 116.7, 112.8, 99.1, 43.8, 40.6, 28.4. 31P{1H} NMR (162 MHz, 
DMSO-d6): δ -144.2 (sep, 1J = 711.2 Hz, PF6–). FT-IR (ATR, cm-1): ν = 3340 (N-H), 1633 
(sh, C=Npyr), 1615 (sh, C=Nbenz/quin), 1604 (C=Nppy), 1581 (C=C). ESI-MS: m/z 824.1747 












Methyl-substituted N^N-coordinated Rh(III)-ppy complex (13b) 
[Rh(ppy)2Cl]2 (0.0787 g, 0.0881 
mmol), compound 6b (0.0754 g, 
0.176 mmol) and NH4PF6 
(0.0328 g, 0.201 mmol). Product: 
Dark orange powder. Yield: 
0.0154 g, 89.0%. M.p. 225.9 – 
228.1 °C. 1H NMR (600 MHz, 
DMSO-d6): δ 9.04 (m, 1H, H-10), 8.58 (d, 3JHH = 8.3 Hz, 1H, H-22), 8.52 (d, 3JHH = 9.2 Hz, 
1H, H-7), 8.47 (d, 3JHH = 6.7 Hz, 1H, H-2), 8.27 (d, 3JHH = 8.2 Hz, 1H, H-44), 8.21 (d, 3JHH = 
8.3 Hz, 1H, H-33), 8.12 (td, 3JHH = 8.0, 4JHH = 1.6 Hz, 1H, H-23), 8.03 – 7.91 (overlapping m, 
6H, H-4/25/27/34/38/45), 7.78 (d, 3JHH = 8.6 Hz, 1H, H-15), 7.70 – 7.65 (overlapping m, 
3H, H-6/24/47), 7.64 (d, 3JHH = 5.7 Hz, 1H, H-36), 7.19 – 7.16 (overlapping m, 3H, 
H-35/39/46), 7.13 (dd, 3JHH = 8.7, 4JHH = 1.4 Hz, 1H, H-16), 7.10 (td, 3JHH = 7.6, 4JHH = 1.1 
Hz, 1H, H-28), 7.03 – 6.96 (overlapping m, 2H, H-40/29), 6.69 (d, 3JHH = 6.8 Hz, 1H, H-1), 
6.30 (d, 3JHH = 7.7 Hz, 1H, H-41), 6.23 (d, 3JHH = 7.6 Hz, 1H, H-30), 5.85 (m, 1H, H-18), 5.00 
(m, 2H, H-13), 3.63 (m, 2H, H-11), 2.36 (m, 2H, H-12), 2.02 (s, 3H, H-17’). 13C{1H} NMR 
(151 MHz, DMSO-d6): δ 168.9, 168.7, 166.3, 166.1, 164.7, 164.6, 154.6, 151.1, 149.8, 
149.7, 149.5, 146.5, 145.6, 144.9, 144.4, 140.5, 139.6, 139.2, 139.1, 137.5, 135.2, 134.3, 
133.3, 132.5, 130.4, 129.7, 128.2, 127.3, 126.7, 125.7, 125.3, 125.0, 124.3, 124.2, 123.7, 
123.4, 121.6, 120.6, 120.4, 117.6, 116.4, 112.2, 99.0, 43.8, 40.5, 28.3, 21.5. 31P{1H} NMR 
(162 MHz, DMSO-d6): δ -144.2 (sep, 1J = 711.2 Hz, PF6–). FT-IR (ATR, cm-1): ν = 3345 
(N–H), 1629 (sh, C=Npyr), 1615 (sh, C=Nbenz/quin), 1604 (C=Nppy), 1580 (C=C). ESI-MS: m/z 












Trifluoromethyl-substituted N^N-coordinated Rh(III)-ppy complex (13c)  
[Rh(ppy)2Cl]2 (0.0516 g, 0.0578 
mmol), compound 6c (0.0557 g, 
0.116 mmol) and NH4PF6 
(0.0237 g, 0.145 mmol). Product: 
Beige powder. Yield: 0.0849 g, 
70.8%. M.p. 260.0 °C (Decomp. 
w/o melting). 1H NMR (600 
MHz, DMSO-d6): δ 8.60 (d, 3JHH = 8.3 Hz, 1H, H-22), 8.39 (d, 3JHH = 6.0 Hz, 1H, H-2), 8.30 – 
8.27 (overlapping m, 2H, H-7/44), 8.22 (d, 3JHH = 8.3 Hz, 1H, H-33), 8.15 (d, 3JHH = 8.9 Hz, 
1H, H-15), 8.08 – 7.92 (overlapping m, 7H, H-10/23/25/27/34/38/45), 7.83 (d, 4JHH = 2.2 
Hz, 1H, H-4), 7.78 (d, 3JHH = 5.7 Hz, 1H, H-47), 7.71 (ddd, 3JHH J = 7.7, 3JHH = 5.3, 4JHH = 0.7 
Hz, 1H, H-24), 7.65 (d, 3JHH = 5.7 Hz, 1H, H-36), 7.61 (dd, 3JHH = 8.9, 4JHH = 1.4 Hz, 1H, H-16), 
7.55 (dd, 3JHH = 9.0, 4JHH = 2.2 Hz, 1H, H-6), 7.19 – 7.14 (overlapping m, 3H, H-35/39/46), 
7.11 (td, 3JHH = 7.6, 4JHH = 1.1 Hz, 1H, H-28), 7.03 – 6.97 (overlapping m, 2H, H-29/40), 
6.49 (d, 3JHH = 6.0 Hz, 1H, H-1), 6.44 (m, 1H, H-18), 6.31 (d, 3JHH = 7.7 Hz, 1H, H-41), 6.21 
(d, 3JHH = 7.6 Hz, 1H, H-30), 5.06 (m, 2H, H-13), 3.51 (m, 2H, H-11), 2.39 (m, 2H, H-12). 
13C{1H} NMR (151 MHz, DMSO-d6): δ 168.3, 168.1, 165.3, 165.1, 164.6, 164.5, 152.5, 
152.3, 151.3, 150.1, 149.6, 149.3, 146.0, 144.8, 144.4, 140.4, 139.3, 139.3, 138.7, 135.6, 
133.2, 132.5, 130.5, 129.9, 128.9, 127.0, 126.0, 125.7, 125.4, 125.2, 125.1, 124.8, 124.4, 
124.3, 123.8, 123.8, 122.0, 120.6, 120.4, 117.2, 115.5, 115.5, 114.3, 99.1, 44.3, 40.5, 28.2. 
31P{1H} NMR (162 MHz, DMSO-d6): δ -144.2 (sep, 1J = 711.2 Hz, PF6–). FT-IR (ATR, 
cm-1): ν = 3345 (N-H), 1629 (sh, C=Npyr), 1615 (sh, C=Nbenz/quin), 1606 (C=Nppy), 1581 








7.6 In vitro Plasmodium falciparum assay 
The samples were tested against the chloroquine-sensitive NF54 strain and chloroquine-
resistant K1 strain of P. falciparum. Continuous in vitro cultures of asexual erythrocyte 
stages of P. falciparum were maintained using a modified method of Trager and Jensen.9 
The in vitro antiplasmodium activity was determined via the parasite lactate 
dehydrogenase (pLDH) assay using a modified method described by Makler et al.10 The 
samples were prepared as 20 mg/ml stock solutions using dimethyl sulfoxide (DMSO) 
and sonicated to enhance solubility. Samples were tested as a suspension if not 
completely dissolved. Stock solutions were stored at -20 °C and further dilutions were 
prepared on the day of the experiment. Chloroquine was used as the reference drug in all 
experiments. A full dose-response measurement was performed for all compounds to 
determine the concentration inhibiting 50% of parasite growth (IC50 value). The samples 
were tested at a starting concentration of 10 μg/ml, which was then serially diluted 2-fold 
in complete medium to give 10 concentrations; with the lowest concentration being 
0.02 μg/ml. The same dilution technique was used for all samples. The positive control 
drugs were tested at a starting concentration of 10 µg/ml. The highest concentration of 
solvent to which the parasites were exposed had no measurable effect on the parasite 
viability. The IC50 values were obtained using a non-linear dose-response curve fitting 
analysis via Graph Pad Prism v.5.0 software. 
Formate study 
For the formate co-administration experiments in the NF54 strain, medium containing 0, 
5, 10 and 20 mM sodium formate was used instead of complete medium (after addition 
of the medium to the 96-well plates, the final sodium formate concentrations are 0, 5, 10 










7.7 Isobologram analysis 
Compound solution preparation 
Stock solutions of the test compounds were prepared at 20 mg/ml using DMSO, and 
solutions were stored at -20 °C. Dilutions and combinations were made on the day of the 
experiment. Initially, dose response assays were performed to determine the IC50 values 
of compounds B1 and B2. For the combination assay, test compound dilutions were made 
to allow the IC50 of compounds B1 and B2 to fall at the fourth 2-fold serial dilution. 
Dilutions of each compound were prepared in fixed ratios and volumes according to 
Table 7.1. The compounds were combined and tested according to a modified method 
described by Fivelman et al.11 
Table 7.1 Combination ratios and volumes of test compounds B1 and B2. 
 Ratio Volume (µl) 
Mixture B1 B2 B1 B2 
1 5 0 1000 0 
2 4 1 800 200 
3 3 2 600 400 
4 1 1 500 500 
5 2 3 400 600 
6 1 4 200 800 
7 0 5 0 100 
 
Plate preparation  
The compounds and combinations were tested against the NF54 strain of P. falciparum 
and the assays were carried out in 96-well plates. Complete medium (100 μl) was added 
into all wells except row A, column 3 to 11. Red blood cells (RBCs) at 2% haematocrit 
were prepared and 100 μl was added to column 1 as the blank. One hundred microlitres 
of parasitized red blood cells (pRBC) at 2% haematocrit and 2% parasitemia were added 
to rows A to H, column 2 and 12 as positive controls. Two hundred microlitres of the top 
concentration of each compound or compound combination was added in triplicate to 
row A, column 3 to 11. The combination solutions were serially diluted (2-fold) from row 
A to H, transferring 100 μl of compound solutions each after mixing and discarding the 
last 100 µl. One hundred microlitres of pRBC were added to all wells in rows A to H, 




columns 3 to 11. The dose-response curves were used to determine IC50 and FIC50 values, 
which were used to construct an isobologram. 
 
7.8 In vitro cytotoxicity assay   
In vitro cytotoxicity of potent target compounds against the Chinese Hamster Ovarian 
(CHO) cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, which determines cellular growth and 
survival.12, 13 For each test compound, a stock solution (2 mg/ml) was prepared in 10% 
DMSO, and then diluted with the assay medium to yield a starting concentration of a 100 
μg/ml. This was then serially diluted (10-fold) to give six assay concentrations ranging 
from 100–0.001 μg/ml. The positive control drug, emetine, was subjected to similar 
dilutions. In all cases, samples were tested in triplicate. The highest concentration of 
DMSO used had no measurable effect on cell viability. A solution of MTT was then added 
after 44 hours of exposure of the cells to the test compound, followed by a further 4 hours 
of incubation at 37 °C. The supernatant was then separated from the cells by suction and 
the formazan crystals were dissolved by addition of DMSO to each well. The amount of 
formazan in each well was determined by measuring the absorbance at 540 nm. The IC50 
values were obtained from dose-response curves, using a non-linear dose-response curve 
analysis via GraphPad Prism v.5.0 software. 
 
7.9 In vivo antimalarial efficacy studies  
In vivo efficacy against Plasmodium berghei was performed using mice (n = 3) which were 
infected with a GFP-transfected P. berghei ANKA strain (donated by A. P. Waters and C. J. 
Janse, Glasgow and Leiden Universities respectively). Parasitemia was determined using 
standard flow cytometry techniques. The detection limit was 1 parasite per 1000 
erythrocytes (0.1%). Activity was calculated as the difference between the mean 
percentage parasitemia for the control and treated groups, expressed as a percentage 
relative to the control group. Compounds were dissolved or suspended in 90/10 
Tween80/ethanol (v/v), diluted 10 times with water and administered orally as four 
consecutive daily doses (4, 24, 48 and 72 h after infection). Animals were considered 




cured if there were no detectable parasites on day 30 post-infection as determined by 
light microscopy. 
 
7.10 β-Haematin inhibition assay 
The β-haematin formation assay was adapted from the method described by Sandlin et 
al.14 Test compounds were prepared as a 10 mM stock solution in 100% DMSO. 
Compounds were tested at concentrations between 500 μM and 5 μM. The stock solution 
was serially diluted to give 12 concentrations in a 96 well flat-bottom assay plate. NP-40 
detergent was then added to mediate the formation of β-haematin (30.55 μM, 
final concentration). A 25 mM stock solution of haematin was prepared by dissolving 
haemin (16.3 mg) in DMSO (1 ml). A 177.76 μl aliquot of haematin stock was suspended 
in 20 ml of a 2 M acetate buffer (pH 4.7). The haematin suspension was then added to the 
plate to give a final haematin concentration of 100 μM. The plate was then incubated for 
16 hours at 37 °C. The assay was analysed using the pyridine ferrihaemochrome method 
developed by Ncokazi and Egan.15 Thirty-two microlitres of a solution of 50% pyridine, 
20% acetone, 20% water, and 10% 2 M HEPES buffer (pH 7.4) was added to each well. 
To this, 60 μl of acetone was then added to each well and mixed. The absorbance of the 
resulting complex was measured at 405 nm on a SpectraMax 340PC plate reader. The IC50 
values were obtained using a non-linear dose-response curve fitting analysis via Graph 
Pad Prism v.5.0 software. 
 
7.11 Cellular haem fractionation assay 
Synchronized ring stage NF54 parasites (5% parasitemia and 2% haematocrit) were 
incubated with varying concentrations of test compounds and controls for 36 h. 
Trophozoites were isolated afterwards by saponin lysis, diluted to 1 ml, counted using a 
hemocytometer and then stored at −80 °C. For measurements, samples were thawed and 
50 µl of water was added before sonication for 5 minutes. Fifty microlitres of 0.2 M HEPES 
buffer (pH 7.5) and 50 µl of water was added, followed by centrifugation at 3600 rpm for 
20 min. Fifty microlitres of 4% SDS was added to the supernatant, which was sonicated 
and incubated at room temperature for 30 minutes. Fifty microliters of 0.3 M NaCl and 50 




µl of 25% pyridine (v/v) were added and the UV−visible spectrum of this fraction (Hb) 
was recorded. Water (50 µl) was added to the pellet, followed by 50 µl of 4% SDS. After 
re-suspending the pellet, the solution was sonicated and incubated for 30 minutes. To the 
centrifuged sample, 50 µl of 0.2 M HEPES, 50 µl of 0.3 M NaCl, and 50 µl of 25% pyridine 
were added. The supernatant was diluted to 400 µl with water and the UV−visible 
spectrum of this fraction (haem) was recorded. To the pellet, 50 µl of water and 50 µl of 
0.3 M NaOH was added, which was sonicated 15 minutes and incubated for 30 minutes. 
Fifty microliters of 0.2 M HEPES, 50 µl of 0.3 M HCl, and 50 µl of 25% pyridine were added 
and the supernatant was diluted to 300 µl. The UV−visible spectrum of this fraction 
(haemozoin) was recorded and percentages of the three haem species (haemoglobin, 
haem and haemozoin) were determined from the absorbance values. 
 
7.12 DNA cleavage assay 
All gel electrophoresis experiments were carried out using hand-cast 1.25% agarose gels 
dissolved in 1× TAE buffer (Sigma Aldrich) in a Mini-Sub-Cell GT® Agarose Gel 
Electrophoresis System (Bio-Rad). Compound-DNA interaction assays (EMSA) were 
performed in tubes containing 25 ng of pUC57 plasmid DNA (ThermoFisher) and an 
appropriate amount of the test compound dissolved in DMSO (to a final concentration of 
10% DMSO) in 1× TAE buffer (Sigma-Aldrich, pH 8.3), for a total volume of 10 μl. The 
samples were incubated at 37 °C for 30 minutes. Four microlitres of loading dye (Sigma 
Aldrich, 0.25% bromophenol blue, 0.25% xylene cyanol, and 40% sucrose) was added to 
each sample and 6 μl aliquots were then loaded onto the gels and electrophoresed at a 
constant 75 V for 90 minutes in 1× TAE buffer. The DNA was stained with an Ethidium 
Bromide solution (0.5 mg/l in Type 1 ultrapure water) for 30 minutes, washed in Type 1 
ultrapure water for 20 minutes and visualized using a G:Box Chemi XRQ gel doc system 
(Syngene) with midwave transillumination and a UV filter (GeneSys 1.4.6.0).  
 
  




7.13 Transfer hydrogenation studies 
1H NMR study 
Approximately 6 mg of the test complex, 20 mg of NAD+ and 40 mg of sodium formate 
were weighed. The NAD+ and sodium formate were each dissolved separately in 600 µl 
of D2O. The complex was then suspended in a mixture of 100 µl of the sodium formate 
solution and 300 µl of the NAD+ solution. To this, 300 µl of MeOD was added. The 
suspension was then mixed well, any solid matter that remained was filtered off and the 
pH of the resulting filtrate adjusted to 7.4 using a NaOH solution. The solution was then 
added to an NMR tube. The 1H NMR spectrum was recorded prior to incubation at 37 °C. 
The tube was then incubated at 37 °C and the spectra recorded after 30 and 60 minutes. 
Cell-free assay 
The compounds were evaluated using a method described by Stringer et al.16 An NAD+ 
solution (50 ml) was prepared by dissolving sodium formate (0.310 g, 4.56 mmol), trizma 
base (0.330 g, 2.72 mmol) and NAD+ (5.50 mg, 0.00829 mmol) in distilled water (25 ml). 
The pH was adjusted to pH 7.4 using HCl and the volume made up to 50 ml with distilled 
water. A tetrazolium (NBT) solution was prepared by dissolving nitroblue tetrazolium 
(0.080 g, 0.0978 mmol) and phenazine ethosulfate (0.004 g, 0.0120 mmol) in distilled 
water (50 ml). Stock solutions (6 mM) of each complex were prepared in DMSO (1 ml). In 
a 96-well plate (plate 1), 200 µl of the complex solution was added to column 3 in 
triplicate. DMSO (100 µl) was added to each well from column 4 to column 12. The 
compounds were serially diluted giving 10 concentrations (2250 µM to 4 µM). Seventy-
five microlitres of the solution from each well was transferred into a second 96-well plate 
(plate 2) into the corresponding well (e.g. 75 µl C1 of plate 1 into C1 of plate 2). The NAD+ 
solution (100 µl) was then added to each well. In column 1, 75 µl DMSO and 100 µl NAD+ 
solution were added to each well only. In column 2, 175 µl DMSO was added to each well 
only. The plate was read at 600 nm to account for the absorbance of the compounds (pre-
read). The plate was then covered with a foil plate cover to prevent evaporation and was 
incubated for 6-8 hours at 37 °C. After this time, 25 µl of the NBT solution was added and 
the plate incubated for a further 16 hours to aid plate developing. Thereafter, the 
absorbance was read at 600 nm again, the data from the pre-read accounted for, and the 
data plotted using Graph Pad Prism v.5.0 at the various concentrations.  




7.14 In vitro Mycobacterium tuberculosis assay 
The minimum inhibitory concentration (MIC) values were determined using the standard 
broth micro dilution method,17 where a 10 ml culture of Mycobacterium tuberculosis 
H37Rv,18 was grown to an absorbance (OD600) of 0.6 – 0.7. The media used were 
Middlebrook 7H9 media (Difco) supplemented with 0.2% Glucose, Middlebrook albumin-
dextrose- catalase (ADC) enrichment (Difco) and 0.05% Tween,19 as well as Middlebrook 
7H9 supplemented with 0.03% casitone, 0.4% glucose, and 0.05% tyloxapol.20 Cultures 
grown in these media were diluted 1:500, prior to inoculation of the MIC assay. The 
compounds to be tested were reconstituted to a concentration of 10 mM in DMSO. 
Duplicate 2-fold serial dilutions of the test compound were prepared across a 96-well 
micro titre plate, in a volume of 50 μl, after which, 50 μl of the diluted M. tuberculosis 
cultures was added to each well in the plate (including control wells). The final volume 
per well is 100 μl. The plate layout is a modification of the method previously described.21 
Controls used were a minimum growth control (rifampicin at 2 × MIC), and a maximum 
growth control (5% DMSO). The micro titre plates were sealed in a secondary container 
and incubated at 37 °C with 5% CO2 and humidification. Alamar Blue reagent was added 
to each well of the assay plate, 24 hours prior to the assay end data, after which the assay 
is re-incubated for 24 hours. Relative fluorescence (excitation 485 nM; emission 520 nM) 
was measured using a plate reader (FLUOstar OPTIMA, BMG LABTECH), at day 7. The raw 
fluorescence data was archived and analysed using the CDD Vault from Collaborative 
Drug Discovery, in which, data was normalised to the minimum and maximum inhibition 
controls to generate a dose response curve (percentage inhibition), using the Levenberg-
Marquardt damped least squares method, from which the MIC90 was calculated.22 The 
lowest concentration of drug that inhibited growth of more than 90% of the 
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